WO2024118596A1 - Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof - Google Patents
Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof Download PDFInfo
- Publication number
- WO2024118596A1 WO2024118596A1 PCT/US2023/081334 US2023081334W WO2024118596A1 WO 2024118596 A1 WO2024118596 A1 WO 2024118596A1 US 2023081334 W US2023081334 W US 2023081334W WO 2024118596 A1 WO2024118596 A1 WO 2024118596A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- cancer
- therapeutic agent
- heterocycloalkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 49
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 title description 7
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 title description 7
- 101150050673 CHK1 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 357
- 238000000034 method Methods 0.000 claims abstract description 251
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 224
- 239000003814 drug Substances 0.000 claims abstract description 210
- 201000011510 cancer Diseases 0.000 claims abstract description 196
- 238000011282 treatment Methods 0.000 claims abstract description 111
- 150000001875 compounds Chemical class 0.000 claims description 381
- -1 c-MET Proteins 0.000 claims description 267
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 162
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 153
- 150000003839 salts Chemical class 0.000 claims description 148
- 239000012453 solvate Substances 0.000 claims description 134
- 210000004881 tumor cell Anatomy 0.000 claims description 121
- 229910052736 halogen Inorganic materials 0.000 claims description 102
- 150000002367 halogens Chemical group 0.000 claims description 102
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 94
- 230000004544 DNA amplification Effects 0.000 claims description 93
- 229910052739 hydrogen Inorganic materials 0.000 claims description 88
- 239000001257 hydrogen Substances 0.000 claims description 88
- 125000001072 heteroaryl group Chemical group 0.000 claims description 83
- 125000003118 aryl group Chemical group 0.000 claims description 81
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 73
- 125000000217 alkyl group Chemical group 0.000 claims description 64
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 53
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 42
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 36
- 230000003321 amplification Effects 0.000 claims description 34
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 34
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 33
- 229910052805 deuterium Inorganic materials 0.000 claims description 33
- 125000004429 atom Chemical group 0.000 claims description 28
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 125000000304 alkynyl group Chemical group 0.000 claims description 26
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 25
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 24
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical group C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 claims description 22
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 22
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 22
- 229950005712 infigratinib Drugs 0.000 claims description 22
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 20
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 20
- 229960004390 palbociclib Drugs 0.000 claims description 19
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical group N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 19
- 239000012830 cancer therapeutic Substances 0.000 claims description 18
- 230000004614 tumor growth Effects 0.000 claims description 18
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 17
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 17
- 125000002947 alkylene group Chemical group 0.000 claims description 17
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 17
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 16
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 16
- 230000009467 reduction Effects 0.000 claims description 16
- 229950001573 abemaciclib Drugs 0.000 claims description 15
- UZWDCWONPYILKI-UHFFFAOYSA-N n-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine Chemical compound C1CN(CC)CCN1CC(C=N1)=CC=C1NC1=NC=C(F)C(C=2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1 UZWDCWONPYILKI-UHFFFAOYSA-N 0.000 claims description 15
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 14
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims description 14
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 13
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 13
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 claims description 13
- 230000002195 synergetic effect Effects 0.000 claims description 13
- KEIPNCCJPRMIAX-HNNXBMFYSA-N 1-[(3s)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC(C#CC=2C3=C(N)N=CN=C3N([C@@H]3CN(CC3)C(=O)C=C)N=2)=C1 KEIPNCCJPRMIAX-HNNXBMFYSA-N 0.000 claims description 12
- 102100030708 GTPase KRas Human genes 0.000 claims description 12
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 12
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 12
- 206010027476 Metastases Diseases 0.000 claims description 12
- 229960001433 erlotinib Drugs 0.000 claims description 12
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 12
- 229940121446 futibatinib Drugs 0.000 claims description 12
- 230000009401 metastasis Effects 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims description 11
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 11
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 11
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 11
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 11
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims description 11
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims description 11
- 102000017274 MDM4 Human genes 0.000 claims description 11
- 108050005300 MDM4 Proteins 0.000 claims description 11
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 claims description 10
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 10
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 230000003247 decreasing effect Effects 0.000 claims description 10
- 229940121647 egfr inhibitor Drugs 0.000 claims description 10
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 9
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 9
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 9
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 230000004044 response Effects 0.000 claims description 9
- 230000004043 responsiveness Effects 0.000 claims description 9
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 8
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 8
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 claims description 8
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 claims description 8
- 102100029974 GTPase HRas Human genes 0.000 claims description 8
- 102100039788 GTPase NRas Human genes 0.000 claims description 8
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims description 8
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 8
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 claims description 8
- 101100119134 Homo sapiens ESRRB gene Proteins 0.000 claims description 8
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims description 8
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 8
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims description 8
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 8
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 claims description 8
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 8
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 claims description 8
- 101000585703 Homo sapiens Protein L-Myc Proteins 0.000 claims description 8
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims description 8
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 8
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 8
- 108700012912 MYCN Proteins 0.000 claims description 8
- 101150022024 MYCN gene Proteins 0.000 claims description 8
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims description 8
- 101150097381 Mtor gene Proteins 0.000 claims description 8
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 8
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims description 8
- 102000055056 N-Myc Proto-Oncogene Human genes 0.000 claims description 8
- 102100029166 NT-3 growth factor receptor Human genes 0.000 claims description 8
- 102000048238 Neuregulin-1 Human genes 0.000 claims description 8
- 108090000556 Neuregulin-1 Proteins 0.000 claims description 8
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims description 8
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 8
- 102100030128 Protein L-Myc Human genes 0.000 claims description 8
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims description 8
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 8
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 8
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 8
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims description 8
- 102100036831 Steroid hormone receptor ERR2 Human genes 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 8
- 108010064892 trkC Receptor Proteins 0.000 claims description 8
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- 229940121317 pemigatinib Drugs 0.000 claims description 7
- 229950009455 tepotinib Drugs 0.000 claims description 7
- AHYMHWXQRWRBKT-UHFFFAOYSA-N tepotinib Chemical group C1CN(C)CCC1COC1=CN=C(C=2C=C(CN3C(C=CC(=N3)C=3C=C(C=CC=3)C#N)=O)C=CC=2)N=C1 AHYMHWXQRWRBKT-UHFFFAOYSA-N 0.000 claims description 7
- 125000006697 (C1-C3) aminoalkyl group Chemical group 0.000 claims description 6
- 125000006699 (C1-C3) hydroxyalkyl group Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- 238000010186 staining Methods 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 4
- 238000011528 liquid biopsy Methods 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims 10
- 101150006084 CHKB gene Proteins 0.000 abstract 1
- 108091092566 Extrachromosomal DNA Proteins 0.000 description 118
- 238000006243 chemical reaction Methods 0.000 description 76
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 74
- 125000004432 carbon atom Chemical group C* 0.000 description 40
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 239000002585 base Substances 0.000 description 28
- 239000003795 chemical substances by application Substances 0.000 description 27
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 26
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 26
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 26
- 229910052760 oxygen Inorganic materials 0.000 description 26
- 239000001301 oxygen Substances 0.000 description 26
- 239000002904 solvent Substances 0.000 description 25
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 24
- 229940125877 compound 31 Drugs 0.000 description 24
- 201000010099 disease Diseases 0.000 description 21
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 125000004043 oxo group Chemical group O=* 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 125000003545 alkoxy group Chemical group 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 108700020796 Oncogene Proteins 0.000 description 13
- NXQKSXLFSAEQCZ-SFHVURJKSA-N sotorasib Chemical compound FC1=CC2=C(N(C(N=C2N2[C@H](CN(CC2)C(C=C)=O)C)=O)C=2C(=NC=CC=2C)C(C)C)N=C1C1=C(C=CC=C1O)F NXQKSXLFSAEQCZ-SFHVURJKSA-N 0.000 description 13
- RHXHGRAEPCAFML-UHFFFAOYSA-N 7-cyclopentyl-n,n-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C2N(C3CCCC3)C(C(=O)N(C)C)=CC2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 RHXHGRAEPCAFML-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 208000005718 Stomach Neoplasms Diseases 0.000 description 12
- IDKAKZRYYDCJDU-HBMMIIHUSA-N chembl2381408 Chemical compound C1([C@H]2[C@@H](N[C@H]([C@]22C3=CC=C(Cl)C=C3NC2=O)CC(C)(C)C)C(=O)N[C@@H]2CC[C@@H](O)CC2)=CC=CC(Cl)=C1F IDKAKZRYYDCJDU-HBMMIIHUSA-N 0.000 description 12
- 206010017758 gastric cancer Diseases 0.000 description 12
- 125000004404 heteroalkyl group Chemical group 0.000 description 12
- 150000002825 nitriles Chemical class 0.000 description 12
- 229950003687 ribociclib Drugs 0.000 description 12
- 150000003384 small molecules Chemical class 0.000 description 12
- 201000011549 stomach cancer Diseases 0.000 description 12
- 239000003054 catalyst Substances 0.000 description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 11
- 125000001188 haloalkyl group Chemical group 0.000 description 11
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 11
- 229960003862 vemurafenib Drugs 0.000 description 11
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- 238000002648 combination therapy Methods 0.000 description 10
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 108091008794 FGF receptors Proteins 0.000 description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 150000007942 carboxylates Chemical class 0.000 description 9
- 101150113535 chek1 gene Proteins 0.000 description 9
- 238000006880 cross-coupling reaction Methods 0.000 description 9
- 125000000392 cycloalkenyl group Chemical group 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 9
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 9
- 125000002950 monocyclic group Chemical group 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- TVTXCJFHQKSQQM-LJQIRTBHSA-N 4-[[(2r,3s,4r,5s)-3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-dimethylpropyl)pyrrolidine-2-carbonyl]amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC(=O)[C@H]1[C@H](C=2C(=C(Cl)C=CC=2)F)[C@@](C#N)(C=2C(=CC(Cl)=CC=2)F)[C@H](CC(C)(C)C)N1 TVTXCJFHQKSQQM-LJQIRTBHSA-N 0.000 description 8
- 102100032187 Androgen receptor Human genes 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 102000043276 Oncogene Human genes 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 108010080146 androgen receptors Proteins 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- PEMUGDMSUDYLHU-ZEQRLZLVSA-N 2-[(2S)-4-[7-(8-chloronaphthalen-1-yl)-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]-6,8-dihydro-5H-pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoroprop-2-enoyl)piperazin-2-yl]acetonitrile Chemical compound ClC=1C=CC=C2C=CC=C(C=12)N1CC=2N=C(N=C(C=2CC1)N1C[C@@H](N(CC1)C(C(=C)F)=O)CC#N)OC[C@H]1N(CCC1)C PEMUGDMSUDYLHU-ZEQRLZLVSA-N 0.000 description 7
- DRLCSJFKKILATL-YWCVFVGNSA-N 2-[(3r,5r,6s)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-[(2s)-3-methyl-1-propan-2-ylsulfonylbutan-2-yl]-2-oxopiperidin-3-yl]acetic acid Chemical compound C1([C@@H]2[C@H](N(C([C@@](C)(CC(O)=O)C2)=O)[C@H](CS(=O)(=O)C(C)C)C(C)C)C=2C=CC(Cl)=CC=2)=CC=CC(Cl)=C1 DRLCSJFKKILATL-YWCVFVGNSA-N 0.000 description 7
- XOQVZSSDIQQUGO-UHFFFAOYSA-N CC1=NC(=NC=C1)OC2=C(C=C(C=C2)C3=C(N(C4=NC=NC(=C34)N)C)C5=CC=C(C=C5)NC(=O)C(=C)C)F Chemical compound CC1=NC(=NC=C1)OC2=C(C=C(C=C2)C3=C(N(C4=NC=NC(=C34)N)C)C5=CC=C(C=C5)NC(=O)C(=C)C)F XOQVZSSDIQQUGO-UHFFFAOYSA-N 0.000 description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 7
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 7
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 7
- 108091008611 Protein Kinase B Proteins 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 229940124988 adagrasib Drugs 0.000 description 7
- 229960005395 cetuximab Drugs 0.000 description 7
- 229960005061 crizotinib Drugs 0.000 description 7
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 229950004444 erdafitinib Drugs 0.000 description 7
- 239000011737 fluorine Substances 0.000 description 7
- 229910052731 fluorine Inorganic materials 0.000 description 7
- 229960002584 gefitinib Drugs 0.000 description 7
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- OLAHOMJCDNXHFI-UHFFFAOYSA-N n'-(3,5-dimethoxyphenyl)-n'-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-n-propan-2-ylethane-1,2-diamine Chemical compound COC1=CC(OC)=CC(N(CCNC(C)C)C=2C=C3N=C(C=NC3=CC=2)C2=CN(C)N=C2)=C1 OLAHOMJCDNXHFI-UHFFFAOYSA-N 0.000 description 7
- 229960000513 necitumumab Drugs 0.000 description 7
- 229960001972 panitumumab Drugs 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229940073531 sotorasib Drugs 0.000 description 7
- VDLGAZDAHPLOIR-VAZUXJHFSA-N sulanemadlin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@]2(C)CCCCCC\C=C\CCC[C@](C)(NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CNC4=CC=CC=C34)NC(=O)[C@H](CC5=CC=C(O)C=C5)NC(=O)[C@H](CCC(O)=O)NC2=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(N)=O VDLGAZDAHPLOIR-VAZUXJHFSA-N 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 239000011593 sulfur Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- LIOLIMKSCNQPLV-UHFFFAOYSA-N 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1C1=NN2C(CC=3C=C4C=CC=NC4=CC=3)=CN=C2N=C1 LIOLIMKSCNQPLV-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CLRSLRWKONPSRQ-IIPSPAQQSA-N C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)C[C@@H]2CC[C@H](CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 Chemical compound C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)C[C@@H]2CC[C@H](CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 CLRSLRWKONPSRQ-IIPSPAQQSA-N 0.000 description 6
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 6
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 description 6
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- QBGKPEROWUKSBK-QPPIDDCLSA-N [(4s,5r)-2-(4-tert-butyl-2-ethoxyphenyl)-4,5-bis(4-chlorophenyl)-4,5-dimethylimidazol-1-yl]-[4-(3-methylsulfonylpropyl)piperazin-1-yl]methanone Chemical compound CCOC1=CC(C(C)(C)C)=CC=C1C(N([C@]1(C)C=2C=CC(Cl)=CC=2)C(=O)N2CCN(CCCS(C)(=O)=O)CC2)=N[C@@]1(C)C1=CC=C(Cl)C=C1 QBGKPEROWUKSBK-QPPIDDCLSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 229960001686 afatinib Drugs 0.000 description 6
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 6
- 229960001292 cabozantinib Drugs 0.000 description 6
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 description 6
- 229950005852 capmatinib Drugs 0.000 description 6
- 238000011284 combination treatment Methods 0.000 description 6
- 229960002465 dabrafenib Drugs 0.000 description 6
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 6
- 229950002205 dacomitinib Drugs 0.000 description 6
- LVXJQMNHJWSHET-AATRIKPKSA-N dacomitinib Chemical compound C=12C=C(NC(=O)\C=C\CN3CCCCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 LVXJQMNHJWSHET-AATRIKPKSA-N 0.000 description 6
- 229950001969 encorafenib Drugs 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 229950002843 idasanutlin Drugs 0.000 description 6
- 239000000543 intermediate Substances 0.000 description 6
- 229960004891 lapatinib Drugs 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 229960003278 osimertinib Drugs 0.000 description 6
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 6
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 6
- AGBSXNCBIWWLHD-FQEVSTJZSA-N siremadlin Chemical compound COC1=NC(OC)=NC=C1C(N1C(C)C)=NC2=C1[C@H](C=1C=CC(Cl)=CC=1)N(C=1C(N(C)C=C(Cl)C=1)=O)C2=O AGBSXNCBIWWLHD-FQEVSTJZSA-N 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- AAFJXZWCNVJTMK-GUCUJZIJSA-N (1s,2r)-1-[(2s)-oxiran-2-yl]-2-[(2r)-oxiran-2-yl]ethane-1,2-diol Chemical compound C([C@@H]1[C@H](O)[C@H](O)[C@H]2OC2)O1 AAFJXZWCNVJTMK-GUCUJZIJSA-N 0.000 description 5
- CVCLJVVBHYOXDC-IAZSKANUSA-N (2z)-2-[(5z)-5-[(3,5-dimethyl-1h-pyrrol-2-yl)methylidene]-4-methoxypyrrol-2-ylidene]indole Chemical compound COC1=C\C(=C/2N=C3C=CC=CC3=C\2)N\C1=C/C=1NC(C)=CC=1C CVCLJVVBHYOXDC-IAZSKANUSA-N 0.000 description 5
- NYNZQNWKBKUAII-KBXCAEBGSA-N (3s)-n-[5-[(2r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide Chemical compound C1[C@@H](O)CCN1C(=O)NC1=C2N=C(N3[C@H](CCC3)C=3C(=CC=C(F)C=3)F)C=CN2N=C1 NYNZQNWKBKUAII-KBXCAEBGSA-N 0.000 description 5
- MDOJTZQKHMAPBK-UHFFFAOYSA-N 4-iodo-3-nitrobenzamide Chemical compound NC(=O)C1=CC=C(I)C([N+]([O-])=O)=C1 MDOJTZQKHMAPBK-UHFFFAOYSA-N 0.000 description 5
- AILRADAXUVEEIR-UHFFFAOYSA-N 5-chloro-4-n-(2-dimethylphosphorylphenyl)-2-n-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]pyrimidine-2,4-diamine Chemical compound COC1=CC(N2CCC(CC2)N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1P(C)(C)=O AILRADAXUVEEIR-UHFFFAOYSA-N 0.000 description 5
- QIEKHLDZKRQLLN-FOIQADDNSA-N 6-(difluoromethyl)-8-[(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound FC(C1=CC2=C(N=C(N=C2)NC2CCN(CC2)S(=O)(=O)C)N(C1=O)[C@H]1[C@](CCC1)(C)O)F QIEKHLDZKRQLLN-FOIQADDNSA-N 0.000 description 5
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 description 5
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 5
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 5
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 5
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 5
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 5
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 5
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- KQXDHUJYNAXLNZ-XQSDOZFQSA-N Salinomycin Chemical compound O1[C@@H]([C@@H](CC)C(O)=O)CC[C@H](C)[C@@H]1[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@@H]1[C@@H](C)C[C@@H](C)[C@@]2(C=C[C@@H](O)[C@@]3(O[C@@](C)(CC3)[C@@H]3O[C@@H](C)[C@@](O)(CC)CC3)O2)O1 KQXDHUJYNAXLNZ-XQSDOZFQSA-N 0.000 description 5
- 239000004189 Salinomycin Substances 0.000 description 5
- 238000006069 Suzuki reaction reaction Methods 0.000 description 5
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 5
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 5
- 239000004012 Tofacitinib Substances 0.000 description 5
- MXDSJQHFFDGFDK-CYBMUJFWSA-N [4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl] (2r)-2,4-dimethylpiperazine-1-carboxylate Chemical compound C=12C=C(OC(=O)N3[C@@H](CN(C)CC3)C)C(OC)=CC2=NC=NC=1NC1=CC=CC(Cl)=C1F MXDSJQHFFDGFDK-CYBMUJFWSA-N 0.000 description 5
- OOUACICUAVTCEC-LZHWUUGESA-N aezs-108 Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)COC(=O)CCCC(=O)NCCCC[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 OOUACICUAVTCEC-LZHWUUGESA-N 0.000 description 5
- 229960001611 alectinib Drugs 0.000 description 5
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 229960003982 apatinib Drugs 0.000 description 5
- 229960000397 bevacizumab Drugs 0.000 description 5
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 description 5
- 229960001467 bortezomib Drugs 0.000 description 5
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 5
- 229950004272 brigatinib Drugs 0.000 description 5
- 229960001602 ceritinib Drugs 0.000 description 5
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 230000000875 corresponding effect Effects 0.000 description 5
- GTBRTGPZZALPNS-MXHVRSFHSA-N cyanoketone Chemical compound C1C=C2C(C)(C)C(=O)[C@H](C#N)C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GTBRTGPZZALPNS-MXHVRSFHSA-N 0.000 description 5
- 229960002448 dasatinib Drugs 0.000 description 5
- 229950000521 entrectinib Drugs 0.000 description 5
- 229960005167 everolimus Drugs 0.000 description 5
- 229950008085 figitumumab Drugs 0.000 description 5
- 229930000755 gossypol Natural products 0.000 description 5
- 229950005277 gossypol Drugs 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 229960002411 imatinib Drugs 0.000 description 5
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 5
- 229950002133 iniparib Drugs 0.000 description 5
- 229950003970 larotrectinib Drugs 0.000 description 5
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 5
- 229960003784 lenvatinib Drugs 0.000 description 5
- 229950001290 lorlatinib Drugs 0.000 description 5
- IIXWYSCJSQVBQM-LLVKDONJSA-N lorlatinib Chemical compound N=1N(C)C(C#N)=C2C=1CN(C)C(=O)C1=CC=C(F)C=C1[C@@H](C)OC1=CC2=CN=C1N IIXWYSCJSQVBQM-LLVKDONJSA-N 0.000 description 5
- 108700003825 lysine(6)-doxorubicin LHRH Proteins 0.000 description 5
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 5
- HAYYBYPASCDWEQ-UHFFFAOYSA-N n-[5-[(3,5-difluorophenyl)methyl]-1h-indazol-3-yl]-4-(4-methylpiperazin-1-yl)-2-(oxan-4-ylamino)benzamide Chemical compound C1CN(C)CCN1C(C=C1NC2CCOCC2)=CC=C1C(=O)NC(C1=C2)=NNC1=CC=C2CC1=CC(F)=CC(F)=C1 HAYYBYPASCDWEQ-UHFFFAOYSA-N 0.000 description 5
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 description 5
- 229950004847 navitoclax Drugs 0.000 description 5
- 229960001346 nilotinib Drugs 0.000 description 5
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 5
- 229950006584 obatoclax Drugs 0.000 description 5
- 229960000572 olaparib Drugs 0.000 description 5
- FAQDUNYVKQKNLD-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC2=C3[CH]C=CC=C3C(=O)N=N2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FAQDUNYVKQKNLD-UHFFFAOYSA-N 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 229960002087 pertuzumab Drugs 0.000 description 5
- YJGVMLPVUAXIQN-HAEOHBJNSA-N picropodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-HAEOHBJNSA-N 0.000 description 5
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229940121602 repotrectinib Drugs 0.000 description 5
- FIKPXCOQUIZNHB-WDEREUQCSA-N repotrectinib Chemical compound C[C@H]1CNC(=O)C2=C3N=C(N[C@H](C)C4=C(O1)C=CC(F)=C4)C=CN3N=C2 FIKPXCOQUIZNHB-WDEREUQCSA-N 0.000 description 5
- 229960001548 salinomycin Drugs 0.000 description 5
- 235000019378 salinomycin Nutrition 0.000 description 5
- WUILNKCFCLNXOK-CFBAGHHKSA-N salirasib Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CSC1=CC=CC=C1C(O)=O WUILNKCFCLNXOK-CFBAGHHKSA-N 0.000 description 5
- 229950008669 salirasib Drugs 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 229960003787 sorafenib Drugs 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 229960001796 sunitinib Drugs 0.000 description 5
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- 238000002626 targeted therapy Methods 0.000 description 5
- 229960000235 temsirolimus Drugs 0.000 description 5
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 5
- 229950009158 tipifarnib Drugs 0.000 description 5
- 229960001350 tofacitinib Drugs 0.000 description 5
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 5
- 229960004066 trametinib Drugs 0.000 description 5
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 229960000575 trastuzumab Drugs 0.000 description 5
- 229940049679 trastuzumab deruxtecan Drugs 0.000 description 5
- 229960001612 trastuzumab emtansine Drugs 0.000 description 5
- 229950003463 tucatinib Drugs 0.000 description 5
- 229960002360 vintafolide Drugs 0.000 description 5
- KUZYSQSABONDME-QRLOMCMNSA-N vintafolide Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C=4C=CC(NCC=5N=C6C(=O)NC(N)=NC6=NC=5)=CC=4)C(O)=O)C(O)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KUZYSQSABONDME-QRLOMCMNSA-N 0.000 description 5
- 229950006580 zoptarelin doxorubicin Drugs 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 description 4
- OZMLUMPWPFZWTP-UHFFFAOYSA-N 2-(tributyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound CCCCP(CCCC)(CCCC)=CC#N OZMLUMPWPFZWTP-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 238000006751 Mitsunobu reaction Methods 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 150000008052 alkyl sulfonates Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 4
- 235000011056 potassium acetate Nutrition 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000001632 sodium acetate Substances 0.000 description 4
- 235000017281 sodium acetate Nutrition 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 229910052723 transition metal Inorganic materials 0.000 description 4
- 150000003624 transition metals Chemical class 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- JVVRJMXHNUAPHW-UHFFFAOYSA-N 1h-pyrazol-5-amine Chemical class NC=1C=CNN=1 JVVRJMXHNUAPHW-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 239000007848 Bronsted acid Substances 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000004103 aminoalkyl group Chemical group 0.000 description 3
- 150000005840 aryl radicals Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 125000005345 deuteroalkyl group Chemical group 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 231100000225 lethality Toxicity 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 3
- OVEHNNQXLPJPPL-UHFFFAOYSA-N lithium;n-propan-2-ylpropan-2-amine Chemical compound [Li].CC(C)NC(C)C OVEHNNQXLPJPPL-UHFFFAOYSA-N 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- FSXCKIBROURMFT-VGSWGCGISA-N (3ar,6ar)-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]-1-methyl-2,3,3a,4,6,6a-hexahydropyrrolo[2,3-c]pyrrole-5-carboxamide Chemical compound C=12C=C(NC(=O)N3C[C@@H]4N(C)CC[C@@H]4C3)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 FSXCKIBROURMFT-VGSWGCGISA-N 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- ODIUNTQOXRXOIV-UHFFFAOYSA-N 1-[6-[[6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]sulfanyl]-1,3-benzothiazol-2-yl]-3-(2-morpholin-4-ylethyl)urea Chemical compound C1=CC(F)=CC=C1C1=NN2C(SC=3C=C4SC(NC(=O)NCCN5CCOCC5)=NC4=CC=3)=NN=C2C=C1 ODIUNTQOXRXOIV-UHFFFAOYSA-N 0.000 description 2
- CEGSUKYESLWKJP-UHFFFAOYSA-N 1-n-[2-(1h-indol-3-yl)ethyl]-4-n-pyridin-4-ylbenzene-1,4-diamine Chemical compound C=1NC2=CC=CC=C2C=1CCNC(C=C1)=CC=C1NC1=CC=NC=C1 CEGSUKYESLWKJP-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- NEUWPDLMDVINSN-UHFFFAOYSA-N 1h-pyrazol-5-ylboronic acid Chemical compound OB(O)C=1C=CNN=1 NEUWPDLMDVINSN-UHFFFAOYSA-N 0.000 description 2
- KJFJIEHJCVSAKJ-UHFFFAOYSA-N 2-(trimethyl-$l^{5}-phosphanylidene)acetonitrile Chemical compound CP(C)(C)=CC#N KJFJIEHJCVSAKJ-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 2
- FPZMKWNKHQRDMW-UHFFFAOYSA-N 4-(15'-acetyloxy-4-hydroxy-2',6,11'-trimethyl-7'-methylidene-2,6'-dioxospiro[3a,4,7,7a-tetrahydro-1-benzofuran-3,13'-5-oxatetracyclo[10.2.1.01,10.04,8]pentadec-10-ene]-5-yl)pentyl acetate Chemical compound CC(CCCOC(=O)C)C1=C(C)CC2OC(=O)C3(CC45C(C)CC6OC(=O)C(=C)C6CC4=C(C)C3C5OC(=O)C)C2C1O FPZMKWNKHQRDMW-UHFFFAOYSA-N 0.000 description 2
- PXACTUVBBMDKRW-UHFFFAOYSA-M 4-bromobenzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=C(Br)C=C1 PXACTUVBBMDKRW-UHFFFAOYSA-M 0.000 description 2
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 2
- SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 2
- QHXLXUIZUCJRKV-UHFFFAOYSA-N 6-(1-cyclopropylpyrazol-4-yl)-3-[difluoro-(6-fluoro-2-methylindazol-5-yl)methyl]-[1,2,4]triazolo[4,3-b]pyridazine Chemical compound FC1=CC2=NN(C)C=C2C=C1C(F)(F)C(N1N=2)=NN=C1C=CC=2C(=C1)C=NN1C1CC1 QHXLXUIZUCJRKV-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 108010014778 ATSP-7041 Proteins 0.000 description 2
- VRQMAABPASPXMW-HDICACEKSA-N AZD4547 Chemical compound COC1=CC(OC)=CC(CCC=2NN=C(NC(=O)C=3C=CC(=CC=3)N3C[C@@H](C)N[C@@H](C)C3)C=2)=C1 VRQMAABPASPXMW-HDICACEKSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- QFUIJOBJAQBGDH-HNNXBMFYSA-N C(C=C)(=O)N1C[C@H](CC1)N1N=C(C(=C1NC)C(=O)N)C#CC1=CC(=CC(=C1)OC)OC Chemical compound C(C=C)(=O)N1C[C@H](CC1)N1N=C(C(=C1NC)C(=O)N)C#CC1=CC(=CC(=C1)OC)OC QFUIJOBJAQBGDH-HNNXBMFYSA-N 0.000 description 2
- YJCZPJQGFSSFOL-MNZPCBJKSA-N CCN1[C@H]([C@H](C2=CC=CC(Cl)=C2F)[C@]2(C(=O)NC3=CC(Cl)=CC=C23)C11CCCCC1)C(=O)NC12CCC(CC1)(CC2)C(O)=O Chemical compound CCN1[C@H]([C@H](C2=CC=CC(Cl)=C2F)[C@]2(C(=O)NC3=CC(Cl)=CC=C23)C11CCCCC1)C(=O)NC12CCC(CC1)(CC2)C(O)=O YJCZPJQGFSSFOL-MNZPCBJKSA-N 0.000 description 2
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 208000006402 Ductal Carcinoma Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 229940124785 KRAS inhibitor Drugs 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 208000000265 Lobular Carcinoma Diseases 0.000 description 2
- 239000012819 MDM2-Inhibitor Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 208000032818 Microsatellite Instability Diseases 0.000 description 2
- 238000003461 Miyaura Borylation reaction Methods 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- DOEOECWDNSEFDN-UHFFFAOYSA-N N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide Chemical compound C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC DOEOECWDNSEFDN-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 2
- WGVWLKXZBUVUAM-UHFFFAOYSA-N Pentanochlor Chemical compound CCCC(C)C(=O)NC1=CC=C(C)C(Cl)=C1 WGVWLKXZBUVUAM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 101100226004 Rattus norvegicus Erc2 gene Proteins 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 2
- 206010061934 Salivary gland cancer Diseases 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 238000006619 Stille reaction Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 2
- 125000005233 alkylalcohol group Chemical group 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 229940008421 amivantamab Drugs 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 150000001499 aryl bromides Chemical class 0.000 description 2
- 150000001500 aryl chlorides Chemical class 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000005604 azodicarboxylate group Chemical group 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 201000003714 breast lobular carcinoma Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- FINPLSBBDVRBPA-UHFFFAOYSA-M chloropalladium(1+);dicyclohexyl-[2-[2,6-di(propan-2-yloxy)phenyl]phenyl]phosphane;2-methoxy-2-methylpropane;2-phenylethanamine Chemical compound [Pd+]Cl.COC(C)(C)C.NCCC1=CC=CC=[C-]1.CC(C)OC1=CC=CC(OC(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 FINPLSBBDVRBPA-UHFFFAOYSA-M 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229950001762 linsitinib Drugs 0.000 description 2
- PKCDDUHJAFVJJB-VLZXCDOPSA-N linsitinib Chemical compound C1[C@](C)(O)C[C@@H]1C1=NC(C=2C=C3N=C(C=CC3=CC=2)C=2C=CC=CC=2)=C2N1C=CN=C2N PKCDDUHJAFVJJB-VLZXCDOPSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 230000004777 loss-of-function mutation Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical group OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 229950010203 nimotuzumab Drugs 0.000 description 2
- 150000002829 nitrogen Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000005956 quaternization reaction Methods 0.000 description 2
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical group OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000005694 sulfonylation reaction Methods 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical group CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 229950005976 tivantinib Drugs 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- CLRSLRWKONPSRQ-CPOWQTMSSA-N (1s)-1-(4-chlorophenyl)-6-methoxy-2-[4-[methyl-[[4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]methyl]amino]phenyl]-7-propan-2-yloxy-1,4-dihydroisoquinolin-3-one Chemical compound C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)CC2CCC(CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 CLRSLRWKONPSRQ-CPOWQTMSSA-N 0.000 description 1
- UNXQGBMZYKHQCO-NVHWNKAKSA-N (2'r,3s,3'r,5'r)-6-chloro-3'-(3-chlorophenyl)-n-[(3s)-3,4-dihydroxybutyl]-5'-(2,2-dimethylpropyl)-5-fluoro-2-oxospiro[1h-indole-3,4'-pyrrolidine]-2'-carboxamide Chemical compound C1([C@H]2[C@@H](N[C@@H]([C@@]22C3=CC(F)=C(Cl)C=C3NC2=O)CC(C)(C)C)C(=O)NCC[C@H](O)CO)=CC=CC(Cl)=C1 UNXQGBMZYKHQCO-NVHWNKAKSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JYFKDBFPRXMUAM-LREBCSMRSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;1-n'-[2-fluoro-4-[2-[[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]amino]pyridin-4-yl]oxyphenyl]-1-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1CN(C)CCN1C1CCN(C(=O)NC=2N=CC=C(OC=3C=C(F)C(NC(=O)C4(CC4)C(=O)NC=4C=CC(F)=CC=4)=CC=3)C=2)CC1 JYFKDBFPRXMUAM-LREBCSMRSA-N 0.000 description 1
- RYAYYVTWKAOAJF-QISPRATLSA-N (3'r,4's,5'r)-n-[(3r,6s)-6-carbamoyltetrahydro-2h-pyran-3-yl]-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxo-1'',2''-dihydrodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indole]-5'-carboxamide Chemical compound C1CC(C)(C)CCC21[C@]1(C3=CC=C(Cl)C=C3NC1=O)[C@@H](C=1C(=C(Cl)N=CC=1)F)[C@H](C(=O)N[C@H]1CO[C@@H](CC1)C(N)=O)N2 RYAYYVTWKAOAJF-QISPRATLSA-N 0.000 description 1
- YYACLQUDUDXAPA-MRXNPFEDSA-N (3r)-n-[3-[5-(2-cyclopropylpyrimidin-5-yl)-1h-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl]-3-fluoropyrrolidine-1-sulfonamide Chemical compound C1[C@H](F)CCN1S(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=NC(=NC=2)C2CC2)=C1F YYACLQUDUDXAPA-MRXNPFEDSA-N 0.000 description 1
- KPJDVVCDVBFRMU-AREMUKBSSA-N (6r)-6-(2-fluorophenyl)-n-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine Chemical compound COCCNCCC1=CC=CC(NC=2N=C3C4=CC=CC=C4[C@H](C=4C(=CC=CC=4)F)CC3=CN=2)=C1 KPJDVVCDVBFRMU-AREMUKBSSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006748 (C2-C10) heterocycloalkenyl group Chemical group 0.000 description 1
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 description 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
- RTAAZCCTCLCXHX-AATRIKPKSA-N (E)-N-[4-(3-chloro-4-fluoroanilino)-7-ethoxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound ClC=1C=C(C=CC=1F)NC1=NC=NC2=CC(=C(C=C12)NC(\C=C\CN(C)C)=O)OCC RTAAZCCTCLCXHX-AATRIKPKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SADXACCFNXBCFY-IYNHSRRRSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2r)-1-methylpyrrolidin-2-yl]prop-2-enamide Chemical compound C=12C=C(NC(=O)\C=C\[C@@H]3N(CCC3)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 SADXACCFNXBCFY-IYNHSRRRSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000005988 1,1-dioxo-thiomorpholinyl group Chemical group 0.000 description 1
- AEBWATHAIVJLTA-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydropentalene Chemical compound C1CCC2CCCC21 AEBWATHAIVJLTA-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- ZRBPIAWWRPFDPY-IRXDYDNUSA-N 1-[(3S)-4-[7-[6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl]-6-chloro-8-fluoro-2-[[(2S)-1-methylpyrrolidin-2-yl]methoxy]quinazolin-4-yl]-3-methylpiperazin-1-yl]prop-2-en-1-one Chemical compound NC1=NC(=C(C(=C1)C)C(F)(F)F)C1=C(Cl)C=C2C(N3CCN(C[C@@H]3C)C(=O)C=C)=NC(=NC2=C1F)OC[C@H]1N(C)CCC1 ZRBPIAWWRPFDPY-IRXDYDNUSA-N 0.000 description 1
- LPFWVDIFUFFKJU-UHFFFAOYSA-N 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one Chemical compound C=12C=C(OC3CCN(CC3)C(=O)C=C)C(OC)=CC2=NC=NC=1NC1=CC=C(Cl)C(Cl)=C1F LPFWVDIFUFFKJU-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- AMMPLVWPWSYRDR-UHFFFAOYSA-N 1-methylbicyclo[2.2.2]oct-2-ene-4-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C)C=C2 AMMPLVWPWSYRDR-UHFFFAOYSA-N 0.000 description 1
- CZDWSKBKCZWXFI-UHFFFAOYSA-N 1-morpholin-4-yl-3-[4-oxo-3-[4-[2-oxo-2-(4-propan-2-ylpiperazin-1-yl)ethoxy]phenyl]-1h-indeno[1,2-c]pyrazol-5-yl]urea Chemical compound C1CN(C(C)C)CCN1C(=O)COC1=CC=C(C=2C=3C(=O)C4=C(NC(=O)NN5CCOCC5)C=CC=C4C=3NN=2)C=C1 CZDWSKBKCZWXFI-UHFFFAOYSA-N 0.000 description 1
- 125000005987 1-oxo-thiomorpholinyl group Chemical group 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- HMBHAQMOBKLWRX-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C(=O)O)COC2=C1 HMBHAQMOBKLWRX-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- QLUYMIVVAYRECT-OCCSQVGLSA-N 2-(2-chlorophenyl)-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O QLUYMIVVAYRECT-OCCSQVGLSA-N 0.000 description 1
- NFTJDXGFOUFNKG-UGBNQVSOSA-N 2-[(E)-2-(2,6-dichlorophenyl)ethenyl]-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one Chemical compound ClC1=C(/C=C/C=2OC3=C(C(=CC(=C3C(C=2)=O)O)O)[C@@H]2[C@@H](CN(CC2)C)O)C(=CC=C1)Cl NFTJDXGFOUFNKG-UGBNQVSOSA-N 0.000 description 1
- MRPGRAKIAJJGMM-OCCSQVGLSA-N 2-[2-chloro-4-(trifluoromethyl)phenyl]-5,7-dihydroxy-8-[(2r,3s)-2-(hydroxymethyl)-1-methylpyrrolidin-3-yl]chromen-4-one Chemical compound OC[C@@H]1N(C)CC[C@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC(=CC=1)C(F)(F)F)Cl)=CC2=O MRPGRAKIAJJGMM-OCCSQVGLSA-N 0.000 description 1
- IFYMUYSGUSHEPI-NTUHNPAUSA-N 2-[5-[(Z)-(6-chloro-7-methylindol-3-ylidene)methyl]-4-hydroxy-2-oxo-1H-imidazol-3-yl]-2-(3,4-difluorophenyl)-N-(1,3-dihydroxypropan-2-yl)acetamide Chemical compound Cc1c2N=C\C(=C/c3[nH]c(=O)n(C(C(=O)NC(CO)CO)c4ccc(F)c(F)c4)c3O)c2ccc1Cl IFYMUYSGUSHEPI-NTUHNPAUSA-N 0.000 description 1
- PDGKHKMBHVFCMG-UHFFFAOYSA-N 2-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[7,8-dihydropyrazino[5,6]pyrrolo[1,2-d]pyrimidine-9,1'-cyclohexane]-6-one Chemical compound C1CN(C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 PDGKHKMBHVFCMG-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical group C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000006088 2-oxoazepinyl group Chemical group 0.000 description 1
- 125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
- 125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- PUMGFEMNXBLDKD-UHFFFAOYSA-N 3,6-diaminoacridine-9-carbonitrile Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C(C#N)=C21 PUMGFEMNXBLDKD-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- XYDNMOZJKOGZLS-NSHDSACASA-N 3-[(1s)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine Chemical compound N1=C2N([C@H](C3=CN4C=CN=C4C=C3)C)N=NC2=NC=C1C=1C=NN(C)C=1 XYDNMOZJKOGZLS-NSHDSACASA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- ORRNXRYWGDUDOG-UHFFFAOYSA-N 4-[2-fluoro-4-[(2-phenylacetyl)carbamothioylamino]phenoxy]-7-methoxy-n-methylquinoline-6-carboxamide Chemical compound C1=CN=C2C=C(OC)C(C(=O)NC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=S)NC(=O)CC1=CC=CC=C1 ORRNXRYWGDUDOG-UHFFFAOYSA-N 0.000 description 1
- SCLLZBIBSFTLIN-INOGPEIASA-N 4-[4-[(1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl]-8-fluoro-2-[[(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methoxy]pyrido[4,3-d]pyrimidin-7-yl]-5-ethynyl-6-fluoronaphthalen-2-ol Chemical compound C#CC1=C2C(C(N=CC(C(N3C[C@H](CC4)N[C@H]4C3)=N3)=C4N=C3OC[C@](CCC3)(C5)N3C[C@@H]5F)=C4F)=CC(O)=CC2=CC=C1F SCLLZBIBSFTLIN-INOGPEIASA-N 0.000 description 1
- HNLRRJSKGXOYNO-UHFFFAOYSA-N 4-[[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl]piperazin-2-one Chemical compound N12N=CN=C(N)C2=C(C=2SC3=C(OC)C=C(C)C=C3C=2)C(COC)=C1CN1CCNC(=O)C1 HNLRRJSKGXOYNO-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- DQAZPZIYEOGZAF-UHFFFAOYSA-N 4-ethyl-n-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]piperazine-1-carboxamide Chemical compound C1CN(CC)CCN1C(=O)NC(C(=CC1=NC=N2)OC)=CC1=C2NC1=CC=CC(C#C)=C1 DQAZPZIYEOGZAF-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- 125000005986 4-piperidonyl group Chemical group 0.000 description 1
- NGFFVZQXSRKHBM-FKBYEOEOSA-N 5-[[(1r,1as,6br)-1-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]-1a,6b-dihydro-1h-cyclopropa[b][1]benzofuran-5-yl]oxy]-3,4-dihydro-1h-1,8-naphthyridin-2-one Chemical compound N1C(=O)CCC2=C1N=CC=C2OC(C=C1[C@@H]23)=CC=C1O[C@@H]3[C@H]2C1=NC2=CC=C(C(F)(F)F)C=C2N1 NGFFVZQXSRKHBM-FKBYEOEOSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- DWHXUGDWKAIASB-CQSZACIVSA-N 6-[(1r)-1-[8-fluoro-6-(1-methylpyrazol-4-yl)-[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl]-3-(2-methoxyethoxy)-1,6-naphthyridin-5-one Chemical compound C=1N2C([C@@H](C)N3C=CC4=NC=C(C=C4C3=O)OCCOC)=NN=C2C(F)=CC=1C=1C=NN(C)C=1 DWHXUGDWKAIASB-CQSZACIVSA-N 0.000 description 1
- KOAWAWHSMVKCON-UHFFFAOYSA-N 6-[difluoro-(6-pyridin-4-yl-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl]quinoline Chemical compound C=1C=C2N=CC=CC2=CC=1C(F)(F)C(N1N=2)=NN=C1C=CC=2C1=CC=NC=C1 KOAWAWHSMVKCON-UHFFFAOYSA-N 0.000 description 1
- JRWCBEOAFGHNNU-UHFFFAOYSA-N 6-[difluoro-[6-(1-methyl-4-pyrazolyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl]quinoline Chemical compound C1=NN(C)C=C1C1=NN2C(C(F)(F)C=3C=C4C=CC=NC4=CC=3)=NN=C2C=C1 JRWCBEOAFGHNNU-UHFFFAOYSA-N 0.000 description 1
- SGJLSPUSUBJWHO-UHFFFAOYSA-N 6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperidin-4-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1C1CCNCC1 SGJLSPUSUBJWHO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HEAIZQNMNCHNFD-UHFFFAOYSA-N AMG-208 Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OCC(N1N=2)=NN=C1C=CC=2C1=CC=CC=C1 HEAIZQNMNCHNFD-UHFFFAOYSA-N 0.000 description 1
- ZRPZPNYZFSJUPA-UHFFFAOYSA-N ARS-1620 Chemical compound Oc1cccc(F)c1-c1c(Cl)cc2c(ncnc2c1F)N1CCN(CC1)C(=O)C=C ZRPZPNYZFSJUPA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 238000012815 AlphaLISA Methods 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108091012583 BCL2 Proteins 0.000 description 1
- 229940126029 BDTX-189 Drugs 0.000 description 1
- 229940126643 BLU-945 Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 101100307232 Buchnera aphidicola subsp. Baizongia pistaciae (strain Bp) rpsN gene Proteins 0.000 description 1
- 238000007125 Buchwald synthesis reaction Methods 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- PITORJXKOJWMTN-SJLPKXTDSA-N C(C)(=O)C=1C(N(C2=CC(=NC=C2C=1C)N[C@H]1[C@@H](COCC1)O)C1CCCC1)=O Chemical compound C(C)(=O)C=1C(N(C2=CC(=NC=C2C=1C)N[C@H]1[C@@H](COCC1)O)C1CCCC1)=O PITORJXKOJWMTN-SJLPKXTDSA-N 0.000 description 1
- FZPYULHBUBXPIG-UHFFFAOYSA-N C1=C(NC2=NC=CC3=C(NC4=C(C=CC=N4)C4=C5N=CNC5=NC=N4)C(C)=CC=C23)C=C(OC(F)(F)F)C=C1 Chemical compound C1=C(NC2=NC=CC3=C(NC4=C(C=CC=N4)C4=C5N=CNC5=NC=N4)C(C)=CC=C23)C=C(OC(F)(F)F)C=C1 FZPYULHBUBXPIG-UHFFFAOYSA-N 0.000 description 1
- DKFRWZJCNPETGI-SJORKVTESA-N C1=NC(=C(C(=N1)C1CC1)N1C2=C(C=C(C(C3=C(C=CC=C3N)F)=N2)F)C(N2C[C@@H](C)N(C[C@@H]2C)C(=O)C=C)=NC1=O)C1CC1 Chemical compound C1=NC(=C(C(=N1)C1CC1)N1C2=C(C=C(C(C3=C(C=CC=C3N)F)=N2)F)C(N2C[C@@H](C)N(C[C@@H]2C)C(=O)C=C)=NC1=O)C1CC1 DKFRWZJCNPETGI-SJORKVTESA-N 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- GHKOONMJXNWOIW-UHFFFAOYSA-N CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)C)C Chemical compound CN(CCN(C1=NC(=C(C=C1NC(C=C)=O)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)OCC(F)(F)F)C)C GHKOONMJXNWOIW-UHFFFAOYSA-N 0.000 description 1
- BPMZUKYFIDPLEA-UHFFFAOYSA-N CN(CCOC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)C Chemical compound CN(CCOC1=C(C=C(C(=C1)OC)NC1=NC=CC(=N1)C1=CN(C2=CC=CC=C12)C)NC(C=C)=O)C BPMZUKYFIDPLEA-UHFFFAOYSA-N 0.000 description 1
- RYBLECYFLJXEJX-UHFFFAOYSA-N CN1C=C(C=N1)C1=CN2C(C=C1)=NC=C2S(=O)(=O)N1N=CC2=NC=C(C=C12)C1=CN(C)N=C1 Chemical compound CN1C=C(C=N1)C1=CN2C(C=C1)=NC=C2S(=O)(=O)N1N=CC2=NC=C(C=C12)C1=CN(C)N=C1 RYBLECYFLJXEJX-UHFFFAOYSA-N 0.000 description 1
- AVIOBQFPAGEICQ-UHFFFAOYSA-N COC1=CC(F)=CC=C1C1=C(C)SC2=C1N=C(NC1=CN(N=C1)C1CCNCC1)N=C2 Chemical compound COC1=CC(F)=CC=C1C1=C(C)SC2=C1N=C(NC1=CN(N=C1)C1CCNCC1)N=C2 AVIOBQFPAGEICQ-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010050337 Cerumen impaction Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- VVLVISDSGRHLMB-UHFFFAOYSA-N ClC1=C(C=CC(=C1NC=1C(=C2C(N(C=NC2=CC=1)C)=O)C)F)NS(=O)(=O)CCCF Chemical compound ClC1=C(C=CC(=C1NC=1C(=C2C(N(C=NC2=CC=1)C)=O)C)F)NS(=O)(=O)CCCF VVLVISDSGRHLMB-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101710190440 Cytotoxin 1 Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical group OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102100037713 Down syndrome cell adhesion molecule Human genes 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- RIHUDRGMCALEAK-HXUWFJFHSA-N FC1(CN(CC[C@H]1OC=1C=C2C(=NC=NC2=CC=1OC)NC1=C(C(=CC=C1)C#C)F)C)F Chemical compound FC1(CN(CC[C@H]1OC=1C=C2C(=NC=NC2=CC=1OC)NC1=C(C(=CC=C1)C#C)F)C)F RIHUDRGMCALEAK-HXUWFJFHSA-N 0.000 description 1
- 229940125407 FGF401 Drugs 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 description 1
- 229940126265 GDC-6036 Drugs 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical group OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 238000003649 HTRF KinEASE Methods 0.000 description 1
- 238000007341 Heck reaction Methods 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 description 1
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 description 1
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 1
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000005577 Kumada cross-coupling reaction Methods 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical group OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229940125430 LUT-014 Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Chemical group OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- LIMFPAAAIVQRRD-BCGVJQADSA-N N-[2-[(3S,4R)-3-fluoro-4-methoxypiperidin-1-yl]pyrimidin-4-yl]-8-[(2R,3S)-2-methyl-3-(methylsulfonylmethyl)azetidin-1-yl]-5-propan-2-ylisoquinolin-3-amine Chemical compound F[C@H]1CN(CC[C@H]1OC)C1=NC=CC(=N1)NC=1N=CC2=C(C=CC(=C2C=1)C(C)C)N1[C@@H]([C@H](C1)CS(=O)(=O)C)C LIMFPAAAIVQRRD-BCGVJQADSA-N 0.000 description 1
- PLUKVDOZEJBBIS-UHFFFAOYSA-N N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=C(C=C(C(=C1)NC1=NC=CC(=N1)C1=C2N(C3=CC=CC=C13)CCCC2)OC)N(C)CCN(C)C PLUKVDOZEJBBIS-UHFFFAOYSA-N 0.000 description 1
- WDPGHXINXNBHAS-UHFFFAOYSA-N N-[2-[2-(dimethylamino)ethyl-methylamino]-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]-6-(2,2,2-trifluoroethoxy)pyridin-3-yl]prop-2-enamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CN(C)CCN(C)c1nc(OCC(F)(F)F)c(Nc2nccc(n2)-c2cn(C)c3ccccc23)cc1NC(=O)C=C WDPGHXINXNBHAS-UHFFFAOYSA-N 0.000 description 1
- MBWRLLRCTIYXDW-UHFFFAOYSA-N N-[2-[[6-[(2,6-dichloro-3,5-dimethoxyphenyl)carbamoyl-methylamino]pyrimidin-4-yl]amino]-5-(4-ethylpiperazin-1-yl)phenyl]prop-2-enamide Chemical compound ClC1=C(C(=C(C=C1OC)OC)Cl)NC(N(C)C1=CC(=NC=N1)NC1=C(C=C(C=C1)N1CCN(CC1)CC)NC(C=C)=O)=O MBWRLLRCTIYXDW-UHFFFAOYSA-N 0.000 description 1
- HIBPKFXWOPYJPZ-UHFFFAOYSA-N N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-7-(2-morpholin-4-ylethoxy)quinazolin-6-yl]prop-2-enamide Chemical compound ClC1=C(OCC2=NC=CC=C2)C=CC(NC2=NC=NC3=CC(OCCN4CCOCC4)=C(NC(=O)C=C)C=C23)=C1 HIBPKFXWOPYJPZ-UHFFFAOYSA-N 0.000 description 1
- RRMJMHOQSALEJJ-UHFFFAOYSA-N N-[5-[[4-[4-[(dimethylamino)methyl]-3-phenylpyrazol-1-yl]pyrimidin-2-yl]amino]-4-methoxy-2-morpholin-4-ylphenyl]prop-2-enamide Chemical compound CN(C)CC=1C(=NN(C=1)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N1CCOCC1)OC)C1=CC=CC=C1 RRMJMHOQSALEJJ-UHFFFAOYSA-N 0.000 description 1
- BTMKEDDEMKKSEF-QGZVFWFLSA-N N-[5-[[4-[5-chloro-4-fluoro-2-(2-hydroxypropan-2-yl)anilino]pyrimidin-2-yl]amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl]prop-2-enamide Chemical compound C(C=C)(=O)NC1=C(C=C(C(=C1)NC1=NC=CC(=N1)NC1=C(C=C(C(=C1)Cl)F)C(C)(C)O)OC)N1C[C@@H](CC1)N(C)C BTMKEDDEMKKSEF-QGZVFWFLSA-N 0.000 description 1
- BHKDKKZMPODMIQ-UHFFFAOYSA-N N-[5-cyano-4-(2-methoxyethylamino)pyridin-2-yl]-7-formyl-6-[(4-methyl-2-oxopiperazin-1-yl)methyl]-3,4-dihydro-2H-1,8-naphthyridine-1-carboxamide Chemical compound COCCNc1cc(NC(=O)N2CCCc3cc(CN4CCN(C)CC4=O)c(C=O)nc23)ncc1C#N BHKDKKZMPODMIQ-UHFFFAOYSA-N 0.000 description 1
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 description 1
- ZYSKXRAGBGLELB-UHFFFAOYSA-N N1(C)CCN(CC1)C1CCN(CC1)C1=C(C)C=C(C(OC)=C1)NC1=NC=C(Br)C(NC2=C(P(=O)(C)C)C3=C(C=C2)N=CC=N3)=N1 Chemical compound N1(C)CCN(CC1)C1CCN(CC1)C1=C(C)C=C(C(OC)=C1)NC1=NC=C(Br)C(NC2=C(P(=O)(C)C)C3=C(C=C2)N=CC=N3)=N1 ZYSKXRAGBGLELB-UHFFFAOYSA-N 0.000 description 1
- OZUPICRWMLEFCS-LBPRGKRZSA-N NC1=C(C#N)C2=C(S1)C(F)=CC=C2C1=C(F)C=C2C(OCC[C@H]3CN(CCN3C2=O)C(=O)C=C)=C1Cl Chemical compound NC1=C(C#N)C2=C(S1)C(F)=CC=C2C1=C(F)C=C2C(OCC[C@H]3CN(CCN3C2=O)C(=O)C=C)=C1Cl OZUPICRWMLEFCS-LBPRGKRZSA-N 0.000 description 1
- MKCYPWYURWOKST-INIZCTEOSA-N NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 Chemical compound NC1=NC=NC2=C1C(=C1C(=C[C@@H](CN21)NC(C=C)=O)C)C=1C=NC2=CC=CC=C2C=1 MKCYPWYURWOKST-INIZCTEOSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 238000006411 Negishi coupling reaction Methods 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- DGVCEXQFNYYRQI-BTJKTKAUSA-N OC(=O)\C=C/C(O)=O.CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 Chemical compound OC(=O)\C=C/C(O)=O.CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 DGVCEXQFNYYRQI-BTJKTKAUSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000025618 Paget disease of nipple Diseases 0.000 description 1
- 208000024024 Paget disease of the nipple Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000002163 Phyllodes Tumor Diseases 0.000 description 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102100024933 Protein CASP Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108010086229 SYN-004 Proteins 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010054184 Small intestine carcinoma Diseases 0.000 description 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- VWMJHAFYPMOMGF-ZCFIWIBFSA-N TAK-580 Chemical compound N([C@H](C)C=1SC(=CN=1)C(=O)NC=1N=CC(Cl)=C(C=1)C(F)(F)F)C(=O)C1=NC=NC(N)=C1Cl VWMJHAFYPMOMGF-ZCFIWIBFSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- 238000006887 Ullmann reaction Methods 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- MUJMYVFVAWFUJL-SNAWJCMRSA-O [(e)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium Chemical compound CN1C=NC([N+]([O-])=O)=C1C[N+](C)(C)C\C=C\C(=O)NC(N=CC1=NC=N2)=CC1=C2NC1=CC=C(Cl)C(Br)=C1 MUJMYVFVAWFUJL-SNAWJCMRSA-O 0.000 description 1
- KXDZWUPUSDCGDD-UHFFFAOYSA-N [3-[[4-(2-amino-3-chloropyridin-4-yl)oxy-3-fluorophenyl]carbamoyl]-5-(4-fluorophenyl)-4-oxopyridin-1-yl]methyl dihydrogen phosphate Chemical compound NC1=NC=CC(OC=2C(=CC(NC(=O)C=3C(C(C=4C=CC(F)=CC=4)=CN(COP(O)(O)=O)C=3)=O)=CC=2)F)=C1Cl KXDZWUPUSDCGDD-UHFFFAOYSA-N 0.000 description 1
- BEMNJULZEQTDJY-UHFFFAOYSA-N [5-amino-1-(2-methyl-3h-benzimidazol-5-yl)pyrazol-4-yl]-(1h-indol-2-yl)methanone Chemical compound C1=CC=C2NC(C(=O)C=3C=NN(C=3N)C=3C=C4N=C(NC4=CC=3)C)=CC2=C1 BEMNJULZEQTDJY-UHFFFAOYSA-N 0.000 description 1
- UOFYSRZSLXWIQB-UHFFFAOYSA-N abivertinib Chemical compound C1CN(C)CCN1C(C(=C1)F)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(C=CN2)C2=N1 UOFYSRZSLXWIQB-UHFFFAOYSA-N 0.000 description 1
- 229940121401 abivertinib Drugs 0.000 description 1
- RPFYDENHBPRCTN-OAQYLSRUSA-N ac1ladru Chemical compound C1=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@@]5(O)CC)C4=NC2=CC2=C1OCO2 RPFYDENHBPRCTN-OAQYLSRUSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229940121523 aldafermin Drugs 0.000 description 1
- 108700013806 aldafermin Proteins 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- QUQGQIASFYWKAB-UHFFFAOYSA-N alofanib Chemical compound C1=C(C=2C=NC=CC=2)C(C)=CC([N+]([O-])=O)=C1NS(=O)(=O)C1=CC=CC(C(O)=O)=C1 QUQGQIASFYWKAB-UHFFFAOYSA-N 0.000 description 1
- 229950000749 alofanib Drugs 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 125000004653 anthracenylene group Chemical group 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229940124998 aumolertinib Drugs 0.000 description 1
- 125000002785 azepinyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229940038392 belvarafenib Drugs 0.000 description 1
- 229950009566 bemarituzumab Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005870 benzindolyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 125000005875 benzo[b][1,4]dioxepinyl group Chemical group 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005878 benzonaphthofuranyl group Chemical group 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
- GNTFBMAGLFYMMZ-UHFFFAOYSA-N bicyclo[3.2.2]nonane Chemical compound C1CC2CCC1CCC2 GNTFBMAGLFYMMZ-UHFFFAOYSA-N 0.000 description 1
- WMRPOCDOMSNXCQ-UHFFFAOYSA-N bicyclo[3.3.2]decane Chemical compound C1CCC2CCCC1CC2 WMRPOCDOMSNXCQ-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical group O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 210000002939 cerumen Anatomy 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229940075419 choline hydroxide Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- NNBZCPXTIHJBJL-AOOOYVTPSA-N cis-decalin Chemical compound C1CCC[C@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-AOOOYVTPSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940126523 co-drug Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 125000005507 decahydroisoquinolyl group Chemical group 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 229950002756 depatuxizumab Drugs 0.000 description 1
- 229940069586 derazantinib Drugs 0.000 description 1
- 125000005509 dibenzothiophenyl group Chemical group 0.000 description 1
- IWMMXPNBCHCFCY-UHFFFAOYSA-M dicyclohexyl-[3,6-dimethoxy-2-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane;palladium(2+);2-phenylethanamine;chloride Chemical compound [Pd+]Cl.NCCC1=CC=CC=[C-]1.COC1=CC=C(OC)C(C=2C(=CC(=CC=2C(C)C)C(C)C)C(C)C)=C1P(C1CCCCC1)C1CCCCC1 IWMMXPNBCHCFCY-UHFFFAOYSA-M 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- HXINDCTZKGGRDE-JPKZNVRTSA-L disodium;[3-[5-[2-[[(3r)-1-(1-methylpyrazol-3-yl)sulfonylpiperidin-3-yl]amino]pyrimidin-4-yl]imidazo[2,1-b][1,3]oxazol-6-yl]phenoxy]methyl phosphate Chemical compound [Na+].[Na+].CN1C=CC(S(=O)(=O)N2C[C@@H](CCC2)NC=2N=C(C=CN=2)C=2N3C=COC3=NC=2C=2C=C(OCOP([O-])([O-])=O)C=CC=2)=N1 HXINDCTZKGGRDE-JPKZNVRTSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940126354 elzovantinib Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- IBCIAMOTBDGBJN-NRLRZRKLSA-N epertinib Chemical compound C=1C=C2N=CN=C(NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=CC=1C(/C#CC)=N/OC[C@H]1COCCN1 IBCIAMOTBDGBJN-NRLRZRKLSA-N 0.000 description 1
- 229950005076 epertinib Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000003020 exocrine pancreas Anatomy 0.000 description 1
- 201000008815 extraosseous osteosarcoma Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- PWUOOJVYZQILBG-UHFFFAOYSA-N fascaplysine Chemical compound [Cl-].C1=CC=C2C3=CC=[N+]4C5=CC=CC=C5C(=O)C4=C3NC2=C1 PWUOOJVYZQILBG-UHFFFAOYSA-N 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 229950002846 ficlatuzumab Drugs 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- MGZKYOAQVGSSGC-DLBZAZTESA-N fisogatinib Chemical compound COc1cc(OC)c(Cl)c(c1Cl)-c1ccc2nc(N[C@@H]3COCC[C@@H]3NC(=O)C=C)ncc2c1 MGZKYOAQVGSSGC-DLBZAZTESA-N 0.000 description 1
- 229940121561 fisogatinib Drugs 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 229950008692 foretinib Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000003844 furanonyl group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000000174 gluconic acid Chemical group 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Chemical group 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229940125219 gunagratinib Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 102000048620 human CHEK1 Human genes 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- BNRNAKTVFSZAFA-UHFFFAOYSA-N hydrindane Chemical compound C1CCCC2CCCC21 BNRNAKTVFSZAFA-UHFFFAOYSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 229950007440 icotinib Drugs 0.000 description 1
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 description 1
- 229950005646 imgatuzumab Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229950009640 lazertinib Drugs 0.000 description 1
- YPJRHEKCFKOVRT-UHFFFAOYSA-N lerociclib Chemical compound C1CN(C(C)C)CCN1C(C=N1)=CC=C1NC1=NC=C(C=C2N3C4(CCCCC4)CNC2=O)C3=N1 YPJRHEKCFKOVRT-UHFFFAOYSA-N 0.000 description 1
- 229940121577 lerociclib Drugs 0.000 description 1
- 229950009767 lifirafenib Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- WGOPGODQLGJZGL-UHFFFAOYSA-N lithium;butane Chemical compound [Li+].CC[CH-]C WGOPGODQLGJZGL-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000010453 lymph node cancer Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229950002736 marizomib Drugs 0.000 description 1
- 210000001006 meconium Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229950009580 merestinib Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 229950009775 milademetan Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229940015637 mobocertinib Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- JSKJFDXTKYWPAH-UHFFFAOYSA-N n-[2-chloro-3-(1-cyclopropyl-8-methoxy-2h-pyrazolo[3,4-c]isoquinolin-7-yl)-4-fluorophenyl]-3-fluoropropane-1-sulfonamide Chemical compound COC1=CC=2C3=C(C4CC4)NN=C3N=CC=2C=C1C1=C(F)C=CC(NS(=O)(=O)CCCF)=C1Cl JSKJFDXTKYWPAH-UHFFFAOYSA-N 0.000 description 1
- FDMQDKQUTRLUBU-UHFFFAOYSA-N n-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide Chemical compound C1CN(C)CCN1C(C=C1)=CC=C1NC1=NC(OC=2C=C(NC(=O)C=C)C=CC=2)=C(SC=C2)C2=N1 FDMQDKQUTRLUBU-UHFFFAOYSA-N 0.000 description 1
- AEJACXAFHXBVHF-UHFFFAOYSA-N n-[3-[5-[(1-ethylpiperidin-4-yl)-methylamino]-3-pyrimidin-5-ylpyrrolo[3,2-b]pyridin-1-yl]-2,4-difluorophenyl]propane-1-sulfonamide Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(N2C3=CC=C(N=C3C(C=3C=NC=NC=3)=C2)N(C)C2CCN(CC)CC2)=C1F AEJACXAFHXBVHF-UHFFFAOYSA-N 0.000 description 1
- QHADVLVFMKEIIP-UHFFFAOYSA-N n-[3-fluoro-4-[1-methyl-6-(1h-pyrazol-4-yl)indazol-5-yl]oxyphenyl]-1-(4-fluorophenyl)-6-methyl-2-oxopyridine-3-carboxamide Chemical compound O=C1N(C=2C=CC(F)=CC=2)C(C)=CC=C1C(=O)NC(C=C1F)=CC=C1OC1=CC=2C=NN(C)C=2C=C1C=1C=NNC=1 QHADVLVFMKEIIP-UHFFFAOYSA-N 0.000 description 1
- DGMFNZXEGKFREH-UHFFFAOYSA-N n-[4-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-4-yloxy)-3-fluorophenyl]-5-(4-fluorophenyl)-4-oxo-1h-pyridine-3-carboxamide Chemical compound C1=CC(F)=CC=C1C(C1=O)=CNC=C1C(=O)NC(C=C1F)=CC=C1OC1=CC=NC2=C1CCN2 DGMFNZXEGKFREH-UHFFFAOYSA-N 0.000 description 1
- KJBZQIKLKWQVLL-UHFFFAOYSA-N n-[4-(3-chloro-4-fluoroanilino)-7-[(7-methyl-7-azaspiro[3.5]nonan-2-yl)methoxy]quinazolin-6-yl]prop-2-enamide Chemical compound C1CN(C)CCC11CC(COC=2C(=CC3=C(NC=4C=C(Cl)C(F)=CC=4)N=CN=C3C=2)NC(=O)C=C)C1 KJBZQIKLKWQVLL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229940126426 narazaciclib Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 229950000908 nazartinib Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Chemical group CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940015721 olafertinib Drugs 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229950000778 olmutinib Drugs 0.000 description 1
- 229950000846 onartuzumab Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- 229940016624 pamufetinib Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 210000002705 pancreatic stellate cell Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Chemical group OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 125000005562 phenanthrylene group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 229950009215 phenylbutanoic acid Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- DIJNSQQKNIVDPV-UHFFFAOYSA-N pleiadene Chemical compound C1=C2[CH]C=CC=C2C=C2C=CC=C3[C]2C1=CC=C3 DIJNSQQKNIVDPV-UHFFFAOYSA-N 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229950009876 poziotinib Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- AZSRSNUQCUDCGG-UHFFFAOYSA-N propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate Chemical compound C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C AZSRSNUQCUDCGG-UHFFFAOYSA-N 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 229940075576 pyrotinib Drugs 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229950006546 riviciclib Drugs 0.000 description 1
- 229950010624 rogaratinib Drugs 0.000 description 1
- CBTICXFNIGNHEP-UHFFFAOYSA-N s-[2-(2-methylpropanoylamino)phenyl] 2-methylpropanethioate Chemical compound CC(C)C(=O)NC1=CC=CC=C1SC(=O)C(C)C CBTICXFNIGNHEP-UHFFFAOYSA-N 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- NGWSFRIPKNWYAO-SHTIJGAHSA-N salinosporamide A Chemical compound C([C@@H]1[C@H](O)[C@]23C(=O)O[C@]2([C@H](C(=O)N3)CCCl)C)CCC=C1 NGWSFRIPKNWYAO-SHTIJGAHSA-N 0.000 description 1
- NGWSFRIPKNWYAO-UHFFFAOYSA-N salinosporamide A Natural products N1C(=O)C(CCCl)C2(C)OC(=O)C21C(O)C1CCCC=C1 NGWSFRIPKNWYAO-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229950003500 savolitinib Drugs 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940121612 serclutamab Drugs 0.000 description 1
- 229950007933 serdemetan Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229940121498 siremadlin Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Chemical group 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229950009177 telisotuzumab vedotin Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005985 thienyl[1,3]dithianyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229950004288 tosilate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N trans-decahydronaphthalene Natural products C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- NNBZCPXTIHJBJL-MGCOHNPYSA-N trans-decalin Chemical compound C1CCC[C@@H]2CCCC[C@H]21 NNBZCPXTIHJBJL-MGCOHNPYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- PBIMIGNDTBRRPI-UHFFFAOYSA-N trifluoro borate Chemical compound FOB(OF)OF PBIMIGNDTBRRPI-UHFFFAOYSA-N 0.000 description 1
- 229950007127 trilaciclib Drugs 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- 125000005455 trithianyl group Chemical group 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229950003294 voruciclib Drugs 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
- 229940073676 zoligratinib Drugs 0.000 description 1
- 229940021170 zorifertinib Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- a method of treating a tumor or tumor cells comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a selected cancer-targeted therapeutic agent to a subject identified as having the tumor or tumor cells, wherein the tumor or tumor cells comprise a gene amplification, whereby growth or size of the tumor or growth or number of tumor cells is reduced.
- Also disclosed herein is a method of delaying resistance to a selected cancer-targeted therapeutic agent, the method comprising: administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, to a subject in an amount sufficient to induce replication stress in tumor or tumor cells and administering the selected cancer-targeted therapeutic agent concurrently or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- Also disclosed herein is a method of treating a subject having a tumor or tumor cells that are non- responsive to a prior cancer-targeted therapeutic agent comprising administering a compound of Formula (I), Attorney Docket No.57547-724.601 or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a selected cancer- targeted therapeutic agent to the subject.
- a compound of Formula (I) Attorney Docket No.57547-724.601 or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a selected cancer- targeted therapeutic agent to the subject.
- the subject received one or more administrations of the prior cancer-targeted therapeutic agent prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and wherein the tumor or tumor cells developed decreased responsiveness or resistance to the prior cancer-targeted therapeutic agent.
- Also disclosed herein is a method of provoking a response in a subject having a tumor or tumor cells that are non-responsive or have decreased responsiveness to a prior cancer-targeted therapeutic agent comprising administering a Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a selected cancer-targeted therapeutic agent to the subject; wherein the prior cancer-targeted therapeutic agent is the same as the selected cancer-targeted therapeutic agent.
- a Formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof
- the tumor or tumor cells prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, comprise a gene amplification and wherein the prior cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification.
- the selected cancer-targeted therapeutic agent is administered concurrent or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- the selected cancer-targeted therapeutic agent is administered prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is administered in an amount sufficient to induce replication stress in the tumor or tumor cells.
- the subject is identified as having the tumor or tumor cells comprising a gene amplification.
- the gene amplification is a focal gene amplification.
- the gene amplification is an ecDNA-derived amplification.
- the gene amplification is comprised on ecDNA or an HSR (homogeneously staining region).
- the tumor or tumor cells comprise an ecDNA signature.
- the selected cancer-targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification.
- cells comprised within the tumor or the tumor cells are ecDNA competent.
- treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the selected cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the selected cancer-targeted therapeutic agent when administered alone.
- the greater effect is a synergistic effect.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the selected cancer- targeted therapeutic agent is administered orally.
- treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the selected cancer-targeted therapeutic agent over a treatment period.
- the gene amplification comprises an amplification of a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3C ⁇ , PIK3CA/B, RET, and ROS1.
- a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2,
- the gene amplification comprises an amplification of a gene selected from the group consisting of CDK4, CDK6, c-MET, EGFR, FGFR1, FGFR2, FGFR3, and FGFR4.
- the selected cancer therapeutic agent is an FGFR inhibitor.
- the FGFR inhibitor is infigratinib, futibatinib, or pemigatinib.
- the selected cancer therapeutic agent is a CDK4/6 inhibitor.
- the CDK4/6 inhibitor is palbociclib or abemaciclib.
- the selected cancer therapeutic agent is an EGFR inhibitor. In some embodiments of a method disclosed herein, the EGFR inhibitor is erlotinib.
- the selected cancer therapeutic agent is a c- MET inhibitor. In some embodiments of a method disclosed herein, the c-MET inhibitor is tepotinib.
- the tumor or tumor cells prior to treatment the tumor or tumor cells comprise ecDNA and wherein the treatment results in a reduction in the amount of ecDNA in the tumor or tumor cells.
- Attorney Docket No.57547-724.601 [0033]
- prior to treatment the tumor or tumor cells comprise ecDNA and wherein level or amount of ecDNA subsequent to the treatment is not increased as compared to prior to treatment.
- the method further comprises assessing a sample from a subject for the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature.
- the method further comprises obtaining information of the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature in the tumor or tumor cells from the subject prior to, during or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- the information is obtained from blood, tissue or one or more cells.
- the information is obtained by liquid biopsy or tissue biopsy.
- the prior cancer-targeted therapeutic agent is targeted to the protein encoded by a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3C ⁇ , PIK3CA/B, RET, and ROS1.
- a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FG
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is Formula (I) as disclosed herein.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is a compound of Formula (Ib): Attorney Docket No.57547-724.601 Formula (Ib).
- FIG.1A shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the pan-FGFR inhibitor infigratinib (15 mg/kg PO dosed QD) in the ecDNA+ FGFR2 amplified gastric cancer SNU-16 CDX model.
- FIG.1B shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the pan-FGFR inhibitor infigratinib (15 mg/kg PO dosed QD) in the ecDNA+ FGFR2 amplified gastric cancer CTG-0353 PDX model.
- FIG.1C shows the survival curves following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the pan-FGFR inhibitor infigratinib (15 mg/kg PO dosed QD) in the ecDNA+ FGFR2 amplified gastric cancer CTG-0353 PDX model.
- FIG.1D shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the pan-FGFR inhibitor futibatinib (12.5 mg/kg PO dosed QD) in the ecDNA+ FGFR2 amplified gastric cancer SNU-16 CDX model.
- FIG.1E shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the pan-FGFR inhibitor pemigatinib (1 mg/kg PO dosed QD) in the ecDNA+ FGFR2 amplified gastric cancer SNU-16 CDX model.
- FIG.2A shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the CDK4/6 inhibitors palbociclib (50 mg/kg PO dosed QD) in the ecDNA+ CDK4 amplified osteosarcoma SJSA-1 CDX tumor model.
- FIG.2B shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the CDK4/6 inhibitors abemaciclib (10.5 mg/kg PO dosed QD) in the ecDNA+ CDK4 amplified osteosarcoma SJSA-1 CDX tumor model.
- FIG.3 shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the EGFR inhibitor erlotinib (50 mg/kg PO dosed QD) in the ecDNA+ EGFR amplified NSCLC PDX tumor models LU1206.
- FIG.4 shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the MET inhibitor tepotinib (25 mg/kg PO dosed Q2D) in the ecDNA+ MET amplified NSCLC PDX tumor models LU1902.
- FIG.5 shows that combination treatment of infigratinib plus Compound 31 blocked the increase of FGFR2 copy number on ecDNA that otherwise was induced by single agent infigratinib.
- Alkyl refers to a straight-chain or branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3- methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1- pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1- butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-penty
- a numerical range such as “C 1 -C 6 alkyl” or “C 1-6 alkyl”, means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated.
- the alkyl is a C1-10alkyl.
- the alkyl is a C1-6alkyl.
- the alkyl is a C 1-5 alkyl.
- the alkyl is a C 1-4 alkyl.
- the alkyl is a C 1-3 alkyl.
- an alkyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the alkyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH 2 , or -NO 2 .
- alkyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkyl is optionally substituted with halogen.
- alkenyl refers to a straight-chain, or branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms. The group may be in either the cis or trans conformation about the double bond(s), and should be understood to include both isomers.
- a numerical range such as “C 2 -C 6 alkenyl” or “C 2-6 alkenyl”, means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated.
- an alkenyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the alkenyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2.
- the alkenyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkenyl is optionally substituted with halogen.
- Alkynyl refers to a straight-chain or branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butynyl, 1,3- butadiynyl and the like.
- an alkynyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the alkynyl is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2.
- the alkynyl is optionally substituted with halogen, -CN, - OH, or -OMe.
- alkynyl is optionally substituted with halogen.
- Alkylene refers to a straight or branched divalent hydrocarbon chain. Unless stated otherwise specifically in the specification, an alkylene group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the alkylene is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkylene is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkylene is optionally substituted with halogen. [0055] “Alkoxy” refers to a radical of the formula -OR a where R a is an alkyl radical as defined.
- an alkoxy group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the alkoxy is optionally substituted with halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH 2 , or -NO 2 .
- the alkoxy is optionally substituted with halogen, -CN, -OH, or -OMe.
- the alkoxy is optionally substituted with halogen.
- Aryl refers to a radical derived from a hydrocarbon ring system comprising 6 to 30 carbon atoms and at least one aromatic ring.
- the aryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is bonded through an aromatic ring atom) or bridged ring systems.
- the aryl is a 6- to 10- membered aryl.
- the aryl is a 6-membered aryl (phenyl).
- Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
- an aryl may be optionally substituted, for example, with halogen, Attorney Docket No.57547-724.601 amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF 3 , -OH, -OMe, -NH 2 , or -NO 2 .
- the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3 , -OH, or -OMe. In some embodiments, the aryl is optionally substituted with halogen.
- Cycloalkyl refers to a partially or fully saturated, monocyclic, or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems. In some embodiments, the cycloalkyl is fully saturated.
- Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms (C3-C15 cycloalkyl or C3-C15 cycloalkenyl), from three to ten carbon atoms (C3-C10 cycloalkyl or C3- C10 cycloalkenyl), from three to eight carbon atoms (C3-C8 cycloalkyl or C3-C8 cycloalkenyl), from three to six carbon atoms (C3-C6 cycloalkyl or C3-C6 cycloalkenyl), from three to five carbon atoms (C3-C5 cycloalkyl or C3-C5 cycloalkenyl), or three to four carbon atoms (C3-C4 cycloalkyl or C3-C4 cycloalkenyl).
- the cycloalkyl is a 3- to 10-membered cycloalkyl or a 3- to 10-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 3- to 6-membered cycloalkyl or a 3- to 6-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 5- to 6-membered cycloalkyl or a 5- to 6-membered cycloalkenyl.
- Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, and 7,7- dimethyl-bicyclo[2.2.1]heptanyl.
- Partially saturated cycloalkyls include, for example cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
- a cycloalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.
- a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe.
- the cycloalkyl is optionally substituted with halogen.
- Halo or “halogen” refers to bromo, chloro, fluoro or iodo.
- halogen is fluoro or chloro. In some embodiments, halogen is fluoro.
- Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2- trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.
- “Hydroxyalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more hydroxyls. In some embodiments, the alkyl is substituted with one hydroxyl. In some embodiments, the alkyl is substituted with one, two, or three hydroxyls. Hydroxyalkyl include, for example, hydroxymethyl, Attorney Docket No.57547-724.601 hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl is hydroxymethyl. [0061] “Aminoalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more amines.
- the alkyl is substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines.
- Aminoalkyl include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl is aminomethyl.
- “Deuteroalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more deuteriums. In some embodiments, the alkyl is substituted with one deuterium. In some embodiments, the alkyl is substituted with one, two, or three deuteriums.
- the alkyl is substituted with one, two, three, four, five, or six deuteriums.
- Deuteroalkyl include, for example, CD3, CH2D, CHD2, CH2CD3, CD2CD3, CHDCD3, CH2CH2D, or CH2CHD2.
- the deuteroalkyl is CD3.
- “Heteroalkyl” refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or combinations thereof.
- a heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl.
- a heteroalkyl is a C1-C6 heteroalkyl wherein the heteroalkyl is comprised of 1 to 6 carbon atoms and one or more atoms other than carbon, e.g., oxygen, nitrogen (e.g. -NH-, -N(alkyl)-), sulfur, phosphorus, or combinations thereof wherein the heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl.
- heteroalkyl examples include, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, -CH(CH3)OCH3, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NHCH3, or - CH2CH2N(CH3)2.
- a heteroalkyl is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF 3 , -OH, or - OMe. In some embodiments, the heteroalkyl is optionally substituted with halogen.
- Heterocycloalkyl refers to a 3- to 24-membered partially or fully saturated ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur. In some embodiments, the heterocycloalkyl is fully saturated. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heterocycloalkyl comprises one to three nitrogens. In some embodiments, the heterocycloalkyl comprises one or two nitrogens.
- the heterocycloalkyl comprises one nitrogen. In some embodiments, the heterocycloalkyl comprises one nitrogen and one oxygen.
- the heterocycloalkyl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems; and the nitrogen, Attorney Docket No.57547-724.601 carbon, or sulfur atoms in the heterocycloalkyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized.
- heterocycloalkyls include, but are not limited to, heterocycloalkyls having from two to fifteen carbon atoms (C 2 -C 15 heterocycloalkyl or C 2 -C 15 heterocycloalkenyl), from two to ten carbon atoms (C 2 -C 10 heterocycloalkyl or C 2 -C 10 heterocycloalkenyl), from two to eight carbon atoms (C 2 -C 8 heterocycloalkyl or C 2 -C 8 heterocycloalkenyl), from two to seven carbon atoms (C 2 -C 7 heterocycloalkyl or C 2 -C 7 heterocycloalkenyl), from two to six carbon atoms (C 2 -C 6 heterocycloalkyl or C 2 - C 6 heterocycloalkenyl), from two to five carbon atoms (C 2 -C 5 heterocycloalkyl or C 2 -C 5 heterocycloalkenyl), or two to four carbon atoms (C 2 -C
- heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, oxetanyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2- oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyr
- heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides, and the oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). In some embodiments, the heterocycloalkyl is a 3- to 8-membered heterocycloalkyl.
- the heterocycloalkyl is a 3- to 7-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 8-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 3- to 7-membered heterocycloalkenyl.
- the heterocycloalkyl is a 3- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkenyl.
- a heterocycloalkyl may be optionally substituted as described below, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.
- the heterocycloalkyl is optionally substituted with halogen, methyl, ethyl, -CN, -CF 3 , -OH, or -OMe. In some embodiments, the heterocycloalkyl is optionally substituted with halogen.
- “Heteroaryl” refers to a 5- to 14-membered ring system radical comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, and Attorney Docket No.57547-724.601 sulfur, and at least one aromatic ring. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur.
- the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heteroaryl comprises one to three nitrogens. In some embodiments, the heteroaryl comprises one or two nitrogens. In some embodiments, the heteroaryl comprises one nitrogen.
- the heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded through an aromatic ring atom) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized.
- the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5- to 6-membered heteroaryl. In some embodiments, the heteroaryl is a 6-membered heteroaryl. In some embodiments, the heteroaryl is a 5- membered heteroaryl.
- Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furany
- a heteroaryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like.
- the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2.
- the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroaryl is optionally substituted with halogen.
- the term “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
- “optionally substituted alkyl” means either “alkyl” or “substituted alkyl” as defined above.
- an optionally substituted group may be un-substituted (e.g., - CH 2 CH 3 ), fully substituted (e.g., -CF 2 CF 3 ), mono-substituted (e.g., -CH 2 CH 2 F) or substituted at a level anywhere in-between fully substituted and mono-substituted (e.g., -CH 2 CHF 2 , -CH 2 CF 3 , -CF 2 CH 3 , - CFHCHF 2 , etc.).
- any substituents described should generally be understood as having a maximum molecular weight of about 1,000 daltons, and more typically, up to about 500 daltons.
- the term “one or more” when referring to an optional substituent means that the subject group is optionally substituted with one, two, three, four, or more substituents. In some embodiments, the subject group is optionally substituted with one, two, three, or four substituents. In some embodiments, the subject group is optionally substituted with one, two, or three substituents. In some embodiments, the subject group is optionally substituted with one or two substituents. In some embodiments, the subject group is optionally substituted with one substituent. In some embodiments, the subject group is optionally substituted with two substituents.
- beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease.
- Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment.
- the terms “treat,” “treated,” “treatment,” or “treating” as well as words stemming therefrom, as used herein, do not necessarily imply 100% or complete treatment. Rather, there are varying degrees of treatment of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect.
- the disclosed methods can provide any amount of any level of treatment of the disorder in a mammal. For example, a disorder, including symptoms or conditions thereof, may be reduced by, for example, about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, or about 10%.
- an “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of a compound disclosed herein being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated, e.g., cancer or an inflammatory disease. In some embodiments, the result is a reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
- an “effective amount” for therapeutic uses is the amount of the composition comprising a compound disclosed herein required to provide a clinically significant decrease in disease symptoms.
- an appropriate “effective” amount in any individual case is determined using techniques, such as a dose escalation study.
- biological sample generally refers to a sample derived from or obtained from a subject, such as a mammal (e.g., a human).
- Biological samples are contemplated to include Attorney Docket No.57547-724.601 but are not limited to, hair, fingernails, skin, sweat, tears, ocular fluids, nasal swab or nasopharyngeal wash, sputum, throat swab, saliva, mucus, blood, serum, plasma, placental fluid, amniotic fluid, cord blood, emphatic fluids, cavity fluids, earwax, oil, glandular secretions, bile, lymph, pus, microbiota, meconium, breast milk, bone marrow, bone, CNS tissue, cerebrospinal fluid, adipose tissue, synovial fluid, stool, gastric fluid, urine, semen, vaginal secretions, stomach, small intestine, large intestine
- tumor or tumor cells
- tumor cells generally refers to cells that grow and divide more than they should or do not die when they should.
- tumor cells are present in a solid mass, such as a solid tumor, or in some cases, tumor cells are found in a non-solid form, such as in blood cancers.
- Tumor or tumor cells also can include metastasis or metastasizing cells, where cancer cells break away from the original (primary) tumor and may form a new tumor in other organs or tissues of the body.
- ecDNA signature as used herein, generally refers to one or more characteristics common to tumors or tumor cells that are ecDNA+.
- the ecDNA signature is selected from the group consisting of a gene amplification; a p53 loss of function mutation; absence of microsatellite instability (MSI-H); a low level of PD-L1 expression; a low level of tumor inflammation signature (TIS); a low level of tumor mutational burden (TMB); an increased frequency of allele substitutions, insertions, or deletions (indels); and any combination thereof.
- the ecDNA signature can include an increase in copy number (gene amplification) in conjunction with particular structural variations.
- the ecDNA signature can include a focal amplification.
- ecDNA signature includes a detection or identification of ecDNA using an imaging technology.
- ecDNA signature does not include any imaging or direct detection of ecDNA.
- W is N. In some embodiments of a compound of Formula (I), W is CR W .
- X is N. In some embodiments of a compound of Formula (I), X is CR X .
- Y is N. In some embodiments of a compound of Formula (I), Y is CR Y .
- Z is N. In some embodiments of a compound of Formula (I), Z is CR Z .
- the compound is a compound of Formula (Ia): [0080] In some embodiments of a compound of Formula (I), the compound is a compound of Formula (Ib): Attorney Docket No.57547-724.601 [0081] In some embodiments of a compound of Formula (I), the compound is a compound of Formula (Ic): Formula (Ic). [0082] In some embodiments of a compound of Formula (I), the compound is a compound of Formula (Id): [0083] In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring A is aryl or heteroaryl.
- Ring A is heteroaryl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring A is 6-membered heteroaryl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring A is pyrazinyl. [0084] In some embodiments of a compound of Formula (I) or (Ia)-(Id), each R 1 is independently deuterium, halogen, -CN, -OH, -OR a , C1-C6alkyl, or C1-C6haloalkyl.
- each R 1 is independently -CN.
- n is 0-2. In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 1 or 2. In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 0 or 1. In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 0. In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 1.
- n is 2. In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 3. [0086] In some embodiments of a compound of Formula (I) or (Ia)-(Id), R 2 is hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R 2 is hydrogen. [0087] In some embodiments of a compound of Formula (I) or (Ia)-(Id), R 3 is hydrogen, deuterium, halogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
- R 3 is hydrogen.
- R 4 is hydrogen or C 1 -C 6 alkyl.
- R 4 is hydrogen.
- L is -O-.
- L is -NR 5 -.
- R 5 is hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R 5 is hydrogen.
- R W is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl and heterocycloalkyl is optionally substituted with one or more R.
- R W is hydrogen, deuterium, halogen, -OH, -OR a , -NR c R d , C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl.
- R W is hydrogen, halogen, -OH, -OR a , C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl.
- R W is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R W is hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R W is hydrogen, halogen, or C 1 -C 6 alkyl.
- R W is hydrogen or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R W is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R W is hydrogen. [0092] In some embodiments of a compound of Formula (I) or (Ia)-(Id), R W is hydrogen, halogen, -OH, - OR a , or -NR c R d .
- R W is hydrogen, -OH, or - OR a . In some embodiments of a compound of Formula (I) or (Ia)-(Id), R W is -OH or -OR a . In some embodiments of a compound of Formula (I) or (Ia)-(Id), R W is halogen or -OR a .
- R X is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R.
- R X is hydrogen, deuterium, halogen, -OH, -OR a , -NR c R d , C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl.
- R X is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl.
- R X is hydrogen, halogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R X is hydrogen, halogen, or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R X is hydrogen or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R X is hydrogen or halogen.
- R X is hydrogen.
- R Y is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R.
- R Y is hydrogen, deuterium, halogen, -OH, -OR a , C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R.
- R Y is hydrogen, halogen, -OH, - OR a , C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, or cycloalkyl; wherein the alkyl and cycloalkyl is optionally substituted with one or more R.
- R Y is hydrogen, deuterium, halogen, -OH, -OR a , -NR c R d , C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl.
- R Y is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R Y is hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R Y is hydrogen, halogen, or C1-C6alkyl.
- R Y is hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R Y is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R Y is hydrogen. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R Y is C1-C6alkyl.
- R Z is hydrogen, deuterium, halogen, -CN, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R.
- R Z is hydrogen, deuterium, halogen, -OH, -OR a , -NR c R d , C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, or cycloalkyl.
- R Z is hydrogen, deuterium, halogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl.
- R Z is hydrogen, halogen, C 1 -C 6 alkyl, or Attorney Docket No.57547-724.601 C 1 -C 6 haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R Z is hydrogen, halogen, or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R Z is hydrogen or C 1 -C 6 alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R Z is hydrogen or halogen.
- R Z is hydrogen. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R Z is C 1 -C 6 alkyl. [0096] In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is cycloalkyl or heterocycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is monocyclic cycloalkyl.
- Ring B is bicyclic cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is monocyclic 4- to 6-membered cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is monocyclic 4- to 5-membered cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is monocyclic 4- membered cycloalkyl.
- Ring B is monocyclic 5-membered cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is monocyclic 6-membered cycloalkyl. [0097] In some embodiments of a compound of Formula (I) or (Ia)-(Id), each R 6 is independently deuterium, halogen, -CN, -OH, -OR a , -NR c R d , C1-C6alkyl, or C1-C6haloalkyl.
- each R 6 is independently -OH, -OR a , or -NR c R d . In some embodiments of a compound of Formula (I) or (Ia)-(Id), each R 6 is independently -NR c R d . [0098] In some embodiments of a compound of Formula (I) or (Ia)-(Id), m is 0. In some embodiments of a compound of Formula (I) or (Ia)-(Id), m is 1. In some embodiments of a compound of Formula (I) or (Ia)- (Id), m is 2.
- m is 3. In some embodiments of a compound of Formula (I) or (Ia)-(Id), m is 0 or 1. In some embodiments of a compound of Formula (I) or (Ia)-(Id), m is 0-2. In some embodiments of a compound of Formula (I) or (Ia)-(Id), m is 1 or 2.
- each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, cycloalkyl, heterocycloalkyl, C 1 -C 6 alkylene(cycloalkyl), or C 1 -C 6 alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cycloalkyl, heterocycloalkyl, C 1 -C 6 alkylene(cycloalkyl), or C 1 -C 6 alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently Attorney Docket No.57547-724.601 optionally substituted with one or more R.
- each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cycloalkyl, or heterocycloalkyl.
- each R a is independently C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, or C 1 -C 6 aminoalkyl. In some embodiments of a compound disclosed herein, each R a is independently C 1 -C 6 alkyl or C 1 -C 6 haloalkyl. In some embodiments of a compound disclosed herein, each R a is independently C 1 -C 6 alkyl.
- each R b is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, C1-C6alkylene(cycloalkyl), or C1-C6alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R b is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, heterocycloalkyl, C1-C6alkylene(cycloalkyl), or C1-C6alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R b is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R b is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R b is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, or heterocycloalkyl.
- each R b is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, or C1-C6aminoalkyl. In some embodiments of a compound disclosed herein, each R b is independently hydrogen, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound disclosed herein, each R b is independently hydrogen or C1-C6alkyl. In some embodiments of a compound disclosed herein, each R b is hydrogen. In some embodiments of a compound disclosed herein, each R b is independently C1-C6alkyl.
- each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, cycloalkyl, heterocycloalkyl, C 1 -C 6 alkylene(cycloalkyl), or C 1 -C 6 alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cycloalkyl, heterocycloalkyl, C 1 -C 6 alkylene(cycloalkyl), or C 1 -C 6 alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, C 1 -C 6 aminoalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and Attorney Docket No.57547-724.601 heterocycloalkyl is independently optionally substituted with one or more R.
- each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R.
- each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, cycloalkyl, or heterocycloalkyl.
- each R c and R d are independently hydrogen, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 1 -C 6 deuteroalkyl, C 1 -C 6 hydroxyalkyl, or C 1 -C 6 aminoalkyl. In some embodiments of a compound disclosed herein, each R c and R d are independently hydrogen, C 1 -C 6 alkyl, or C 1 -C 6 haloalkyl. In some embodiments of a compound disclosed herein, each R c and R d are independently hydrogen or C1-C6alkyl. In some embodiments of a compound disclosed herein, each R c and R d are hydrogen.
- each R c and R d are independently C1-C6alkyl. In some embodiments of a compound disclosed herein, R c and R d are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R.
- each R is independently halogen, -CN, -OH, -OC1-C3alkyl, -OC1-C3haloalkyl, -NH2, -NHC1-C3alkyl, -N(C1-C3alkyl)2, C1-C3alkyl, C1-C3haloalkyl, C1-C3deuteroalkyl, C1-C3hydroxyalkyl, C1-C3aminoalkyl, C1-C3heteroalkyl, or C3-C6cycloalkyl; or two R on the same atom form an oxo.
- each R is independently halogen, -CN, -OH, -OC1-C3alkyl, -OC1-C3haloalkyl, -NH2, C1-C3alkyl, C1- C3haloalkyl, C1-C3deuteroalkyl, C1-C3hydroxyalkyl, C1-C3aminoalkyl, C1-C3heteroalkyl, or C3-C6cycloalkyl; or two R on the same atom form an oxo.
- each R is independently halogen, -CN, -OH, -OC1-C3alkyl, -OC1-C3haloalkyl, -NH2, C1-C3alkyl, or C1-C3haloalkyl; or two R on the same atom form an oxo.
- each R is independently halogen, C1-C3alkyl, C1-C3haloalkyl, C1-C3deuteroalkyl, C1-C3hydroxyalkyl, C1- C3aminoalkyl, or C1-C3heteroalkyl; or two R on the same atom form an oxo.
- each R is independently halogen, -CN, -OH, -NH2, C1-C3alkyl, or C1- C 3 haloalkyl; or two R on the same atom form an oxo.
- each R is independently halogen, C 1 -C 3 alkyl, or C 1 -C 3 haloalkyl; or two R on the same atom form an oxo.
- the compound is selected from a compound of Table 1 or table 2: Attorney Docket No.57547-724.601 TABLE 1 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No.57547-724.601 Attorney Docket No
- the CHK1 inhibitor is compound pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- the CHK1 inhibitor is compound Further Forms of Compounds Disclosed Herein Isomers/Stereoisomers
- the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds.
- the compounds presented herein include all cis, trans, syn, anti,
- E
- Z Greek
- the compounds described herein possess one or more chiral centers and each center exists in the R configuration or S configuration.
- the compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof.
- mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein.
- the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers.
- dissociable complexes are preferred.
- the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities.
- the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility.
- the optically pure enantiomer is then recovered, along with the resolving agent.
- Labeled compounds [00106]
- the compounds described herein exist in their isotopically-labeled forms.
- the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds.
- the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds as pharmaceutical compositions.
- the compounds disclosed herein include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- isotopes that can be incorporated into compounds described herein, or a solvate, tautomer, or stereoisomer thereof, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, and chloride, such as 2 H, 3 H, 13 C, 14 C, l5 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, and 36 Cl, respectively.
- the isotopically labeled compound or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is prepared by any suitable method.
- the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
- the compounds described herein exist as their pharmaceutically acceptable salts.
- the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts.
- the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions.
- the compounds described herein possess acidic or basic groups and therefor react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
- these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed.
- suitable acid or base examples include those salts prepared by reaction of the compounds described herein with a mineral, organic acid, or inorganic base, such salts including acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fumarate
- the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-
- those compounds described herein that comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, or sulfate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
- a suitable base such as the hydroxide, carbonate, bicarbonate, or sulfate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine.
- Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like.
- bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N + (C1-4 alkyl)4, and the like.
- Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like of the tetrazole.
- Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen- containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quaternization.
- Solvates [00114] In some embodiments, the compounds described herein exist as solvates. The disclosure provides for methods of treating diseases by administering such solvates.
- Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed during the processes described herein.
- the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein.
- Tautomers [00116] In some situations, compounds exist as tautomers.
- the compounds described herein include all possible tautomers within the formulas described herein.
- Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH.
- Preparation of the Compounds [00117] The compounds used in the reactions described herein are made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature.
- Suitable reference books and treatises that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation include for example, Attorney Docket No.57547-724.601 “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., New York; S. R. Sandler et al., “Organic Functional Group Preparations,” 2nd Ed., Academic Press, New York, 1983; H. O. House, “Modern Synthetic Reactions”, 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif.1972; T. L. Gilchrist, “Heterocyclic Chemistry”, 2nd Ed., John Wiley & Sons, New York, 1992; J.
- compounds of Formula I may be prepared via metal-catalyzed carbon- carbon bond forming cross-coupling reactions.
- appropriate cross-coupling reactions include the Suzuki, Negishi, Stille, Kumada or Heck reactions.
- the cross- coupling reaction is a Suzuki reaction between an appropriately substituted aryl bromide and an appropriately substituted arylboronic acid or arylboronic ester.
- Scheme I [00122] The synthesis of appropriately substituted intermediate building blocks for Suzuki reactions is described in Scheme I.
- An aryl bromide of formula I-3 may be synthesized by a reaction between an appropriately substituted compound of formula I-1, where L represents a nucleophilic atom, and a compound of formula I-2, where LG represents a suitable leaving group.
- L is oxygen or an optionally substituted nitrogen atom.
- L is oxygen.
- LG is an alkyl halide such as bromine or iodine; in other embodiments, LG may be oxygen.
- I-2 where LG is oxygen it may be activated to increase its reactivity as a leaving group.
- Such activation may occur via synthesis of an alkylsulfonate, such as a mesylate, tosylate, nosylate, brosylate, or other sulfonate known to one having ordinary skill in the art.
- alkylsulfonates may be synthesized from the corresponding alkyl alcohol by reaction with an appropriate sulfonyl chloride or sulfonic anhydride, such as methanesulfonyl chloride or methanesulfonic anhydride.
- Such sulfonylation reactions typically occur in a solvent such as dichloromethane, tetrahydrofuran, or toluene, in the presence of a base such as sodium hydride, triethylamine, diisopropylethylamine, pyridine, potassium carbonate or another base known to one having ordinary skill in the art.
- Reactions typically proceed at sub-ambient or ambient temperature, for example between 0-25 °C. Reactions are typically complete within 1-18 hours and the product may be purified or used directly without purification, if it is unstable to purification.
- an aryl bromide of formula I-3 may be synthesized by a reaction with a compound of formula I-2 where LG represents an alcohol that has been activated in situ without isolation, as in a Mitsunobu reaction.
- activation of the alcohol occurs in the presence of an appropriate azodicarboxylate, such as diethyl azodicarboxylate or diisopropyl azodicarboxylate, and an appropriate phosphine, such as triphenylphosphine.
- the activation may be achieved using an appropriate phosphorane, such as (tributylphosphoranylidene)acetonitrile (CMBP) or (trimethylphosphoranylidene)acetonitrile (CMMP).
- CMBP tributylphosphoranylidene
- CMMP trimethylphosphoranylideneacetonitrile
- Mitsunobu reactions are typically carried out in a Attorney Docket No.57547-724.601 solvent such as dichloromethane, tetrahydrofuran, or toluene, and typically occur at ambient temperature or at elevated temperature from 25 to 110 °C. Reactions are typically complete within 1-18 hours.
- a compound of formula I-3 may be synthesized by a reaction between a compound of formula I-4 and a compound of formula I-5.
- LG is a halide such as fluorine, chlorine, bromine, or iodine.
- L is nitrogen or oxygen.
- L is oxygen.
- the reaction between I-4 and I-5 may proceed under cross-coupling conditions, catalyzed by an appropriate transition metal, or by nucleophilic aromatic substitution.
- the nucleophilic aromatic substitution reaction occurs when LG of I-4 is fluorine or chlorine and L of I-5 is oxygen.
- LG of I-4 is fluorine.
- nucleophilic aromatic substitution reactions typically occur in the presence of a strong base such as sodium hydride, lithium diisopropylamine, lithium bis(trimethylsilyl)amide, or an appropriate base known to one having ordinary skill in the art.
- a strong base such as sodium hydride, lithium diisopropylamine, lithium bis(trimethylsilyl)amide, or an appropriate base known to one having ordinary skill in the art.
- nucleophilic aromatic substitution reactions typically occur in a solvent such as tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, N,N-dimethylformamide or N,N-dimethylacetamide.
- Such nucleophilic aromatic substitution reactions typically occur at reduced temperature, such as -78 °C or 0 °C; in some embodiments, the reaction may occur at ambient temperature or elevated temperature, from 25 to 110 °C.
- a compound of formula I-8 may be synthesized from an appropriately substituted aminopyrazole of formula I-6 via reaction with an appropriately substituted compound of formula I-7, where ring A contains a suitable leaving group LG.
- a leaving group may be a chloride, bromide, iodide or activated alcohol such as a mesylate or tosylate.
- ring A may be aromatic and the leaving group may be an aryl chloride.
- the reaction may occur in the presence of a suitable base such as sodium hydride, triethylamine, diisopropylethylamine, pyridine, potassium carbonate or another base known to one having ordinary skill in the art.
- a suitable base such as sodium hydride, triethylamine, diisopropylethylamine, pyridine, potassium carbonate or another base known to one having ordinary skill in the art.
- Such reactions typically occur in a solvent such as tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, N,N-dimethylformamide or N,N-dimethylacetamide.
- Reactions may occur at ambient temperature or at elevated temperatures from 60- 110 °C. Reactions are typically complete within 1-18 hours.
- a pyrazoleboronic ester compound of formula I-9 may be synthesized from a compound of formula I-8 by reaction with an appropriate borylating agent.
- the compound of formula I-9 may contain a mixture of pyrazoleboronic ester and pyrazoleboronic acid. In some embodiments, the compound of formula I-9 may contain mostly pyrazoleboronic acid. In some embodiments, the compound of formula I-9 is synthesized by a Miyaura borylation reaction and the appropriate borylating agent is bis(pinacolato)diboron.
- the Miyaura borylation reaction is carried out in the presence of a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), or another catalyst system known to one having ordinary skill in the art.
- a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), or another catalyst system known to one having ordinary skill in the art.
- a suitable base such as sodium carbonate, potassium carbonate, potassium tert-butoxide, sodium acetate, potassium acetate, or another base known to one having ordinary skill in the art.
- the Miyaura Attorney Docket No.57547-724.601 reaction is typically carried out in a solvent such as 1,4-dioxane, ethyl acetate, or toluene at elevated temperature, typically between 60-110 °C. Reactions are typically complete within 6-24 hours.
- Scheme II [00127] As shown in Scheme II, a compound of Formula I may be synthesized by a Suzuki reaction between a compound of formula I-3 and a compound of formula I-9.
- Such a reaction will typically occur in the presence of a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), RuPhos palladacycle G3, or another catalyst system known to one having ordinary skill in the art.
- a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), RuPhos palladacycle G3, or another catalyst system known to one having ordinary skill in the art.
- a suitable base such as sodium carbonate, potassium carbonate, potassium tert-butoxide, sodium acetate, potassium acetate, or another base known to one having ordinary skill in the art.
- a cyanoketone intermediate of formula III- 5 may be synthesized from a compound of formula I-3.
- a compound of formula I-3 may be converted to a vinyl enol ether of formula III-1.
- Such a reaction may occur between a compound of formula I-3 and an appropriately substituted vinyl building block under palladium-catalyzed cross-coupling conditions.
- the cross-coupling reaction may be a Suzuki or a Stille reaction.
- the vinyl building block will be substituted as a boronic ester, a boronic acid, a trifluoroborate or an alkylstannane.
- Such cross-coupling reactions will typically occur in the presence of a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), RuPhos palladacycle G3, or another catalyst system known to one having ordinary skill in the art.
- a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), RuPhos palladacycle G3, or another catalyst system known to one having ordinary skill in the art.
- a suitable base such as sodium carbonate, potassium carbonate, potassium tert-butoxide, sodium acetate, potassium acetate, or another base known to one having ordinary skill in the art.
- the cross-coupling reaction is typically carried out in a solvent such as 1,4-dioxane, ethyl acetate, or toluene.
- the reaction will occur at elevated temperature, typically between 60-110 °C. Reactions are typically complete within 6-24 hours.
- a compound of formula III-1 may be purified or used directly in the next step without purification, as it may be unstable to standard purification conditions.
- a compound of formula III-1 may be converted to a ketone of formula III-2 via acidic hydrolysis.
- Such a reaction is typically carried out using a strong Br ⁇ nsted acid, such as hydrochloric acid, in aqueous media. The reaction may take place at sub-ambient, ambient, or elevated temperature, typically between 0- 80 °C.
- a ketone of formula III-2 may be converted to an enamine compound of formula III- 3 by reaction with N,N-dimethylformamide dimethyl acetal. In some embodiments, this reaction occurs in N,N-dimethylformamide as the solvent at elevated temperature, typically between 60-110 °C. Reactions are typically complete in 2-24 hours.
- a compound of formula III-3 may be purified, or in some embodiments it may be used directly in the next step without purification, as it may be unstable to standard purification conditions.
- a compound of formula III-3 may be converted to an isoxazole of formula III-4 by reaction with hydroxylamine. In some embodiments this reaction may employ hydroxylamine as free base or as a salt.
- the reaction is carried out using hydroxylamine hydrochloride.
- the reaction typically proceeds at ambient or elevated temperature between 25-110 °C in an appropriate solvent such as methanol, ethanol, isopropanol, n-butanol, tert-butanol, or toluene.
- the reaction is typically complete within 2-24 hours.
- An isoxazole of formula III-4 may be converted to a cyanoketone of formula III-5 by treatment with an appropriate base, such as lithium hydroxide, sodium hydroxide or potassium hydroxide.
- the base is potassium hydroxide.
- a cyanoketone of formula III-5 may be synthesized from an ester as shown in Scheme IV.
- An ester of formula IV-5 may be synthesized from appropriate building blocks of formula IV-1, where L represents a nucleophilic atom, and a compound of formula IV-2, where LG represents a suitable leaving group.
- L is oxygen or an optionally substituted nitrogen atom.
- L is oxygen.
- LG is an alkyl halide such as bromine or iodine; in other embodiments, it may be oxygen.
- it may be activated to increase its reactivity as a leaving group. Such activation may occur via synthesis of an alkylsulfonate, such as a mesylate, tosylate, nosylate, brosylate, or other sulfonate known to one having ordinary skill in the art.
- alkylsulfonates may be synthesized from the corresponding alkyl alcohol by reaction with an appropriate sulfonyl chloride or sulfonic anhydride, such as methanesulfonyl chloride or methanesulfonic anhydride.
- sulfonylation reactions typically occur in a solvent such as dichloromethane, tetrahydrofuran, or toluene, in the presence of a base such as sodium hydride, triethylamine, diisopropylethylamine, pyridine, potassium carbonate or another base known to one having ordinary skill in the art. Reactions typically proceed at low temperature or at ambient temperature, for example at 0 °C.
- an ester of formula IV-5 may be synthesized by a reaction with a compound of formula IV-2, where LG represents an alcohol that has been activated in situ without isolation, as in a Mistunobu reaction. Activation of the alcohol occurs in the presence of an appropriate azodicarboxylate, such as diethyl azodicarboxylate or diisopropyl azodicarboxylate, and an appropriate phosphine, such as triphenylphosphine.
- an appropriate azodicarboxylate such as diethyl azodicarboxylate or diisopropyl azodicarboxylate
- an appropriate phosphine such as triphenylphosphine.
- the activation may be achieved using an appropriate phosphorane, such as (tributylphosphoranylidene)acetonitrile (CMBP) or (trimethylphosphoranylidene)acetonitrile (CMMP).
- CMBP tributylphosphoranylidene
- CMMP trimethylphosphoranylideneacetonitrile
- Mitsunobu reactions are typically carried out in a solvent such as dichloromethane, tetrahydrofuran, or toluene, and typically occur at ambient temperature or at elevated temperature, from 25 to 110 °C. Reactions are typically complete within 1-18 hours.
- a compound of formula IV-5 may be synthesized from a compound of formula IV-3 and a compound of formula IV-4.
- LG is a halide such as fluorine, chlorine, bromine, or iodine.
- L is nitrogen or oxygen.
- L is oxygen.
- the reaction between IV-3 and IV-4 may proceed under cross-coupling conditions, catalyzed by an appropriate transition metal, or by nucleophilic aromatic substitution.
- the nucleophilic aromatic substitution reaction occurs when LG of IV-3 is fluorine or chlorine and L is oxygen.
- LG of IV-3 is fluorine.
- nucleophilic aromatic substitution reactions typically occur in the presence of a strong base such as sodium hydride, lithium diisopropylamine, lithium bis(trimethylsilyl)amide, or an appropriate base known to one having ordinary skill in the art.
- a strong base such as sodium hydride, lithium diisopropylamine, lithium bis(trimethylsilyl)amide, or an appropriate base known to one having ordinary skill in the art.
- nucleophilic aromatic substitution reactions typically occur in a solvent such as tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, N,N-dimethylformamide or N,N-dimethylacetamide.
- Such nucleophilic aromatic substitution reactions typically occur at reduced temperature, such as -78 °C or 0 °C; in some embodiments, the reaction may occur at ambient temperature or elevated temperature such as 100 °C. Reactions are typically complete within 1-18 hours.
- An ester of formula IV-5 may be converted to a cyanoketone of formula III-5 in a reaction with the carbanion of an optionally substituted nitrile.
- the nitrile is acetonitrile.
- acetonitrile is deprotonated with a suitable strong base, such as sodium hydride, potassium tert- butoxide, n-butyllithium, sec-butyllithium, lithium diisopropylamine, lithium bis(trimethylsilyl)amide, or an appropriate base known to one having ordinary skill in the art.
- the reaction may be carried out using acetonitrile as the solvent, or in another appropriate solvent such as tetrahydrofuran or diethyl ether. In some embodiments, the solvent is tetrahydrofuran.
- the reaction typically occurs at reduced temperature, such as - 78 °C or 0 °C; in some embodiments, the reaction may occur at ambient temperature. The reaction is typically complete within 1-18 hours.
- Scheme V [00136]
- a cyanoketone of formula III-5 may be converted to an aminopyrazole of formula V-I as shown in Scheme V. Such a reaction may be performed using an optionally substituted hydrazine to form the aminopyrazole.
- the optionally substituted hydrazine is hydrazine or hydrazine monohydrate.
- the reaction is typically carried out in the presence of a Br ⁇ nsted acid, such as acetic acid or hydrochloric acid.
- the reaction is carried out in an appropriate solvent such as methanol, ethanol, isopropanol, n-butanol, tert-butanol, or toluene.
- the reaction may be carried out at ambient or elevated temperature between 25-110 °C.
- the reaction is typically complete within 2-18 hours.
- a compound of formula V-I may react with an appropriately substituted compound of formula I- 7, where ring A contains a suitable leaving group LG, to give a compound of Formula I.
- a leaving group LG may be a chloride, bromide, iodide or activated alcohol such as a mesylate or tosylate.
- ring A may be aromatic and the leaving group may be an aryl chloride.
- the reaction may occur in the presence of a suitable base such as sodium hydride, triethylamine, diisopropylethylamine, pyridine, potassium carbonate or another base known to one having ordinary skill in the art.
- reaction between a compound of formula V-I and a compound of formula I-7 may be carried out in the presence of an appropriate transition metal catalyst.
- the transition metal is a copper catalyst as in an Ullmann reaction.
- the catalyst is a palladium complex as in a Buchwald reaction.
- Such cross-coupling reactions will typically occur in the presence of a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), BrettPhos palladacycle G3, or another catalyst system known to one having ordinary skill in the art.
- a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), BrettPhos palladacycle G3, or another catalyst system known to one having ordinary skill in the art.
- a suitable base such as sodium carbonate, potassium carbonate, potassium tert-butoxide, sodium acetate, potassium acetate, triethylamine or another base known to one having ordinary skill in the art
- reaction is typically carried out in a solvent such as 1,4-dioxane or toluene.
- the reaction will occur at elevated temperature, typically between 60-110 °C. Reactions are typically complete within 6-24 hours.
- Scheme VI One having ordinary skill in the art will recognize that at times, it may be necessary to mask a reactive functional group or groups on a molecule with an appropriate protecting group.
- the protecting group or groups may be carried through several synthetic steps.
- the protecting group or groups may all be removed in a single global deprotection step.
- the protecting group or groups will mask amine functional groups.
- the protecting group or groups will be tert-butylcarbamate groups.
- the tert-butylcarbamate protected amine will be on ring B.
- a tert-butylcarbamate protecting group is typically removed via treatment with a Br ⁇ nsted acid, such as trifluoroacetic acid, hydrogen chloride or hydrochloric acid. Typical cleavage reactions occur in an appropriate solvent such as ethyl acetate, 1,4-dioxane, diethyl ether or dichloromethane. Reactions typically proceed at sub-ambient or ambient temperature but may proceed at elevated temperature, typically between 0-60 °C.
- a compound of Formula I prepared under such conditions may be purified by standard methods including chromatography or recrystallization. In some embodiments the compound of Formula I is isolated directly from the deprotection reaction as a salt. In some embodiments the compound of Formula I is purified by preparative HPLC using an appropriate column and eluent conditions.
- Pharmaceutical Compositions [00140] In certain embodiments, the compound described herein is administered as a pure chemical.
- the compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21 st Ed. Mack Pub. Co., Easton, PA (2005)).
- a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable excipient.
- the compound provided herein is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1% of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.
- Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient’s disease, the particular form of the active ingredient, and the method of administration.
- an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as increased overall response rate, increased duration of response, more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity.
- therapeutic and/or prophylactic benefit e.g., an improved clinical outcome, such as increased overall response rate, increased duration of response, more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity.
- Optimal doses are generally determined using experimental models and/or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient.
- the pharmaceutical composition is formulated for oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, intrapulmonary, intradermal, intrathecal, epidural, or intranasal administration.
- Parenteral administration includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
- the pharmaceutical composition is formulated for intravenous injection, oral administration, inhalation, nasal administration, topical administration, or ophthalmic administration.
- the pharmaceutical composition is formulated for oral administration.
- the pharmaceutical composition is formulated for intravenous injection.
- the pharmaceutical composition is formulated as a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop, or an ear drop.
- the pharmaceutical composition is formulated as a tablet.
- Suitable doses and dosage regimens are determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound disclosed herein.
- Methods [00146] Disclosed herein is a method of treating a tumor or tumor cells, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a cancer-targeted therapeutic agent to a subject identified as having the tumor or tumor cells, wherein the tumor or tumor cells comprise a gene amplification, whereby growth or size of the tumor or growth or number of tumor cells is reduced.
- Also disclosed herein is a method of delaying resistance to a cancer-targeted therapeutic agent, the method comprising: administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, to a subject in an amount sufficient to induce replication stress in tumor or tumor cells and administering a cancer-targeted therapeutic agent concurrently or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- a tumor or tumor cells in a subject comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- the subject has had one or more prior treatments with a first cancer- targeted therapeutic agent (also referred to herein as a “prior cancer-targeted therapeutic agent”) prior to treatment with a compound of Formula (I).
- a first cancer- targeted therapeutic agent also referred to herein as a “prior cancer-targeted therapeutic agent”
- the compound of Formula (I) is administered in conjunction with the administration of a second cancer-targeted therapeutic agent (also referred to herein as a “selected cancer-targeted therapeutic agent”).
- Also disclosed herein is a method of treating a subject having a tumor or tumor cells that are non- responsive to a first (prior) cancer-targeted therapeutic agent comprising administering a compound of Attorney Docket No.57547-724.601 Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a second (selected) cancer-targeted therapeutic agent to the subject.
- a compound of Attorney Docket No.57547-724.601 Formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof
- Also disclosed herein is a method of provoking a response in a subject having a tumor or tumor cells that are non-responsive or have decreased responsiveness to a first (prior) cancer-targeted therapeutic agent comprising administering a Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the first (prior) cancer-targeted therapeutic agent to the subject.
- the cancer-targeted therapeutic agent is administered concurrent or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- the first (prior) cancer-targeted therapeutic agent is administered concurrent or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- the second (selected) cancer-targeted therapeutic agent is administered concurrent or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- the cancer-targeted therapeutic agent is administered prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- the first (prior) cancer-targeted therapeutic agent is administered prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- the second (selected) cancer-targeted therapeutic agent is administered prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is administered in an amount sufficient to induce replication stress in the tumor or tumor cells.
- the subject is identified as having the tumor or tumor cells comprising a gene amplification.
- the gene amplification is a focal gene amplification.
- the gene amplification is an ecDNA-derived amplification.
- the gene amplification is comprised on ecDNA or an HSR (homogeneously staining region).
- the cancer-targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification.
- the first (prior) cancer-targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification.
- the second (selected) cancer-targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification.
- the tumor or tumor cells comprise an ecDNA signature.
- cells comprised within the tumor or the tumor cells are ecDNA competent.
- an ecDNA competent tumor cell may have detectable levels of ecDNA amplification or an ecDNA competent tumor cell has the capacity to generate ecDNA amplification in response to selective pressure such as targeted therapy (e.g., a cancer-targeted therapeutic agent described herein).
- targeted therapy e.g., a cancer-targeted therapeutic agent described herein.
- treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the cancer-targeted therapeutic agent when administered alone.
- treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the first (prior) cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the first (prior) cancer-targeted therapeutic agent when administered alone.
- treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the second (selected) cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the second (selected) cancer-targeted therapeutic agent when administered alone.
- the greater effect is a synergistic effect.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer-targeted therapeutic agent is administered orally.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the first (prior) cancer- targeted therapeutic agent is administered orally.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second (selected) cancer-targeted therapeutic agent is administered orally.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer-targeted therapeutic agent is administered parentally.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the first (prior) cancer- targeted therapeutic agent is administered parentally.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second (selected) cancer-targeted therapeutic agent is administered parentally.
- treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer-targeted therapeutic agent over a treatment period.
- treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the first (prior) cancer-targeted therapeutic agent over a treatment period.
- treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second (selected) cancer-targeted therapeutic agent over a treatment period.
- the gene amplification comprises an amplification of a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HER2, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3C ⁇ , PIK3CA/B, RET, and ROS1.
- a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1,
- the gene amplification comprises an amplification of a gene selected from the group consisting of CDK4, CDK6, c-MET, EGFR, FGFR1, FGFR2, FGFR3, and FGFR4.
- the first (prior) cancer-targeted therapeutic agent is different than the second (selected) cancer-targeted therapeutic agent.
- the first (prior) cancer-targeted therapeutic agent is the same as the second (selected) cancer-targeted therapeutic agent.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is selected from the group consisting of abemaciclib, ado-trastuzumab emtansine, afatinib, alectinib, ALRN-6924, AMG232, AMG-510, apatinib, ARS-3248, AXL1717, AZD- Attorney Docket No.57547-724.601 3759, bevacizumab, BI 1701963, bortezomib, brigatinib, cabozantinib, capmatinib, ceritinib, cetuximab, CGM097, crizotinib, dabrafenib, dacomitinib, dasatinib, DS-3032b, encor
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of EFGR, FGFR, CDK4/CDK6 or KRAS.
- the EGFR inhibitor is erlotinib, gefitinib, or an analog thereof, or an antibody such as cetuximab, necitumumab, nimotuzumab, and panitumumab.
- the FGFR inhibitor is erdafitinib, futibatinib, infigratinib, pemigatinib, RLY-4008, or an analog thereof.
- the KRAS inhibitor is adagrasib, BI 1701963, sotorasib, or an analog thereof.
- the CDK4/CDK6 inhibitor is abemaciclib, palbociclib, ribociclib, PF-06873600, PF-07220060, or an analog thereof.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of BRAF.
- the BRAF inhibitors include ASN-003, AZ-304, AZ-628, DP-2874, EBI-907, EBI-945, GDC-0879, LYN 204, NMS-P285, NMS-P730, PF-04880594, TL-241, UAI-201,and UB-941.
- the BRAF inhibitors include ABM-1310, agerafenib (RXDX-105), ARQ-736, BAL-3833, belvarafenib, BGB-3245, BI-882370, DAY101, lifirafenib, LUT-014, PF-07284890, PLX-8394, RX-208, VS-6766, and XL-281.
- the BRAF inhibitors include dabrafenib, encorafenib, and vemurafenib.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of MDM2 or MDM4.
- MDM2 inhibitors include AD-021.32, CYC700, DS-5272, MI-1061, MI-219, MI-43, MD-224, MK-8242, NU-8231, OM-301, PXN-527, Rigel-3, RO-2468, RO-5353, RO-5963, and SIL-43.
- MDM2 inhibitors include ALRN-6924, APG-115, ASTX-295, ATSP-7041, BI-907828, CGM-097, idasanutlin, KRT-232 (AMG-232), MI-77301 (SAR405838, SAR299155), NVP-CGM097, RAIN-32 (milademetan), RG7112 (RO5045337), RG7388 (RG7775), serdemetan (JNJ-26854165), siremadlin, and UBX-0101.
- the MDM4 inhibitors include 17AAG, 489-PXN, CTX1, FL-118, Inulanolide A, K-178, and SAH-p53-8.
- the MDM4 inhibitors include APG-115, ALRN-6924, ATSP-7041, and BI-907828. Attorney Docket No.57547-724.601 [00187]
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of MET.
- the MET small molecule inhibitors such as ABP-1130, BPI-1831, BPI-2021, BYON-3521, CG-203306, CX-1003, Debio-1144, EMD-94283, EMT-100, EMT-101, HE-003, LMV-12, LS-177, NX-125, OMO-2, PF-4254644, PRX-MET, PTX-2173, QBH-196, RP-1400, SAB-Y14, SAR-125844, SGX-126, SYD-3521, WXSH-0011, X-379, and XL-265, and anti-MET antibodies such as ABX-900, GB-263, FS-101, LY-3164530, LY-3343544, PMC- 002, and SAIT-301.
- the MET small molecule inhibitors such as ABN-401, ABT-700, AMG-208, AMG-337, ARGX-111, BAY-85-3474, BMS-817378, bozitinib, BPI-9016M, glumetinib, golvatinib tartrate, GST-HG161, HQP-8361, I-020, JNJ-38877605, kanitinib, merestinib, MK-2461, MK- 8033, OMO-1, pamufetinib, S-49076, savolitinib, SPH-3348, tivantinib, SAR-125844, SCR-1515, and TPX- 0022, and anti-MET antibodies such as APL-101, CKD-702, EMB-01, EMI-137, ficlatuzumab, HLX-55, HS-10241, MCLA-129, MT-8633, NOV-11
- the MET small molecule inhibitors such as amivantamab, capmatinib, crizotinib, and tepotinib.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of CDK4/6.
- the CDK4/6 inhibitors include AG-122275, AM-5992, AU2-94, IIIM-985, IIIM-290, GW-491619, HEC-80797, MM-D37K, MS- 140, NP-102, QHRD-110, R-547, RGB-286199, RGT-419B, riviciclib, RO-0505124, THR-53, THR-79, TQB-3303, TY-302, VS2-370, XH-30002, and WXWH-0240.
- the CDK4/6 inhibitors include auceliciclib, AT-7519, BEBT-209, BPI-1178, BPI-16350, CS-3002, fascaplysin, FCN-437, FN- 1501, GLR-2007, HS-10342, lerociclib, milciclib maleate, NUV-422, ON-123300, PF-06842874, PF- 06873600, PF-07220060, SHR-6390, TQB-3616, TY-302, voruciclib, and XZP-3287.
- the CDK4/6 inhibitors include abemaciclib, palbociclib, ribociclib, and trilaciclib.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is palbociclib or abemaciclib.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of EGFR.
- the EGFR inhibitors include small molecule inhibitors such as APL-1898, BDTX-1535, BLU-701, BPI-361175, CH-7233163, DS-2087, E-10C, FWD-1509, IN-A008, JS-111, JS-113, LL-191, LYN 205, neptinib, NT-004, ORIC-114, PRB-001, SIM-200, TGRX-360, WJ-13404, yinlitinib maleate, and ZSP-0391, and anti-EGFR antibodies such as 705, 707, ABX-900, CMAB-017, GB-263, KN-023, SSGJ-612, and SHR-A1307.
- small molecule inhibitors such as APL-1898, BDTX-1535, BLU-701, BPI-361175, CH-7233163, DS-2087, E-10C, FWD-1509, IN-A008, JS-111, JS-113, LL-191, LYN
- the EGFR inhibitors include small molecule inhibitors such as abivertinib, alflutinib mesylate, agerafenib (RXDX-105), ASK-120067, BBT-176, BDTX-189, BEBT-109, befortinib mesylate, beitatini, Attorney Docket No.57547-724.601 BPI-7711, BPI-D0316, BLU-945, CK-101, dositinib, DFP-17729, DZD-9008, epertinib, epitinib (HMPL- 813), ES-072, FCN-411, FHND-9041, furmonertinib, GMA-204, Hemay-022, JRF-103, KP-673, larotinib, lazertinib, maihuatinib, marizomib, mobocertinib, naputinib tosil
- the EGFR inhibitors include small molecule inhibitors such as afatinib, amivantamab, aumolertinib (almonertinib), dacomitinib, erlotinib, gefitinib, icotinib, lapatinib, osimertinib, and pyrotinib, and anti-EGFR antibodies such as cetuximab, necitumumab, nimotuzumab, and panitumumab.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is erlotinib.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of FGFR.
- FGFR inhibitors include small molecule inhibitors such as ABSK-012, ABSK-061, AST-56100, BIO-1262, BGS-2219, EVT-601, FPI-1966, JAB-6000, KIN-3248, SAR-439115, SC-0011, and WXSH-0011, and anti- FGFR antibodies such as M-6123, OM-RCA-001.
- FGFR inhibitors include small molecule inhibitors such as 3D-185, ABSK-011, ABSK-091, aldafermin, alofanib, AZD-4547, BFKB-8488A, BPI-17509, BPI-43487, CPL-304-110, derazantinib, E- 7090, EVER-4010001, FGF-401, fisogatinib, futibatinib, gunagratinib, H3B-6527, HH-185, HMPL-453, HS-236, ICP-105, ICP-192, infigratinib, MAX-40279, RLY-4008, rogaratinib, SAR-442501, SY-4798, TT- 00434, and zoligratinib (FF-284), and anti- FGFR antibodies such as bemarituzumab.
- small molecule inhibitors such as 3D-185, ABSK-011, ABSK-091, aldafermin, al
- FGFR inhibitors include small molecule inhibitors such as erdafitinib and pemigatinib.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is infigratinib, futibatinib, or pemigatinib.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of KRAS.
- the KRAS inhibitor include small molecule inhibitors such as ABREV01, ARS-1620, APG-1842, ATG-012, BBP-454, BEPT- 607, BI-2852, BI-1823911, BPI-421286, BTX-2541, COTI-219, IMM-1811900, JAB-21000, JAB-22000, JAB-23000, JAB-BX300, JP-002, KR-12, LYN 202, MRTX-1133, RAS-F, RMC-6236, RMC-6291, SDGR 5, STX-301, and YL-15293, and anti-KRAS antibodies such as SBT-100, SBT-102, and SBT-300.
- small molecule inhibitors such as ABREV01, ARS-1620, APG-1842, ATG-012, BBP-454, BEPT- 607, BI-2852, BI-1823911, BPI-421286, BTX-2541, COTI-219, IMM-1811900,
- the KRAS include small molecule inhibitors such as adagrasib, ARS-3248, D-1553, GDC- 6036, JDQ-443, LY3537982, sotorasib (AMG 510), and BI 1701963.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of c-MET, HER2, androgen receptor (AR), KIT, PDGFRA PI3K, AKT, BCL2, or MCL1.
- the c-MET inhibitor includes crizotinib, tivantinib, cabozantinib, foretinib), or a monoclonal antibody against c-MET such as onartuzumab.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is a c-MET inhibitor.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is tepotinib.
- the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent targets a protein encoded by one or more genes provided in Table 3.
- the tumor or tumor cells prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, comprise a gene amplification and wherein the cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification.
- the tumor or tumor cells prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, comprise a gene amplification and wherein the first (prior) cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification.
- the tumor or tumor cells prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, comprise a gene amplification and wherein the second cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification.
- the tumor or tumor cells prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, comprise a gene amplification and wherein the selected cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification.
- the subject received one or more administrations of the first (prior) cancer-targeted therapeutic agent prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and wherein the tumor or tumor cells developed resistance to the first (prior) cancer-targeted therapeutic agent.
- Attorney Docket No.57547-724.601 [00205]
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is administered concurrently or prior to the administration of the cancer-targeted therapeutic agent.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is administered concurrently or prior to the administration of the selected cancer-targeted therapeutic agent.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is administered concurrently or prior to the administration of the first (prior) cancer-targeted therapeutic agent.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is administered concurrently or prior to the administration of the second (selected) cancer-targeted therapeutic agent.
- the subject received one or more administrations of the first (prior) cancer-targeted therapeutic agent prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and wherein the tumor or tumor cells developed decreased responsiveness or resistance to the first (prior) cancer-targeted therapeutic agent.
- treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the cancer-targeted therapeutic agent when administered alone.
- treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the first (prior) cancer- targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the first (prior) cancer-targeted therapeutic agent when administered alone.
- treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the second (selected) cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the second (selected) cancer-targeted therapeutic agent when administered alone.
- different therapeutically effective dosages of the compounds disclosed herein will be utilized in formulating a pharmaceutical composition and/or in treatment regimens when the compounds disclosed herein are administered in combination with a second (selected) therapeutic agent.
- Therapeutically effective dosages of drugs and other agents for use in combination treatment regimens are optionally determined by means similar to those set forth hereinabove for the actives themselves. Furthermore, the methods of prevention/treatment described herein encompasses the use of metronomic dosing, i.e., providing more frequent, lower doses in order to minimize toxic side effects.
- a combination treatment regimen encompasses treatment regimens in which administration of a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is initiated prior to, during, or after treatment with a second (selected) agent described herein, and continues until any time during treatment with the second (selected) agent or after termination of treatment with the second (selected) agent. It also includes treatments in which a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the second (selected) agent being used in combination are administered simultaneously or at different times and/or at decreasing or increasing intervals during the treatment period.
- Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient.
- the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought is modified in accordance with a variety of factors (e.g., the disease, disorder, or condition from which the subject suffers; the age, weight, sex, diet, and medical condition of the subject).
- the dosage regimen employed varies and, in some embodiments, deviates from the dosage regimens set forth herein.
- dosages of the co-administered compounds vary depending on the type of co-drug employed, on the specific drug employed, on the disease or condition being treated, and so forth.
- the compounds described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, as well as combination therapies, are administered before, during, or after the occurrence of a disease or condition, and the timing of administering the composition containing a compound varies.
- the compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is administered in combination with an adjuvant.
- the therapeutic effectiveness of one of the compounds described herein is enhanced by administration of an adjuvant (i.e., by itself the adjuvant has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced).
- the subject identified as having the tumor or tumor cells has cancer.
- the cancer includes malignant tumors whose size can be decreased, whose growth or spread can be slowed or halted, or whose symptom is in remission or alleviated, reduced, and/or completely cured by deleting or suppressing and/or inhibiting functions of Chk1.
- Malignant tumors of interest are, but not limited to, head and neck cancer, gastrointestinal cancer (esophageal cancer, gastric cancer, duodenal cancer, liver cancer, biliary tract cancer (gallbladder, bile duct cancer, etc.), pancreatic cancer, colorectal cancer (colon cancer, rectal cancer, etc.), etc.), lung cancer (non-small cell lung cancer, small cell lung cancer, squamous cell lung carcinoma, mesothelioma, etc.), breast cancer, genital cancer (ovarian cancer, Attorney Docket No.57547-724.601 uterine cancer, cervical cancer, endometrial cancer, etc.), urinary cancer (kidney cancer, bladder cancer, prostate cancer, testicular tumor, etc.), hematopoietic tumors (leukemia, malignant lymphoma, multiple myeloma, etc.), bone and soft tissue tumors (e.g., soft tissue sarcomas and osteosarcomas), skin cancer
- cancer is used in accordance with its plain ordinary meaning in light of the present disclosure and refers to all types of cancer, neoplasm or malignant tumors found in mammals, including leukemias, lymphomas, melanomas, neuroendocrine tumors, carcinomas, and sarcomas.
- Exemplary cancers that may be treated with a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, pharmaceutical compositions include acute myeloid leukemia, adrenal cortical cancer, adrenal gland cancer, bladder cancer, bone cancer, brain cancer, breast cancer (e.g., ductal carcinoma, lobular carcinoma, primary, metastatic), breast cancer, cancer of the endocrine system, cancer of the hepatic stellate cells, cancer of the pancreatic stellate cells, cervical cancer, colon cancer, colorectal cancer, ductal carcinoma, endometrial cancer, esophageal cancer, gastric cancer, genitourinary tract cancer, glioblastoma, glioma, head and neck cancer, hepatocellular carcinoma, Hodgkin’s Disease, kidney cancer, leukemia (e.g., lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia), liver cancer (e.g.,
- the cancer is selected from bladder cancer, breast cancer, colon cancer, esophageal cancer, esophageal cancer, glioblastoma, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, salivary gland cancer, soft tissue sarcoma, squamous cell lung carcinoma, stomach cancer, and uterine cancer.
- Gene amplification plays a role in the response of a tumor or tumor cells to cancer-directed therapies and in the development of resistance to targeted therapies.
- gene amplification includes amplification of one or more genes, such as oncogenes, in a focal amplification, where the one or more oncogenes are in higher copy number, whereas surrounding genetic material (e.g., from the chromosomal location of such amplified gene) is not amplified or not at the same level of amplification.
- Focal amplifications may be located on ecDNA or ecDNA-derived, (i.e., derived from ecDNA, such as ecDNA that has reintegrated into a chromosomal location).
- ecDNA mediates an important and clinically Attorney Docket No.57547-724.601 distinct mechanism of resistance to targeted therapies.
- Tumor cells with ecDNA and/or ecDNA-derived amplifications may become non-responsive, less responsive, or resistant to a targeted therapy.
- the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof may be used in combination with a therapeutic agent to treat an ecDNA+ cancer, ecDNA+ tumor or ecDNA+ tumor cells (i.e., tumor cells containing gene amplifications on ecDNA or derived from ecDNA).
- a therapeutic agent to treat an ecDNA+ cancer, ecDNA+ tumor or ecDNA+ tumor cells (i.e., tumor cells containing gene amplifications on ecDNA or derived from ecDNA).
- the combination of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and a therapeutic agent may be used to treat tumors, such as with one or more amplified oncogenes (e.g., BRAF, CDK4, CDK6, EGFR, FGFR, HER2, KRAS, MET, MDM2 amplifications); in some cases, the one or more amplified oncogenes comprise non-mutant forms of the oncogene and in some cases, the amplified oncogenes comprises mutant forms of the oncogenes.
- one or more amplified oncogenes e.g., BRAF, CDK4, CDK6, EGFR, FGFR, HER2, KRAS, MET, MDM2 amplifications
- the one or more amplified oncogenes comprise non-mutant forms of the oncogene and in some cases, the amplified oncogenes comprises mutant forms of the onc
- the one or more amplified oncogenes are extrachromosomal (i.e., on ecDNA) and/or are ecDNA-derived and located on a chromosome.
- the therapeutic agent used in combination with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is an inhibitor of a protein encoded by a gene that is amplified on ecDNA or the ecDNA-derived amplification.
- the combinations described herein may be used to treat tumors that have developed resistance to another therapy such as a resistance to a targeted agent.
- a tumor (or tumor cells) treated with a first (prior) targeted agent develops resistance to the first (prior) targeted agent or becomes less responsive or non-responsive to the first (prior) targeted agent.
- the first (prior) therapeutic agent is an inhibitor of a protein encoded by a gene that is amplified on ecDNA or the ecDNA-derived amplification and the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and the first (prior) targeted agent may be used to treat such tumors or tumor cells.
- the first (prior) therapeutic agent is an inhibitor of a protein encoded by a gene that is amplified on ecDNA or the ecDNA-derived amplification and the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and a second (selected) targeted agent may be used to treat such tumors or tumor cells, where the second (selected) targeted agent is an inhibitor of a different protein from the protein target of the first (prior) targeted agent.
- a tumor background is identified as hyper-sensitive to a Chk1 inhibitor and allows a sufficient therapeutic index to enable tolerated doses that are efficacious.
- synthetic lethality arises with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof in combination with a cancer-targeted agent where the tumor Attorney Docket No.57547-724.601 or tumor cells are ecDNA+ (i.e., contain ecDNA or ecDNA-derived gene amplification) .
- a cancer-targeted agent where the tumor Attorney Docket No.57547-724.601 or tumor cells are ecDNA+ (i.e., contain ecDNA or ecDNA-derived gene amplification) .
- Chk1 inhibition results in reduced ecDNA copy number.
- Chk1 inhibition results in enhanced cytotoxicity in ecDNA+ cells.
- enhanced cytotoxicity results from the combination of Chk1 inhibition and inhibition of a cancer-target, such as an oncogene.
- the tumor or tumor cells prior to treatment the tumor or tumor cells comprise ecDNA and wherein the treatment results in a reduction in the amount of ecDNA in the tumor or tumor cells.
- prior to treatment the tumor or tumor cells comprise ecDNA and wherein level or amount of ecDNA subsequent to the treatment is not increased as compared to prior to treatment.
- the method further comprises assessing a sample from a subject for the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature.
- the method further comprises obtaining information of the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature in the tumor or tumor cells from the subject prior to, during or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- information is obtained prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and a targeted cancer therapeutic agent.
- such information is obtained during the course of treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof inhibitor and a targeted cancer therapeutic agent.
- such information is obtained after treatment with a first (prior) targeted cancer therapeutic agent but prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and if the information indicates the presence of ecDNA, or an ecDNA-derived gene amplification, the subject is treated with a combination of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and the first (prior) targeted cancer therapeutic agent or with a combination of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and a second (selected) targeted cancer therapeutic agent.
- a tumor or tumor cells are determined to have an ecDNA signature. In some cases, a tumor or tumor cells are determined to have an ecDNA signature when the tumor or tumor cells have one or more characteristics associated with ecDNA+ tumors or tumor cells.
- the ecDNA signature is selected from the group consisting of a gene amplification; a focal gene amplification; characterization of a structural variation; a p53 loss of function mutation; absence of microsatellite instability (MSI-H); a low level of PD-L1 expression; a low level of tumor inflammation Attorney Docket No.57547-724.601 signature (TIS); a low level of tumor mutational burden (TMB); an increased frequency of allele substitutions, insertions, or deletions (indels); and any combination thereof.
- the tumor or tumor cells have an ecDNA signature.
- the tumor or tumor cells develop the ecDNA signature after administration of a first (prior) cancer-targeted therapeutic agent. In some cases, the tumor or tumor cells develop the ecDNA signature prior to treatment. [00227] In some embodiments of a method disclosed herein, the information of the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature in the tumor or tumor cells is obtained from blood, tissue or one or more cells.
- the information of the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature in the tumor or tumor cells is obtained by liquid biopsy or tissue biopsy.
- Embodiment 1 A method of treating a tumor or tumor cells, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a cancer-targeted therapeutic agent to a subject identified as having the tumor or tumor cells, wherein the tumor or tumor cells comprise a gene amplification, whereby growth or size of the tumor or growth or number of tumor cells is reduced.
- Embodiment 2 The method of embodiment 1, wherein the cancer-targeted therapeutic agent is administered concurrent or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- Embodiment 3 The method of embodiment 1 or embodiment 2, wherein the cancer-targeted therapeutic agent is administered prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- Embodiment 4 The method of any one of embodiments 1-3, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered in an amount sufficient to induce replication stress in the tumor or tumor cells.
- Embodiment 5 A method of delaying resistance to a cancer-targeted therapeutic agent, the method comprising: administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, to a subject in an amount sufficient to induce replication stress in tumor or tumor cells and administering a cancer-targeted therapeutic agent concurrently or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- Embodiment 6 The method of embodiment 5, wherein the subject is identified as having the tumor or tumor cells comprising a gene amplification.
- Embodiment 7 The method of any one of embodiments 1-4 or 6, wherein the gene amplification is a focal gene amplification. Attorney Docket No.57547-724.601 [00236] Embodiment 8: The method of any one of embodiments 1-4, 6, or 7, wherein the gene amplification is an ecDNA-derived amplification. [00237] Embodiment 9: The method of any one of embodiments 1-4 or 6-8, wherein the gene amplification is comprised on ecDNA or an HSR (homogeneously staining region).
- HSR homogeneously staining region
- Embodiment 10 The method of any one of embodiments 1-4 or 6-9, wherein the cancer-targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification.
- Embodiment 11 The method of any one of embodiments 1-10, wherein the tumor or tumor cells comprise an ecDNA signature.
- Embodiment 12 The method of any one of embodiments 1-11, wherein cells comprised within the tumor or the tumor cells are ecDNA competent.
- Embodiment 13 The method of any one of embodiments 1-12, wherein treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the cancer therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the cancer therapeutic agent when administered alone.
- Embodiment 14 The method of embodiment 13, wherein the greater effect is a synergistic effect.
- Embodiment 15 The method of any one of embodiments 1-14, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer- targeted therapeutic agent is administered orally.
- Embodiment 16 The method of any one of embodiments 1-14, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer- targeted therapeutic agent is administered parentally.
- Embodiment 17 The method of any one of embodiments 1-16, wherein treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer-targeted therapeutic agent over a treatment period.
- Embodiment 18 The method of any one of embodiments 1-4 or 6-17, wherein the gene amplification comprises an amplification of a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HER2, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3C ⁇ , PIK3CA/B, RET, and ROS1.
- a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EG
- Embodiment 19 The method of any one of embodiments 1-18, wherein the cancer therapeutic agent is selected from the group consisting of abemaciclib, ado-trastuzumab emtansine, afatinib, alectinib, ALRN-6924, AMG232, AMG-510, apatinib, ARS-3248, AXL1717, AZD-3759, bevacizumab, BI 1701963, bortezomib, brigatinib, cabozantinib, capmatinib, ceritinib, cetuximab, CGM097, crizotinib, dabrafenib, dacomitinib, dasatinib, DS-3032b, encorafenib, entrectinib, ERAS-801, erdafitinib, erlotinib, everolimus, fam-t
- Embodiment 20 A method of treating a subject having a tumor or tumor cells that are non- responsive to a first cancer-targeted therapeutic agent comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a second cancer- targeted therapeutic agent to the subject.
- Embodiment 21 The method of the embodiment 20, wherein prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, the tumor or tumor cells comprise a gene amplification and wherein the first cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification.
- Embodiment 22 The method of embodiment 21, wherein the subject received one or more administrations of the first cancer-targeted therapeutic agent prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and wherein the tumor or tumor cells developed resistance to the first cancer-targeted therapeutic agent.
- Embodiment 23 The method of any one of embodiments 20-22, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered concurrently or prior to the administration of the second cancer-targeted therapeutic agent.
- Embodiment 24 The method of any one of embodiments 21-23, wherein the gene amplification is a focal gene amplification.
- Embodiment 25 The method of any one of embodiments 21-24, wherein the gene amplification is an ecDNA-derived amplification.
- Embodiment 26 The method of any one of embodiments 21-25, wherein the gene amplification is comprised on ecDNA or an HSR (homogeneously staining region).
- Embodiment 27 The method of any one of embodiments 21-26, wherein the second cancer- targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification.
- Embodiment 28 The method of any one of embodiments 20-27, wherein the tumor or tumor cells comprise an ecDNA signature.
- Embodiment 29 The method of any one of embodiments 20-28, wherein cells comprised within the tumor or the tumor cells are ecDNA competent.
- Embodiment 30 The method of any one of embodiments 20-29, wherein treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the cancer therapeutic agent has a greater effect or a longer duration of effect on reduction of one or Attorney Docket No.57547-724.601 more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the cancer therapeutic agent when administered alone.
- Embodiment 31 The method of embodiment 30, wherein the greater effect is a synergistic effect.
- Embodiment 32 The method of any one of embodiments 20-31, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second cancer-targeted therapeutic agent is administered orally.
- Embodiment 33 The method of any one of embodiments 20-31, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second cancer-targeted therapeutic agent is administered parentally.
- Embodiment 34 The method of any one of embodiments 20-33, wherein treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second cancer-targeted therapeutic agent over a treatment period.
- Embodiment 35 The method of any one of embodiments 21-34, wherein the gene amplification comprises an amplification of a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL- 2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3C ⁇ , PIK3CA/B, RET, and ROS1.
- a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL- 2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER,
- Embodiment 36 The method of any one of embodiments 20-35, wherein the first cancer-targeted therapeutic agent is selected from the group consisting of abemaciclib, ado-trastuzumab emtansine, afatinib, alectinib, ALRN-6924, AMG232, AMG-510, apatinib, ARS-3248, AXL1717, AZD-3759, bevacizumab, BI 1701963, bortezomib, brigatinib, cabozantinib, capmatinib, ceritinib, cetuximab, CGM097, crizotinib, dabrafenib, dacomitinib, dasatinib, DS-3032b, encorafenib, entrectinib, ERAS-801, erdafitinib, erlotinib, everolimus,
- Embodiment 37 The method of any one of embodiments 20-35, wherein the second cancer- targeted therapeutic agent is selected from the group consisting of abemaciclib, ado-trastuzumab emtansine, afatinib, alectinib, ALRN-6924, AMG232, AMG-510, apatinib, ARS-3248, AXL1717, AZD-3759, bevacizumab, BI 1701963, bortezomib, brigatinib, cabozantinib, capmatinib, ceritinib, cetuximab, CGM097, crizotinib, dabrafenib, dacomitinib, dasatinib, DS-3032b, encorafenib, entrectinib, ERAS-801, erdafitinib, erlotinib, everolimus,
- Embodiment 38 A method of provoking a response in a subject having a tumor or tumor cells that are non-responsive or have decreased responsiveness to a first cancer-targeted therapeutic agent comprising administering a Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the first cancer-targeted therapeutic agent to the subject.
- a Formula (I) or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof
- Embodiment 39 The method of the embodiment 38, wherein prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, the tumor or tumor cells comprise a gene amplification and wherein the first cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification.
- Embodiment 40 The method of embodiment 38 or embodiment 39, wherein the subject received one or more administrations of the first cancer-targeted therapeutic agent prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and wherein the tumor or tumor cells developed decreased responsiveness or resistance to the first cancer- targeted therapeutic agent.
- Embodiment 41 The method of embodiment 39 or embodiment 40, wherein the gene amplification is a focal gene amplification.
- Embodiment 42 The method of any one of embodiments 39-41, wherein the gene amplification is an ecDNA-derived amplification.
- Embodiment 43 The method of any one of embodiments 39-42, wherein the gene amplification is comprised on ecDNA or an HSR (homogeneously staining region).
- Embodiment 44 The method of any one of embodiments 38-43, wherein the tumor or tumor cells comprise an ecDNA signature.
- Embodiment 45 The method of any one of embodiments 38-44, wherein cells comprised within the tumor or the tumor cells are ecDNA competent.
- Embodiment 46 The method of any one of embodiments 38-45, wherein treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the first cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the first cancer-targeted therapeutic agent when administered alone.
- Embodiment 47 The method of embodiment 46, wherein the greater effect is a synergistic effect.
- Embodiment 48 The method of any one of embodiments 38-47, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the first cancer-targeted therapeutic agent is administered orally.
- Embodiment 49 The method of any one of embodiments 38-47, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second cancer-targeted therapeutic agent is administered parentally.
- Embodiment 50 The method of any one of embodiments 38-49, wherein treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the first cancer-targeted therapeutic agent over a treatment period.
- Embodiment 51 The method of any one of embodiments 39-50, wherein the gene amplification comprises an amplification of a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL- 2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3C ⁇ , PIK3CA/B, RET, and ROS1.
- a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL- 2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER,
- Embodiment 52 The method of any one of embodiments 20-51, wherein the first cancer-targeted therapeutic agent is selected from the group consisting of abemaciclib, ado-trastuzumab emtansine, afatinib, alectinib, ALRN-6924, AMG232, AMG-510, apatinib, ARS-3248, AXL1717, AZD-3759, bevacizumab, BI 1701963, bortezomib, brigatinib, cabozantinib, capmatinib, ceritinib, cetuximab, CGM097, crizotinib, dabrafenib, dacomitinib, dasatinib, DS-3032b, encorafenib, entrectinib, ERAS-801, erdafitinib, erlotinib, everolimus,
- Embodiment 53 The method of any one of embodiments 1-52, wherein prior to treatment the tumor or tumor cells comprise ecDNA and wherein the treatment results in a reduction in the amount of ecDNA in the tumor or tumor cells.
- Embodiment 54 The method of any one of embodiments 1-52, wherein prior to treatment the tumor or tumor cells comprise ecDNA and wherein level or amount of ecDNA subsequent to the treatment is not increased as compared to prior to treatment.
- Embodiment 55 The method of any one of embodiments 1-54, wherein the method further comprises assessing a sample from a subject for the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature.
- Embodiment 56 The method of any one of embodiments 1-55, wherein the method further comprises obtaining information of the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature in the tumor or tumor cells from the subject prior to, during or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
- Embodiment 57 The method of embodiment 55, wherein the information is obtained from blood, tissue or one or more cells.
- Embodiment 58 The method of embodiment 55, wherein the information is obtained by liquid biopsy or tissue biopsy.
- Example 1 Kinase HTRF biochemical assay
- Chk1 enzyme activity was measured using an HTRF KinEASE assay (Cisbio, catalog no. 62ST1PEC).
- Full-length human CHK1 protein (GenBank accession number NP_001265.1) was obtained from Carna Biosciences, Inc. (Kobe, Japan, catalog no.02-117). The enzyme reaction was carried out in assay buffer containing (final concentrations): CHK1 enzyme (0.012 ng/ ⁇ L), MgCl2 (5 mM) and DTT (1 mM).
- DMSO stock solutions were serially diluted in a 10-point concentration series in duplicate.
- Compound solution 50 nL was added to 384-well assay plates (Greiner, catalog no.784075). To each well containing compound solution was added assay buffer solution (5 ⁇ L). Plates were centrifuged at 1000 rpm for 1 minute, then incubated at room temperature for 10 minutes. The reaction was started by addition of substrate buffer (5 ⁇ L/well) containing (final concentrations): STK substrate 1-biotin (120 nM) and ATP (1 mM). Assay plates were centrifuged at 1000 rpm for 1 minute, then incubated at room temperature for 60 minutes.
- the reaction was stopped by addition of detection buffer (Cisbio, 10 ⁇ L) containing (final concentrations): STK antibody-cryptate (0.25 nM) and streptavidin-XL665 (7.5 nM). Plates were centrifuged at 1000 rpm for 1 minute, then incubated at 25 °C for 2 hours.
- HTRF signal was read on an EnVision multimode plate reader (CisBio) in HTRF mode. Data were fit to dose- response curves using XLfit (IDBS, Surrey, UK) or Prism (GraphPad Software, La Jolla, CA, US) to calculate IC50 values for each compound tested.
- Example 2 AlphaLisa cellular assay
- Compound activity in cells was measured using an AlphaLISA® SureFire® UltraTM p-CHK1 (Ser345) assay (Perkin Elmer, catalog no. ALSU-PCHK1-A10K).
- HT29 cells were cultured in McCoy 5A medium with 10% FBS and 1% penicillin-streptomycin and seeded to 96-well plates (Corning, catalog no. 3599).
- Compounds were serially diluted in DMSO over a 10-point dose range with 3-fold dilution and to each well containing cells was added compound solution. Plates were centrifuged at 1000 rpm for 30 seconds. Plates were incubated at 37 °C for 16 h.
- mice were implanted with the tumor cells and once the tumors were established (e.g., reached a volume of about 100-350 mm 3 ), the mice were started on the therapeutic regimens as further described below.
- synergy of the combination therapy compared to corresponding single agent arms was determined using the Fractional Product Method (Webb et al., 1963). A summary of the results is shown in Table 5. Fraction unaffected (fu) is the % where tumor growth inhibition was not observed.
- the fu observed with the combination treatment (fu)A+B (“observed fu”) was compared to the predicted fu calculated as the product of the observed fu for the single treatments (fu)A x (fu)B.
- CDK4/6 [00295] The combination of Compound 31 (50 mg/kg PO dosed Q2D) plus the CDK4/6 inhibitors palbociclib (50 mg/kg PO dosed QD) or abemaciclib (10.5 mg/kg PO dosed QD) was evaluated in the ecDNA+ CDK4 amplified osteosarcoma SJSA-1 CDX tumor model. Results are shown in FIG.2A (Palbociclib) and FIG.2B (abemaciclib).
- the combination of Compound 31 plus palbociclib or abemaciclib Attorney Docket No.57547-724.601 resulted in significant anti-tumor activity, including tumor regressions, when compared to vehicle.
- the combination of Compound 31 plus abemaciclib was determined to be synergistic.
- EGFR [00296] The combination of Compound 31 (50 mg/kg PO dosed Q2D) plus the EGFR inhibitor erlotinib (50 mg/kg PO dosed QD) was evaluated in the ecDNA+ EGFR amplified NSCLC PDX tumor models LU1206. Results are shown in FIG.3.
- the combination therapy resulted in significant tumor growth inhibition when compared to vehicle, and the therapy was determined to be synergistic.
- Example 4 Suppression of ecDNA amplification
- Prolonged treatment of SNU-16 tumor cells in vitro and SNU-16 CDX tumors in vivo with the pan-FGFR tyrosine kinase inhibitor infigratinib resulted in tumor cell stasis for a period of 1-2 weeks but acquired resistance to infigratinib treatment occurred resulting in re-initiation of tumor growth.
- Infigratinib resistance was directly correlated with increased amplification of FGFR2 (copy number) on ecDNA.
- Combination treatment of infigratinib plus Compound 31 blocked the increase of FGFR2 copy number on ecDNA that otherwise was induced by single agent infigratinib.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Provided herein are methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chkl inhibitor disclosed herein in combination with an additional therapeutic agent.
Description
Attorney Docket No.57547-724.601 CHECKPOINT KINASE 1 (CHK1) INHIBITORS COMBINATIONS AND USES THEREOF CROSS-REFERENCE [0001] This application claims the benefit of U. S. Provisional Application Serial No.63/385,347 filed November 29, 2022 which is hereby incorporated by reference in its entirety. FIELD OF THE INVENTION [0002] Described herein are combinations, comprising compounds for inhibiting checkpoint kinase 1 (Chk1). BACKGROUND OF THE INVENTION [0003] Some cancers prove resistant to the therapeutics that are used to treat them, frustrating efforts to maintain a durable and progression free survival in cancer patients. Patients whose tumors harbor oncogene amplification can prove particularly difficult to treat. For example, patients whose tumors harbor oncogene amplification on or derived from extrachromosomal DNA (ecDNA) may fail to respond to targeted or immune therapy and have poor prognosis. [0004] Single agent therapies may be less effective in some patient populations or have shorter durability before the tumor or tumor cells develop resistance. There is a need to develop multiple points of attack on such cancers. However, combinations of therapeutic agents have also proven susceptible to similar development of resistance or reduced responsiveness. [0005] There is a need for combinations are potent therapeutic treatments with increased durability and longevity of effect to address the need for safe and effective treatments of cancer. BRIEF SUMMARY OF THE INVENTION [0006] Disclosed herein is a method of treating a tumor or tumor cells, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a selected cancer-targeted therapeutic agent to a subject identified as having the tumor or tumor cells, wherein the tumor or tumor cells comprise a gene amplification, whereby growth or size of the tumor or growth or number of tumor cells is reduced. [0007] Also disclosed herein is a method of delaying resistance to a selected cancer-targeted therapeutic agent, the method comprising: administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, to a subject in an amount sufficient to induce replication stress in tumor or tumor cells and administering the selected cancer-targeted therapeutic agent concurrently or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [0008] Also disclosed herein is a method of treating a subject having a tumor or tumor cells that are non- responsive to a prior cancer-targeted therapeutic agent comprising administering a compound of Formula (I),
Attorney Docket No.57547-724.601 or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a selected cancer- targeted therapeutic agent to the subject. [0009] In some embodiments of a method disclosed herein, the subject received one or more administrations of the prior cancer-targeted therapeutic agent prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and wherein the tumor or tumor cells developed decreased responsiveness or resistance to the prior cancer-targeted therapeutic agent. [0010] Also disclosed herein is a method of provoking a response in a subject having a tumor or tumor cells that are non-responsive or have decreased responsiveness to a prior cancer-targeted therapeutic agent comprising administering a Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a selected cancer-targeted therapeutic agent to the subject; wherein the prior cancer-targeted therapeutic agent is the same as the selected cancer-targeted therapeutic agent. [0011] In some embodiments of a method disclosed herein, prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, the tumor or tumor cells comprise a gene amplification and wherein the prior cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification. [0012] In some embodiments of a method disclosed herein, the selected cancer-targeted therapeutic agent is administered concurrent or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [0013] In some embodiments of a method disclosed herein, the selected cancer-targeted therapeutic agent is administered prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [0014] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered in an amount sufficient to induce replication stress in the tumor or tumor cells. [0015] In some embodiments of a method disclosed herein, the subject is identified as having the tumor or tumor cells comprising a gene amplification. [0016] In some embodiments of a method disclosed herein, the gene amplification is a focal gene amplification. [0017] In some embodiments of a method disclosed herein, the gene amplification is an ecDNA-derived amplification. [0018] In some embodiments of a method disclosed herein, the gene amplification is comprised on ecDNA or an HSR (homogeneously staining region). [0019] In some embodiments of a method disclosed herein, the tumor or tumor cells comprise an ecDNA signature. [0020] In some embodiments of a method disclosed herein, the selected cancer-targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification.
Attorney Docket No.57547-724.601 [0021] In some embodiments of a method disclosed herein, cells comprised within the tumor or the tumor cells are ecDNA competent. [0022] In some embodiments of a method disclosed herein, treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the selected cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the selected cancer-targeted therapeutic agent when administered alone. [0023] In some embodiments of a method disclosed herein, the greater effect is a synergistic effect. [0024] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the selected cancer- targeted therapeutic agent is administered orally. [0025] In some embodiments of a method disclosed herein, treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the selected cancer-targeted therapeutic agent over a treatment period. [0026] In some embodiments of a method disclosed herein, the gene amplification comprises an amplification of a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3Cδ, PIK3CA/B, RET, and ROS1. [0027] In some embodiments of a method disclosed herein, the gene amplification comprises an amplification of a gene selected from the group consisting of CDK4, CDK6, c-MET, EGFR, FGFR1, FGFR2, FGFR3, and FGFR4. [0028] In some embodiments of a method disclosed herein, the selected cancer therapeutic agent is an FGFR inhibitor. In some embodiments of a method disclosed herein, the FGFR inhibitor is infigratinib, futibatinib, or pemigatinib. [0029] In some embodiments of a method disclosed herein, the selected cancer therapeutic agent is a CDK4/6 inhibitor. In some embodiments of a method disclosed herein, the CDK4/6 inhibitor is palbociclib or abemaciclib. [0030] In some embodiments of a method disclosed herein, the selected cancer therapeutic agent is an EGFR inhibitor. In some embodiments of a method disclosed herein, the EGFR inhibitor is erlotinib. [0031] In some embodiments of a method disclosed herein, the selected cancer therapeutic agent is a c- MET inhibitor. In some embodiments of a method disclosed herein, the c-MET inhibitor is tepotinib. [0032] In some embodiments of a method disclosed herein, prior to treatment the tumor or tumor cells comprise ecDNA and wherein the treatment results in a reduction in the amount of ecDNA in the tumor or tumor cells.
Attorney Docket No.57547-724.601 [0033] In some embodiments of a method disclosed herein, prior to treatment the tumor or tumor cells comprise ecDNA and wherein level or amount of ecDNA subsequent to the treatment is not increased as compared to prior to treatment. [0034] In some embodiments of a method disclosed herein, the method further comprises assessing a sample from a subject for the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature. [0035] In some embodiments of a method disclosed herein, the method further comprises obtaining information of the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature in the tumor or tumor cells from the subject prior to, during or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [0036] In some embodiments of a method disclosed herein, the information is obtained from blood, tissue or one or more cells. [0037] In some embodiments of a method disclosed herein, the information is obtained by liquid biopsy or tissue biopsy. [0038] In some embodiments of a method disclosed herein, the prior cancer-targeted therapeutic agent is targeted to the protein encoded by a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3Cδ, PIK3CA/B, RET, and ROS1. [0039] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is
Formula (I) as disclosed herein. [0040] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is a compound of Formula (Ib):
Attorney Docket No.57547-724.601
Formula (Ib). [0041] In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof,
pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. INCORPORATION BY REFERENCE [0042] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference for the specific purposes identified herein. BRIEF DESCRIPTION OF THE DRAWINGS [0043] The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which: [0044] FIG.1A shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the pan-FGFR inhibitor infigratinib (15 mg/kg PO dosed QD) in the ecDNA+ FGFR2 amplified gastric cancer SNU-16 CDX model. FIG.1B shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the pan-FGFR inhibitor infigratinib (15 mg/kg PO dosed QD) in the ecDNA+ FGFR2 amplified gastric cancer CTG-0353 PDX model. FIG.1C shows the survival curves following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the pan-FGFR inhibitor infigratinib (15 mg/kg PO dosed QD) in the ecDNA+ FGFR2 amplified gastric cancer CTG-0353 PDX model.
Attorney Docket No.57547-724.601 FIG.1D shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the pan-FGFR inhibitor futibatinib (12.5 mg/kg PO dosed QD) in the ecDNA+ FGFR2 amplified gastric cancer SNU-16 CDX model. FIG.1E shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the pan-FGFR inhibitor pemigatinib (1 mg/kg PO dosed QD) in the ecDNA+ FGFR2 amplified gastric cancer SNU-16 CDX model. FIG.2A shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the CDK4/6 inhibitors palbociclib (50 mg/kg PO dosed QD) in the ecDNA+ CDK4 amplified osteosarcoma SJSA-1 CDX tumor model. FIG.2B shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the CDK4/6 inhibitors abemaciclib (10.5 mg/kg PO dosed QD) in the ecDNA+ CDK4 amplified osteosarcoma SJSA-1 CDX tumor model. FIG.3 shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the EGFR inhibitor erlotinib (50 mg/kg PO dosed QD) in the ecDNA+ EGFR amplified NSCLC PDX tumor models LU1206. FIG.4 shows the tumor volume following treatment with the combination of Compound 31 (50 mg/kg PO dosed Q2D) and the MET inhibitor tepotinib (25 mg/kg PO dosed Q2D) in the ecDNA+ MET amplified NSCLC PDX tumor models LU1902. FIG.5 shows that combination treatment of infigratinib plus Compound 31 blocked the increase of FGFR2 copy number on ecDNA that otherwise was induced by single agent infigratinib. DETAILED DESCRIPTION OF THE INVENTION Definitions [0045] In the following description, certain specific details are set forth in order to provide a thorough understanding of various embodiments. However, one skilled in the art will understand that the invention may be practiced without these details. In other instances, well-known structures have not been shown or described in detail to avoid unnecessarily obscuring descriptions of the embodiments. Unless the context requires otherwise, throughout the specification and claims which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense, that is, as “including, but not limited to.” Further, headings provided herein are for convenience only and do not interpret the scope or meaning of the claimed invention. [0046] Reference throughout this specification to “some embodiments” or “an embodiment” means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Also, as used in this specification and the appended claims, the singular forms
Attorney Docket No.57547-724.601 “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. [0047] The terms below, as used herein, have the following meanings, unless indicated otherwise: [0048] “oxo” refers to =O. [0049] “Carboxyl” refers to -COOH. [0050] “Cyano” refers to -CN. [0051] “Alkyl” refers to a straight-chain or branched-chain saturated hydrocarbon monoradical having from one to about ten carbon atoms, more preferably one to six carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3- methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1- pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1- butyl, 2-ethyl-1-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl and hexyl, and longer alkyl groups, such as heptyl, octyl and the like. Whenever it appears herein, a numerical range such as “C1-C6 alkyl” or “C1-6alkyl”, means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated. In some embodiments, the alkyl is a C1-10alkyl. In some embodiments, the alkyl is a C1-6alkyl. In some embodiments, the alkyl is a C1-5alkyl. In some embodiments, the alkyl is a C1-4alkyl. In some embodiments, the alkyl is a C1-3alkyl. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkyl is optionally substituted with halogen. [0052] “Alkenyl” refers to a straight-chain, or branched-chain hydrocarbon monoradical having one or more carbon-carbon double-bonds and having from two to about ten carbon atoms, more preferably two to about six carbon atoms. The group may be in either the cis or trans conformation about the double bond(s), and should be understood to include both isomers. Examples include, but are not limited to ethenyl (- CH=CH2), 1-propenyl (-CH2CH=CH2), isopropenyl [-C(CH3)=CH2], butenyl, 1,3-butadienyl and the like. Whenever it appears herein, a numerical range such as “C2-C6 alkenyl” or “C2-6alkenyl”, means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated. Unless stated otherwise specifically in the specification, an alkenyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkenyl is optionally substituted with oxo, halogen, -CN, -COOH, -COOMe, -OH, -OMe, -NH2, or -NO2. In
Attorney Docket No.57547-724.601 some embodiments, the alkenyl is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkenyl is optionally substituted with halogen. [0053] “Alkynyl” refers to a straight-chain or branched-chain hydrocarbon monoradical having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, more preferably from two to about six carbon atoms. Examples include, but are not limited to ethynyl, 2-propynyl, 2-butynyl, 1,3- butadiynyl and the like. Whenever it appears herein, a numerical range such as “C2-C6 alkynyl” or “C2- 6alkynyl”, means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated. Unless stated otherwise specifically in the specification, an alkynyl group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkynyl is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkynyl is optionally substituted with halogen, -CN, - OH, or -OMe. In some embodiments, the alkynyl is optionally substituted with halogen. [0054] “Alkylene” refers to a straight or branched divalent hydrocarbon chain. Unless stated otherwise specifically in the specification, an alkylene group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkylene is optionally substituted with oxo, halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkylene is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkylene is optionally substituted with halogen. [0055] “Alkoxy” refers to a radical of the formula -ORa where Ra is an alkyl radical as defined. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkoxy is optionally substituted with halogen, -CN, -COOH, COOMe, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkoxy is optionally substituted with halogen, -CN, -OH, or -OMe. In some embodiments, the alkoxy is optionally substituted with halogen. [0056] “Aryl” refers to a radical derived from a hydrocarbon ring system comprising 6 to 30 carbon atoms and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the aryl is bonded through an aromatic ring atom) or bridged ring systems. In some embodiments, the aryl is a 6- to 10- membered aryl. In some embodiments, the aryl is a 6-membered aryl (phenyl). Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless stated otherwise specifically in the specification, an aryl may be optionally substituted, for example, with halogen,
Attorney Docket No.57547-724.601 amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the aryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the aryl is optionally substituted with halogen. [0057] “Cycloalkyl” refers to a partially or fully saturated, monocyclic, or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems. In some embodiments, the cycloalkyl is fully saturated. Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms (C3-C15 cycloalkyl or C3-C15 cycloalkenyl), from three to ten carbon atoms (C3-C10 cycloalkyl or C3- C10 cycloalkenyl), from three to eight carbon atoms (C3-C8 cycloalkyl or C3-C8 cycloalkenyl), from three to six carbon atoms (C3-C6 cycloalkyl or C3-C6 cycloalkenyl), from three to five carbon atoms (C3-C5 cycloalkyl or C3-C5 cycloalkenyl), or three to four carbon atoms (C3-C4 cycloalkyl or C3-C4 cycloalkenyl). In some embodiments, the cycloalkyl is a 3- to 10-membered cycloalkyl or a 3- to 10-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 3- to 6-membered cycloalkyl or a 3- to 6-membered cycloalkenyl. In some embodiments, the cycloalkyl is a 5- to 6-membered cycloalkyl or a 5- to 6-membered cycloalkenyl. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls include, for example, adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, and 7,7- dimethyl-bicyclo[2.2.1]heptanyl. Partially saturated cycloalkyls include, for example cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless stated otherwise specifically in the specification, a cycloalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a cycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl is optionally substituted with halogen. [0058] “Halo” or “halogen” refers to bromo, chloro, fluoro or iodo. In some embodiments, halogen is fluoro or chloro. In some embodiments, halogen is fluoro. [0059] “Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2- trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. [0060] “Hydroxyalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more hydroxyls. In some embodiments, the alkyl is substituted with one hydroxyl. In some embodiments, the alkyl is substituted with one, two, or three hydroxyls. Hydroxyalkyl include, for example, hydroxymethyl,
Attorney Docket No.57547-724.601 hydroxyethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In some embodiments, the hydroxyalkyl is hydroxymethyl. [0061] “Aminoalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more amines. In some embodiments, the alkyl is substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines. Aminoalkyl include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the aminoalkyl is aminomethyl. [0062] “Deuteroalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more deuteriums. In some embodiments, the alkyl is substituted with one deuterium. In some embodiments, the alkyl is substituted with one, two, or three deuteriums. In some embodiments, the alkyl is substituted with one, two, three, four, five, or six deuteriums. Deuteroalkyl include, for example, CD3, CH2D, CHD2, CH2CD3, CD2CD3, CHDCD3, CH2CH2D, or CH2CHD2. In some embodiments, the deuteroalkyl is CD3. [0063] “Heteroalkyl” refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, phosphorus, or combinations thereof. A heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. In one aspect, a heteroalkyl is a C1-C6 heteroalkyl wherein the heteroalkyl is comprised of 1 to 6 carbon atoms and one or more atoms other than carbon, e.g., oxygen, nitrogen (e.g. -NH-, -N(alkyl)-), sulfur, phosphorus, or combinations thereof wherein the heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. Examples of such heteroalkyl are, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, -CH(CH3)OCH3, -CH2NHCH3, -CH2N(CH3)2, -CH2CH2NHCH3, or - CH2CH2N(CH3)2. Unless stated otherwise specifically in the specification, a heteroalkyl is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heteroalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or - OMe. In some embodiments, the heteroalkyl is optionally substituted with halogen. [0064] “Heterocycloalkyl” refers to a 3- to 24-membered partially or fully saturated ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur. In some embodiments, the heterocycloalkyl is fully saturated. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heterocycloalkyl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heterocycloalkyl comprises one to three nitrogens. In some embodiments, the heterocycloalkyl comprises one or two nitrogens. In some embodiments, the heterocycloalkyl comprises one nitrogen. In some embodiments, the heterocycloalkyl comprises one nitrogen and one oxygen. Unless stated otherwise specifically in the specification, the heterocycloalkyl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems; and the nitrogen,
Attorney Docket No.57547-724.601 carbon, or sulfur atoms in the heterocycloalkyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. Representative heterocycloalkyls include, but are not limited to, heterocycloalkyls having from two to fifteen carbon atoms (C2-C15 heterocycloalkyl or C2-C15 heterocycloalkenyl), from two to ten carbon atoms (C2-C10 heterocycloalkyl or C2-C10 heterocycloalkenyl), from two to eight carbon atoms (C2-C8 heterocycloalkyl or C2-C8 heterocycloalkenyl), from two to seven carbon atoms (C2-C7 heterocycloalkyl or C2-C7 heterocycloalkenyl), from two to six carbon atoms (C2-C6 heterocycloalkyl or C2- C6 heterocycloalkenyl), from two to five carbon atoms (C2-C5 heterocycloalkyl or C2-C5 heterocycloalkenyl), or two to four carbon atoms (C2-C4 heterocycloalkyl or C2-C4 heterocycloalkenyl). Examples of such heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, oxetanyl, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2- oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3-dihydroisobenzofuran-1-yl, 3-oxo-1,3- dihydroisobenzofuran-1-yl, methyl-2-oxo-1,3-dioxol-4-yl, and 2-oxo-1,3-dioxol-4-yl. The term heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to the monosaccharides, the disaccharides, and the oligosaccharides. Unless otherwise noted, heterocycloalkyls have from 2 to 10 carbons in the ring. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). In some embodiments, the heterocycloalkyl is a 3- to 8-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 7-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkyl. In some embodiments, the heterocycloalkyl is a 3- to 8-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 3- to 7-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 4- to 6-membered heterocycloalkenyl. In some embodiments, the heterocycloalkyl is a 5- to 6-membered heterocycloalkenyl. Unless stated otherwise specifically in the specification, a heterocycloalkyl may be optionally substituted as described below, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the heterocycloalkyl is optionally substituted with oxo, halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heterocycloalkyl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heterocycloalkyl is optionally substituted with halogen. [0065] “Heteroaryl” refers to a 5- to 14-membered ring system radical comprising one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, and
Attorney Docket No.57547-724.601 sulfur, and at least one aromatic ring. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. In some embodiments, the heteroaryl comprises one to three heteroatoms selected from the group consisting of nitrogen and oxygen. In some embodiments, the heteroaryl comprises one to three nitrogens. In some embodiments, the heteroaryl comprises one or two nitrogens. In some embodiments, the heteroaryl comprises one nitrogen. The heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded through an aromatic ring atom) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5- to 6-membered heteroaryl. In some embodiments, the heteroaryl is a 6-membered heteroaryl. In some embodiments, the heteroaryl is a 5- membered heteroaryl. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2- oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1- oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). Unless stated otherwise specifically in the specification, a heteroaryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, carboxyl, carboxylate, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -COOH, COOMe, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the heteroaryl is optionally substituted with halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroaryl is optionally substituted with halogen. [0066] The term “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, “optionally substituted alkyl” means either “alkyl” or “substituted alkyl” as defined above. Further, an optionally substituted group may be un-substituted (e.g., - CH2CH3), fully substituted (e.g., -CF2CF3), mono-substituted (e.g., -CH2CH2F) or substituted at a level anywhere in-between fully substituted and mono-substituted (e.g., -CH2CHF2, -CH2CF3, -CF2CH3, - CFHCHF2, etc.). It will be understood by those skilled in the art with respect to any group containing one or more substituents that such groups are not intended to introduce any substitution or substitution patterns
Attorney Docket No.57547-724.601 (e.g., substituted alkyl includes optionally substituted cycloalkyl groups, which in turn are defined as including optionally substituted alkyl groups, potentially ad infinitum) that are sterically impractical and/or synthetically non-feasible. Thus, any substituents described should generally be understood as having a maximum molecular weight of about 1,000 daltons, and more typically, up to about 500 daltons. [0067] The term “one or more” when referring to an optional substituent means that the subject group is optionally substituted with one, two, three, four, or more substituents. In some embodiments, the subject group is optionally substituted with one, two, three, or four substituents. In some embodiments, the subject group is optionally substituted with one, two, or three substituents. In some embodiments, the subject group is optionally substituted with one or two substituents. In some embodiments, the subject group is optionally substituted with one substituent. In some embodiments, the subject group is optionally substituted with two substituents. [0068] The terms “treat,” “treated,” “treatment,” or “treating” as used herein refers to therapeutic treatment, wherein the object is to prevent or slow (lessen) an undesired physiological condition, disorder, or disease, or to obtain beneficial or desired clinical results. For the purposes described herein, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment. The terms “treat,” “treated,” “treatment,” or “treating” as well as words stemming therefrom, as used herein, do not necessarily imply 100% or complete treatment. Rather, there are varying degrees of treatment of which one of ordinary skill in the art recognizes as having a potential benefit or therapeutic effect. In this respect, the disclosed methods can provide any amount of any level of treatment of the disorder in a mammal. For example, a disorder, including symptoms or conditions thereof, may be reduced by, for example, about 100%, about 90%, about 80%, about 70%, about 60%, about 50%, about 40%, about 30%, about 20%, or about 10%. [0069] The terms “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of a compound disclosed herein being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated, e.g., cancer or an inflammatory disease. In some embodiments, the result is a reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition comprising a compound disclosed herein required to provide a clinically significant decrease in disease symptoms. In some embodiments, an appropriate “effective” amount in any individual case is determined using techniques, such as a dose escalation study. [0070] The term “biological sample,” as used herein, generally refers to a sample derived from or obtained from a subject, such as a mammal (e.g., a human). Biological samples are contemplated to include
Attorney Docket No.57547-724.601 but are not limited to, hair, fingernails, skin, sweat, tears, ocular fluids, nasal swab or nasopharyngeal wash, sputum, throat swab, saliva, mucus, blood, serum, plasma, placental fluid, amniotic fluid, cord blood, emphatic fluids, cavity fluids, earwax, oil, glandular secretions, bile, lymph, pus, microbiota, meconium, breast milk, bone marrow, bone, CNS tissue, cerebrospinal fluid, adipose tissue, synovial fluid, stool, gastric fluid, urine, semen, vaginal secretions, stomach, small intestine, large intestine, rectum, pancreas, liver, kidney, bladder, lung, and other tissues and fluids derived from or obtained from a subject. [0071] The term “tumor” or “tumor cells” as used herein, generally refers to cells that grow and divide more than they should or do not die when they should. In some cases, tumor cells are present in a solid mass, such as a solid tumor, or in some cases, tumor cells are found in a non-solid form, such as in blood cancers. Tumor or tumor cells also can include metastasis or metastasizing cells, where cancer cells break away from the original (primary) tumor and may form a new tumor in other organs or tissues of the body. [0072] The term “ecDNA signature” as used herein, generally refers to one or more characteristics common to tumors or tumor cells that are ecDNA+. In some cases, the ecDNA signature is selected from the group consisting of a gene amplification; a p53 loss of function mutation; absence of microsatellite instability (MSI-H); a low level of PD-L1 expression; a low level of tumor inflammation signature (TIS); a low level of tumor mutational burden (TMB); an increased frequency of allele substitutions, insertions, or deletions (indels); and any combination thereof. In some cases, the ecDNA signature can include an increase in copy number (gene amplification) in conjunction with particular structural variations. In some cases, the ecDNA signature can include a focal amplification. In some cases, ecDNA signature includes a detection or identification of ecDNA using an imaging technology. In some cases, ecDNA signature does not include any imaging or direct detection of ecDNA. Compounds [0073] Described herein are Chk1 inhibitor that are useful for the treatment of cancer. [0074] Disclosed herein is a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof:
wherein: Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
Attorney Docket No.57547-724.601 each R1 is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2- C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two R1 on the same atom are taken together to form an oxo; n is 0-4; R2 is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, or heterocycloalkyl; R3 is hydrogen, deuterium, halogen, -CN, -NO2, -OH, -ORa, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, or heterocycloalkyl; R4 is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, or heterocycloalkyl; W is N or CRW; RW is hydrogen, deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, - NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R; X is N or CRX; RX is hydrogen, deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, - NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R; Y is N or CRY; RY is hydrogen, deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, - NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R; Z is N or CRZ;
Attorney Docket No.57547-724.601 RZ is hydrogen, deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, - NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R; provided that at least one of W, X, Y, or Z is N; L is -O- or -NR5-; R5 is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, or heterocycloalkyl; Ring B is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each R6 is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2- C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two R6 on the same atom are taken together to form an oxo; or two R6 on the same carbon are taken together to form a cycloalkyl or a heterocycloalkyl; each optionally substituted with one or more R; or two R6 on different atoms are taken together to form a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl; each optionally substituted with one or more R; m is 0-8; each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; and each Rc and Rd are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R;
Attorney Docket No.57547-724.601 or Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; each R is independently halogen, -CN, -OH, -OC1-C3alkyl, -OC1-C3haloalkyl, -SC1-C3alkyl, -S(=O)C1- C3alkyl, -S(=O)2C1-C3alkyl, -S(=O)2NH2, -S(=O)2NHC1-C3alkyl, -S(=O)2N(C1-C3alkyl)2, -NH2, -NHC1- C3alkyl, -N(C1-C3alkyl)2, -C(=O)C1-C3alkyl, -C(=O)OH, -C(=O)OC1-C3alkyl, -C(=O)NH2, - C(=O)NHC1-C3alkyl, -C(=O)N(C1-C3alkyl)2, C1-C3alkyl, C1-C3haloalkyl, C1-C3deuteroalkyl, C1- C3hydroxyalkyl, C1-C3aminoalkyl, C1-C3heteroalkyl, or C3-C6cycloalkyl; or two R on the same atom form an oxo. [0075] In some embodiments of a compound of Formula (I), W is N. In some embodiments of a compound of Formula (I), W is CRW. [0076] In some embodiments of a compound of Formula (I), X is N. In some embodiments of a compound of Formula (I), X is CRX. [0077] In some embodiments of a compound of Formula (I), Y is N. In some embodiments of a compound of Formula (I), Y is CRY. [0078] In some embodiments of a compound of Formula (I), Z is N. In some embodiments of a compound of Formula (I), Z is CRZ. [0079] In some embodiments of a compound of Formula (I), the compound is a compound of Formula (Ia):
[0080] In some embodiments of a compound of Formula (I), the compound is a compound of Formula (Ib):
Attorney Docket No.57547-724.601 [0081] In some embodiments of a compound of Formula (I), the compound is a compound of Formula (Ic):
Formula (Ic). [0082] In some embodiments of a compound of Formula (I), the compound is a compound of Formula (Id):
[0083] In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring A is aryl or heteroaryl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring A is heteroaryl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring A is 6-membered heteroaryl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring A is pyrazinyl. [0084] In some embodiments of a compound of Formula (I) or (Ia)-(Id), each R1 is independently deuterium, halogen, -CN, -OH, -ORa, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), each R1 is independently -CN. [0085] In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 0-2. In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 1 or 2. In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 0 or 1. In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 0. In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 1. In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 2. In some embodiments of a compound of Formula (I) or (Ia)-(Id), n is 3. [0086] In some embodiments of a compound of Formula (I) or (Ia)-(Id), R2 is hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R2 is hydrogen. [0087] In some embodiments of a compound of Formula (I) or (Ia)-(Id), R3 is hydrogen, deuterium, halogen, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R3 is hydrogen.
Attorney Docket No.57547-724.601 [0088] In some embodiments of a compound of Formula (I) or (Ia)-(Id), R4 is hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R4 is hydrogen. [0089] In some embodiments of a compound of Formula (I) or (Ia)-(Id), L is -O-. In some embodiments of a compound of Formula (I) or (Ia)-(Id), L is -NR5-. [0090] In some embodiments of a compound of Formula (I) or (Ia)-(Id), R5 is hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), R5 is hydrogen. [0091] In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl and heterocycloalkyl is optionally substituted with one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen, deuterium, halogen, -OH, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen, halogen, -OH, -ORa, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen, halogen, or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen. [0092] In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen, halogen, -OH, - ORa, or -NRcRd. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is hydrogen, -OH, or - ORa. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is -OH or -ORa. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RW is halogen or -ORa. [0093] In some embodiments of a compound of Formula (I) or (Ia)-(Id), RX is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RX is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RX is hydrogen, deuterium, halogen, -OH, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RX is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl.
Attorney Docket No.57547-724.601 In some embodiments of a compound of Formula (I) or (Ia)-(Id), RX is hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RX is hydrogen, halogen, or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RX is hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RX is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RX is hydrogen. [0094] In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is hydrogen, deuterium, halogen, -OH, -ORa, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is hydrogen, halogen, -OH, - ORa, C1-C6alkyl, C1-C6haloalkyl, C1-C6hydroxyalkyl, or cycloalkyl; wherein the alkyl and cycloalkyl is optionally substituted with one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is hydrogen, deuterium, halogen, -OH, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is hydrogen, halogen, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is hydrogen, halogen, or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is hydrogen. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RY is C1-C6alkyl. [0095] In some embodiments of a compound of Formula (I) or (Ia)-(Id), RZ is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RZ is hydrogen, deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, cycloalkyl, or heterocycloalkyl; wherein the alkyl, cycloalkyl, and heterocycloalkyl is optionally substituted with one or more R. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RZ is hydrogen, deuterium, halogen, -OH, -ORa, -NRcRd, C1-C6alkyl, C1-C6haloalkyl, or cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RZ is hydrogen, deuterium, halogen, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RZ is hydrogen, halogen, C1-C6alkyl, or
Attorney Docket No.57547-724.601 C1-C6haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RZ is hydrogen, halogen, or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RZ is hydrogen or C1-C6alkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RZ is hydrogen or halogen. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RZ is hydrogen. In some embodiments of a compound of Formula (I) or (Ia)-(Id), RZ is C1-C6alkyl. [0096] In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is cycloalkyl or heterocycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is monocyclic cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is bicyclic cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is monocyclic 4- to 6-membered cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is monocyclic 4- to 5-membered cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is monocyclic 4- membered cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is monocyclic 5-membered cycloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), Ring B is monocyclic 6-membered cycloalkyl. [0097] In some embodiments of a compound of Formula (I) or (Ia)-(Id), each R6 is independently deuterium, halogen, -CN, -OH, -ORa, -NRcRd, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound of Formula (I) or (Ia)-(Id), each R6 is independently -OH, -ORa, or -NRcRd. In some embodiments of a compound of Formula (I) or (Ia)-(Id), each R6 is independently -NRcRd. [0098] In some embodiments of a compound of Formula (I) or (Ia)-(Id), m is 0. In some embodiments of a compound of Formula (I) or (Ia)-(Id), m is 1. In some embodiments of a compound of Formula (I) or (Ia)- (Id), m is 2. In some embodiments of a compound of Formula (I) or (Ia)-(Id), m is 3. In some embodiments of a compound of Formula (I) or (Ia)-(Id), m is 0 or 1. In some embodiments of a compound of Formula (I) or (Ia)-(Id), m is 0-2. In some embodiments of a compound of Formula (I) or (Ia)-(Id), m is 1 or 2. [0099] In some embodiments of a compound disclosed herein, each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, C1-C6alkylene(cycloalkyl), or C1-C6alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Ra is independently C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, heterocycloalkyl, C1-C6alkylene(cycloalkyl), or C1-C6alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Ra is independently C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently
Attorney Docket No.57547-724.601 optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Ra is independently C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound disclosed herein, each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, or C1-C6aminoalkyl. In some embodiments of a compound disclosed herein, each Ra is independently C1-C6alkyl or C1-C6haloalkyl. In some embodiments of a compound disclosed herein, each Ra is independently C1-C6alkyl. [00100] In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, C1-C6alkylene(cycloalkyl), or C1-C6alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, heterocycloalkyl, C1-C6alkylene(cycloalkyl), or C1-C6alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, or C1-C6aminoalkyl. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound disclosed herein, each Rb is independently hydrogen or C1-C6alkyl. In some embodiments of a compound disclosed herein, each Rb is hydrogen. In some embodiments of a compound disclosed herein, each Rb is independently C1-C6alkyl. [00101] In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, heterocycloalkyl, C1-C6alkylene(cycloalkyl), or C1-C6alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, heterocycloalkyl, C1-C6alkylene(cycloalkyl), or C1-C6alkylene(heterocycloalkyl); wherein each alkyl, alkylene, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and
Attorney Docket No.57547-724.601 heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, or heterocycloalkyl; wherein each alkyl, cycloalkyl, and heterocycloalkyl is independently optionally substituted with one or more R. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, cycloalkyl, or heterocycloalkyl. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, or C1-C6aminoalkyl. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen, C1-C6alkyl, or C1-C6haloalkyl. In some embodiments of a compound disclosed herein, each Rc and Rd are independently hydrogen or C1-C6alkyl. In some embodiments of a compound disclosed herein, each Rc and Rd are hydrogen. In some embodiments of a compound disclosed herein, each Rc and Rd are independently C1-C6alkyl. In some embodiments of a compound disclosed herein, Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R. [00102] In some embodiments of a compound disclosed herein, each R is independently halogen, -CN, - OH, -OC1-C3alkyl, -OC1-C3haloalkyl, -NH2, -NHC1-C3alkyl, -N(C1-C3alkyl)2, -C(=O)C1-C3alkyl, - C(=O)OH, -C(=O)OC1-C3alkyl, -C(=O)NH2, -C(=O)NHC1-C3alkyl, -C(=O)N(C1-C3alkyl)2, C1-C3alkyl, C1- C3haloalkyl, C1-C3deuteroalkyl, C1-C3hydroxyalkyl, C1-C3aminoalkyl, C1-C3heteroalkyl, or C3-C6cycloalkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, -CN, -OH, -OC1-C3alkyl, -OC1-C3haloalkyl, -NH2, -NHC1-C3alkyl, -N(C1-C3alkyl)2, C1-C3alkyl, C1-C3haloalkyl, C1-C3deuteroalkyl, C1-C3hydroxyalkyl, C1-C3aminoalkyl, C1-C3heteroalkyl, or C3-C6cycloalkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, -CN, -OH, -OC1-C3alkyl, -OC1-C3haloalkyl, -NH2, C1-C3alkyl, C1- C3haloalkyl, C1-C3deuteroalkyl, C1-C3hydroxyalkyl, C1-C3aminoalkyl, C1-C3heteroalkyl, or C3-C6cycloalkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, -CN, -OH, -OC1-C3alkyl, -OC1-C3haloalkyl, -NH2, C1-C3alkyl, or C1-C3haloalkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, C1-C3alkyl, C1-C3haloalkyl, C1-C3deuteroalkyl, C1-C3hydroxyalkyl, C1- C3aminoalkyl, or C1-C3heteroalkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, -CN, -OH, -NH2, C1-C3alkyl, or C1- C3haloalkyl; or two R on the same atom form an oxo. In some embodiments of a compound disclosed herein, each R is independently halogen, C1-C3alkyl, or C1-C3haloalkyl; or two R on the same atom form an oxo. [00103] In some embodiments of a compound disclosed herein, the compound is selected from a compound of Table 1 or table 2:
Attorney Docket No.57547-724.601 TABLE 1
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
Attorney Docket No.57547-724.601 Table 2
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00104] In some embodiments, the CHK1 inhibitor is compound
pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. In some embodiments, the CHK1 inhibitor is compound
Further Forms of Compounds Disclosed Herein Isomers/Stereoisomers [00105] In some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein possess one or more double bonds. The compounds presented herein include all cis, trans, syn, anti, entgegen (E), and zusammen (Z) isomers as well as the
Attorney Docket No.57547-724.601 corresponding mixtures thereof. In some situations, the compounds described herein possess one or more chiral centers and each center exists in the R configuration or S configuration. The compounds described herein include all diastereomeric, enantiomeric, and epimeric forms as well as the corresponding mixtures thereof. In additional embodiments of the compounds and methods provided herein, mixtures of enantiomers and/or diastereoisomers, resulting from a single preparative step, combination, or interconversion are useful for the applications described herein. In some embodiments, the compounds described herein are prepared as their individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereoisomeric compounds, separating the diastereomers, and recovering the optically pure enantiomers. In some embodiments, dissociable complexes are preferred. In some embodiments, the diastereomers have distinct physical properties (e.g., melting points, boiling points, solubilities, reactivity, etc.) and are separated by taking advantage of these dissimilarities. In some embodiments, the diastereomers are separated by chiral chromatography, or preferably, by separation/resolution techniques based upon differences in solubility. In some embodiments, the optically pure enantiomer is then recovered, along with the resolving agent. Labeled compounds [00106] In some embodiments, the compounds described herein exist in their isotopically-labeled forms. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such isotopically-labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds described herein, or a solvate, tautomer, or stereoisomer thereof, include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine, and chloride, such as 2H, 3H, 13C, 14C, l5N, 18O, 17O, 31P, 32P, 35S, 18F, and 36Cl, respectively. Compounds described herein, and the pharmaceutically acceptable salts, solvates, or stereoisomers thereof that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this disclosure. Certain isotopically-labeled compounds, for example those into which radioactive isotopes such as 3H and 14C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H and carbon-14, i.e., 14C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavy isotopes such as deuterium, i.e., 2H, produces certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. In some embodiments, the isotopically labeled compound or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is prepared by any suitable method. [00107] In some embodiments, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
Attorney Docket No.57547-724.601 Pharmaceutically acceptable salts [00108] In some embodiments, the compounds described herein exist as their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating diseases by administering such pharmaceutically acceptable salts as pharmaceutical compositions. [00109] In some embodiments, the compounds described herein possess acidic or basic groups and therefor react with any of a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds disclosed herein, or by separately reacting a purified compound in its free form with a suitable acid or base, and isolating the salt thus formed. [00110] Examples of pharmaceutically acceptable salts include those salts prepared by reaction of the compounds described herein with a mineral, organic acid, or inorganic base, such salts including acetate, acrylate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, bisulfite, bromide, butyrate, butyn-1,4-dioate, camphorate, camphorsulfonate, caproate, caprylate, chlorobenzoate, chloride, citrate, cyclopentanepropionate, decanoate, digluconate, dihydrogenphosphate, dinitrobenzoate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hexyne-1,6-dioate, hydroxybenzoate, γ-hydroxybutyrate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, iodide, isobutyrate, lactate, maleate, malonate, methanesulfonate, mandelate metaphosphate, methanesulfonate, methoxybenzoate, methylbenzoate, monohydrogenphosphate, 1-napthalenesulfonate, 2-napthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3- phenylpropionate, phosphate, picrate, pivalate, propionate, pyrosulfate, pyrophosphate, propiolate, phthalate, phenylacetate, phenylbutyrate, propanesulfonate, salicylate, succinate, sulfate, sulfite, succinate, suberate, sebacate, sulfonate, tartrate, thiocyanate, tosylate, undecanoate, and xylenesulfonate. [00111] Further, the compounds described herein can be prepared as pharmaceutically acceptable salts formed by reacting the free base form of the compound with a pharmaceutically acceptable inorganic or organic acid, including, but not limited to, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid metaphosphoric acid, and the like; and organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, p-toluenesulfonic acid, tartaric acid, trifluoroacetic acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, arylsulfonic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2- hydroxyethanesulfonic acid, benzenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo-[2.2.2]oct- 2-ene-1-carboxylic acid, glucoheptonic acid, 4,4’-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3- phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid.
Attorney Docket No.57547-724.601 [00112] In some embodiments, those compounds described herein that comprise a free acid group react with a suitable base, such as the hydroxide, carbonate, bicarbonate, or sulfate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, tertiary, or quaternary amine. Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like. Illustrative examples of bases include sodium hydroxide, potassium hydroxide, choline hydroxide, sodium carbonate, N+(C1-4 alkyl)4, and the like. Representative salts include the alkali or alkaline earth salts, like lithium, sodium, potassium, calcium, and magnesium, and aluminum salts and the like of the tetrazole. [00113] Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like. It should be understood that the compounds described herein also include the quaternization of any basic nitrogen- containing groups they contain. In some embodiments, water or oil-soluble or dispersible products are obtained by such quaternization. Solvates [00114] In some embodiments, the compounds described herein exist as solvates. The disclosure provides for methods of treating diseases by administering such solvates. The disclosure further provides for methods of treating diseases by administering such solvates as pharmaceutical compositions. [00115] Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed during the processes described herein. In addition, the compounds provided herein can exist in unsolvated as well as solvated forms. In general, the solvated forms are considered equivalent to the unsolvated forms for the purposes of the compounds and methods provided herein. Tautomers [00116] In some situations, compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. Tautomers are compounds that are interconvertible by migration of a hydrogen atom, accompanied by a switch of a single bond and adjacent double bond. In bonding arrangements where tautomerization is possible, a chemical equilibrium of the tautomers will exist. All tautomeric forms of the compounds disclosed herein are contemplated. The exact ratio of the tautomers depends on several factors, including temperature, solvent, and pH. Preparation of the Compounds [00117] The compounds used in the reactions described herein are made according to organic synthesis techniques known to those skilled in this art, starting from commercially available chemicals and/or from compounds described in the chemical literature. [00118] Suitable reference books and treatises that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example,
Attorney Docket No.57547-724.601 “Synthetic Organic Chemistry”, John Wiley & Sons, Inc., New York; S. R. Sandler et al., “Organic Functional Group Preparations,” 2nd Ed., Academic Press, New York, 1983; H. O. House, “Modern Synthetic Reactions”, 2nd Ed., W. A. Benjamin, Inc. Menlo Park, Calif.1972; T. L. Gilchrist, “Heterocyclic Chemistry”, 2nd Ed., John Wiley & Sons, New York, 1992; J. March, “Advanced Organic Chemistry: Reactions, Mechanisms and Structure”, 4th Ed., Wiley-Interscience, New York, 1992. Additional suitable reference books and treatises that detail the synthesis of reactants useful in the preparation of compounds described herein, or provide references to articles that describe the preparation, include for example, Fuhrhop, J. and Penzlin G. “Organic Synthesis: Concepts, Methods, Starting Materials”, Second, Revised and Enlarged Edition (1994) John Wiley & Sons ISBN: 3-527-29074-5; Hoffman, R.V. “Organic Chemistry, An Intermediate Text” (1996) Oxford University Press, ISBN 0-19-509618-5; Larock, R. C. “Comprehensive Organic Transformations: A Guide to Functional Group Preparations” 2nd Edition (1999) Wiley-VCH, ISBN: 0-471-19031-4; March, J. “Advanced Organic Chemistry: Reactions, Mechanisms, and Structure” 4th Edition (1992) John Wiley & Sons, ISBN: 0-471-60180-2; Otera, J. (editor) “Modern Carbonyl Chemistry” (2000) Wiley-VCH, ISBN: 3- 527-29871-1; Patai, S. “Patai’s 1992 Guide to the Chemistry of Functional Groups” (1992) Interscience ISBN: 0-471-93022-9; Solomons, T. W. G. “Organic Chemistry” 7th Edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, J.C., “Intermediate Organic Chemistry” 2nd Edition (1993) Wiley- Interscience, ISBN: 0-471-57456-2; “Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann’s Encyclopedia” (1999) John Wiley & Sons, ISBN: 3-527-29645-X, in 8 volumes; “Organic Reactions” (1942-2000) John Wiley & Sons, in over 55 volumes; and “Chemistry of Functional Groups” John Wiley & Sons, in 73 volumes. [00119] Specific and analogous reactants are optionally identified through the indices of known chemicals prepared by the Chemical Abstract Service of the American Chemical Society, which are available in most public and university libraries, as well as through on-line. Chemicals that are known but not commercially available in catalogs are optionally prepared by custom chemical synthesis houses, where many of the standard chemical supply houses (e.g., those listed above) provide custom synthesis services. A reference for the preparation and selection of pharmaceutical salts of the compounds described herein is P. H. Stahl & C. G. Wermuth “Handbook of Pharmaceutical Salts,” Verlag Helvetica Chimica Acta, Zurich, 2002. [00120] Compounds of Formula I may be synthesized as described in the general Schemes I-VI below. [00121] In some embodiments, compounds of Formula I may be prepared via metal-catalyzed carbon- carbon bond forming cross-coupling reactions. In some embodiments, appropriate cross-coupling reactions include the Suzuki, Negishi, Stille, Kumada or Heck reactions. In a particular embodiment, the cross- coupling reaction is a Suzuki reaction between an appropriately substituted aryl bromide and an appropriately substituted arylboronic acid or arylboronic ester.
Attorney Docket No.57547-724.601 Scheme I
[00122] The synthesis of appropriately substituted intermediate building blocks for Suzuki reactions is described in Scheme I. An aryl bromide of formula I-3 may be synthesized by a reaction between an appropriately substituted compound of formula I-1, where L represents a nucleophilic atom, and a compound of formula I-2, where LG represents a suitable leaving group. In some embodiments of I-1, L is oxygen or an optionally substituted nitrogen atom. In some embodiments, L is oxygen. In some embodiments of I-2, LG is an alkyl halide such as bromine or iodine; in other embodiments, LG may be oxygen. In some embodiments of I-2 where LG is oxygen, it may be activated to increase its reactivity as a leaving group. Such activation may occur via synthesis of an alkylsulfonate, such as a mesylate, tosylate, nosylate, brosylate, or other sulfonate known to one having ordinary skill in the art. Such alkylsulfonates may be synthesized from the corresponding alkyl alcohol by reaction with an appropriate sulfonyl chloride or sulfonic anhydride, such as methanesulfonyl chloride or methanesulfonic anhydride. Such sulfonylation reactions typically occur in a solvent such as dichloromethane, tetrahydrofuran, or toluene, in the presence of a base such as sodium hydride, triethylamine, diisopropylethylamine, pyridine, potassium carbonate or another base known to one having ordinary skill in the art. Reactions typically proceed at sub-ambient or ambient temperature, for example between 0-25 °C. Reactions are typically complete within 1-18 hours and the product may be purified or used directly without purification, if it is unstable to purification. [00123] In other embodiments, an aryl bromide of formula I-3 may be synthesized by a reaction with a compound of formula I-2 where LG represents an alcohol that has been activated in situ without isolation, as in a Mitsunobu reaction. In a Mitsunobu reaction, activation of the alcohol occurs in the presence of an appropriate azodicarboxylate, such as diethyl azodicarboxylate or diisopropyl azodicarboxylate, and an appropriate phosphine, such as triphenylphosphine. In some embodiments the activation may be achieved using an appropriate phosphorane, such as (tributylphosphoranylidene)acetonitrile (CMBP) or (trimethylphosphoranylidene)acetonitrile (CMMP). Mitsunobu reactions are typically carried out in a
Attorney Docket No.57547-724.601 solvent such as dichloromethane, tetrahydrofuran, or toluene, and typically occur at ambient temperature or at elevated temperature from 25 to 110 °C. Reactions are typically complete within 1-18 hours. [00124] In some embodiments, a compound of formula I-3 may be synthesized by a reaction between a compound of formula I-4 and a compound of formula I-5. In some embodiments of I-4, LG is a halide such as fluorine, chlorine, bromine, or iodine. In some embodiments of I-5, L is nitrogen or oxygen. In some embodiments of I-5, L is oxygen. The reaction between I-4 and I-5 may proceed under cross-coupling conditions, catalyzed by an appropriate transition metal, or by nucleophilic aromatic substitution. In some embodiments, the nucleophilic aromatic substitution reaction occurs when LG of I-4 is fluorine or chlorine and L of I-5 is oxygen. In some embodiments, LG of I-4 is fluorine. When L of I-5 is oxygen, nucleophilic aromatic substitution reactions typically occur in the presence of a strong base such as sodium hydride, lithium diisopropylamine, lithium bis(trimethylsilyl)amide, or an appropriate base known to one having ordinary skill in the art. Such nucleophilic aromatic substitution reactions typically occur in a solvent such as tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, N,N-dimethylformamide or N,N-dimethylacetamide. Such nucleophilic aromatic substitution reactions typically occur at reduced temperature, such as -78 °C or 0 °C; in some embodiments, the reaction may occur at ambient temperature or elevated temperature, from 25 to 110 °C. Reactions are typically complete within 1-18 hours. [00125] A compound of formula I-8 may be synthesized from an appropriately substituted aminopyrazole of formula I-6 via reaction with an appropriately substituted compound of formula I-7, where ring A contains a suitable leaving group LG. In some embodiments, such a leaving group may be a chloride, bromide, iodide or activated alcohol such as a mesylate or tosylate. In some embodiments, ring A may be aromatic and the leaving group may be an aryl chloride. In some embodiments, the reaction may occur in the presence of a suitable base such as sodium hydride, triethylamine, diisopropylethylamine, pyridine, potassium carbonate or another base known to one having ordinary skill in the art. Such reactions typically occur in a solvent such as tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, N,N-dimethylformamide or N,N-dimethylacetamide. Reactions may occur at ambient temperature or at elevated temperatures from 60- 110 °C. Reactions are typically complete within 1-18 hours. [00126] A pyrazoleboronic ester compound of formula I-9 may be synthesized from a compound of formula I-8 by reaction with an appropriate borylating agent. In some embodiments, the compound of formula I-9 may contain a mixture of pyrazoleboronic ester and pyrazoleboronic acid. In some embodiments, the compound of formula I-9 may contain mostly pyrazoleboronic acid. In some embodiments, the compound of formula I-9 is synthesized by a Miyaura borylation reaction and the appropriate borylating agent is bis(pinacolato)diboron. The Miyaura borylation reaction is carried out in the presence of a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), or another catalyst system known to one having ordinary skill in the art. Such reactions typically proceed in the presence of a suitable base, such as sodium carbonate, potassium carbonate, potassium tert-butoxide, sodium acetate, potassium acetate, or another base known to one having ordinary skill in the art. The Miyaura
Attorney Docket No.57547-724.601 reaction is typically carried out in a solvent such as 1,4-dioxane, ethyl acetate, or toluene at elevated temperature, typically between 60-110 °C. Reactions are typically complete within 6-24 hours. Scheme II
[00127] As shown in Scheme II, a compound of Formula I may be synthesized by a Suzuki reaction between a compound of formula I-3 and a compound of formula I-9. Such a reaction will typically occur in the presence of a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), RuPhos palladacycle G3, or another catalyst system known to one having ordinary skill in the art. Such reactions typically proceed in the presence of a suitable base, such as sodium carbonate, potassium carbonate, potassium tert-butoxide, sodium acetate, potassium acetate, or another base known to one having ordinary skill in the art. The Suzuki reaction is typically carried out in a solvent such as 1,4-dioxane, ethyl acetate, or toluene. Water is used as an additive in all cases, independent of solvent choice. The reaction will occur at elevated temperature, typically between 60-110 °C. Reactions are typically complete within 6-24 hours. Scheme III
Attorney Docket No.57547-724.601 [00128] In an alternative embodiment, as shown in Scheme III, a cyanoketone intermediate of formula III- 5 may be synthesized from a compound of formula I-3. In some embodiments, a compound of formula I-3 may be converted to a vinyl enol ether of formula III-1. Such a reaction may occur between a compound of formula I-3 and an appropriately substituted vinyl building block under palladium-catalyzed cross-coupling conditions. In some embodiments, the cross-coupling reaction may be a Suzuki or a Stille reaction. In some embodiments, the vinyl building block will be substituted as a boronic ester, a boronic acid, a trifluoroborate or an alkylstannane. Such cross-coupling reactions will typically occur in the presence of a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), RuPhos palladacycle G3, or another catalyst system known to one having ordinary skill in the art. Such reactions typically proceed in the presence of a suitable base, such as sodium carbonate, potassium carbonate, potassium tert-butoxide, sodium acetate, potassium acetate, or another base known to one having ordinary skill in the art. The cross-coupling reaction is typically carried out in a solvent such as 1,4-dioxane, ethyl acetate, or toluene. The reaction will occur at elevated temperature, typically between 60-110 °C. Reactions are typically complete within 6-24 hours. A compound of formula III-1 may be purified or used directly in the next step without purification, as it may be unstable to standard purification conditions. [00129] A compound of formula III-1 may be converted to a ketone of formula III-2 via acidic hydrolysis. Such a reaction is typically carried out using a strong Brønsted acid, such as hydrochloric acid, in aqueous media. The reaction may take place at sub-ambient, ambient, or elevated temperature, typically between 0- 80 °C. In some embodiments, a ketone of formula III-2 may be converted to an enamine compound of formula III- 3 by reaction with N,N-dimethylformamide dimethyl acetal. In some embodiments, this reaction occurs in N,N-dimethylformamide as the solvent at elevated temperature, typically between 60-110 °C. Reactions are typically complete in 2-24 hours. In some embodiments a compound of formula III-3 may be purified, or in some embodiments it may be used directly in the next step without purification, as it may be unstable to standard purification conditions. [00130] A compound of formula III-3 may be converted to an isoxazole of formula III-4 by reaction with hydroxylamine. In some embodiments this reaction may employ hydroxylamine as free base or as a salt. In some embodiments the reaction is carried out using hydroxylamine hydrochloride. The reaction typically proceeds at ambient or elevated temperature between 25-110 °C in an appropriate solvent such as methanol, ethanol, isopropanol, n-butanol, tert-butanol, or toluene. The reaction is typically complete within 2-24 hours. [00131] An isoxazole of formula III-4 may be converted to a cyanoketone of formula III-5 by treatment with an appropriate base, such as lithium hydroxide, sodium hydroxide or potassium hydroxide. In some embodiments, the base is potassium hydroxide. The reaction will typically proceed in an appropriate solvent such as methanol, ethanol, isopropanol, n-butanol, tert-butanol, or toluene. The reaction may be carried out at ambient or elevated temperature between 25-110 °C, over a reaction time of 1-8 hours.
Attorney Docket No.57547-724.601 Scheme IV
[00132] In an alternative embodiment, a cyanoketone of formula III-5 may be synthesized from an ester as shown in Scheme IV. An ester of formula IV-5 may be synthesized from appropriate building blocks of formula IV-1, where L represents a nucleophilic atom, and a compound of formula IV-2, where LG represents a suitable leaving group. In some embodiments of IV-1, L is oxygen or an optionally substituted nitrogen atom. In some embodiments, L is oxygen. In some embodiments of IV-2, LG is an alkyl halide such as bromine or iodine; in other embodiments, it may be oxygen. In some embodiments of IV-2 where LG is oxygen, it may be activated to increase its reactivity as a leaving group. Such activation may occur via synthesis of an alkylsulfonate, such as a mesylate, tosylate, nosylate, brosylate, or other sulfonate known to one having ordinary skill in the art. Such alkylsulfonates may be synthesized from the corresponding alkyl alcohol by reaction with an appropriate sulfonyl chloride or sulfonic anhydride, such as methanesulfonyl chloride or methanesulfonic anhydride. Such sulfonylation reactions typically occur in a solvent such as dichloromethane, tetrahydrofuran, or toluene, in the presence of a base such as sodium hydride, triethylamine, diisopropylethylamine, pyridine, potassium carbonate or another base known to one having ordinary skill in the art. Reactions typically proceed at low temperature or at ambient temperature, for example at 0 °C. Reactions are typically complete within 1-18 hours and the product may be purified or used directly without purification. [00133] In other embodiments an ester of formula IV-5 may be synthesized by a reaction with a compound of formula IV-2, where LG represents an alcohol that has been activated in situ without isolation, as in a Mistunobu reaction. Activation of the alcohol occurs in the presence of an appropriate azodicarboxylate, such as diethyl azodicarboxylate or diisopropyl azodicarboxylate, and an appropriate phosphine, such as triphenylphosphine. In some embodiments the activation may be achieved using an appropriate phosphorane, such as (tributylphosphoranylidene)acetonitrile (CMBP) or (trimethylphosphoranylidene)acetonitrile (CMMP). Mitsunobu reactions are typically carried out in a solvent such as dichloromethane, tetrahydrofuran, or toluene, and typically occur at ambient temperature or at elevated temperature, from 25 to 110 °C. Reactions are typically complete within 1-18 hours.
Attorney Docket No.57547-724.601 [00134] In some embodiments, a compound of formula IV-5 may be synthesized from a compound of formula IV-3 and a compound of formula IV-4. In some embodiments of IV-3, LG is a halide such as fluorine, chlorine, bromine, or iodine. In some embodiments of IV-4, L is nitrogen or oxygen. In some embodiments of I-5, L is oxygen. The reaction between IV-3 and IV-4 may proceed under cross-coupling conditions, catalyzed by an appropriate transition metal, or by nucleophilic aromatic substitution. In some embodiments, the nucleophilic aromatic substitution reaction occurs when LG of IV-3 is fluorine or chlorine and L is oxygen. In some embodiments, LG of IV-3 is fluorine. When L is oxygen, nucleophilic aromatic substitution reactions typically occur in the presence of a strong base such as sodium hydride, lithium diisopropylamine, lithium bis(trimethylsilyl)amide, or an appropriate base known to one having ordinary skill in the art. Such nucleophilic aromatic substitution reactions typically occur in a solvent such as tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, N,N-dimethylformamide or N,N-dimethylacetamide. Such nucleophilic aromatic substitution reactions typically occur at reduced temperature, such as -78 °C or 0 °C; in some embodiments, the reaction may occur at ambient temperature or elevated temperature such as 100 °C. Reactions are typically complete within 1-18 hours. [00135] An ester of formula IV-5 may be converted to a cyanoketone of formula III-5 in a reaction with the carbanion of an optionally substituted nitrile. In some embodiments, the nitrile is acetonitrile. In such a reaction, acetonitrile is deprotonated with a suitable strong base, such as sodium hydride, potassium tert- butoxide, n-butyllithium, sec-butyllithium, lithium diisopropylamine, lithium bis(trimethylsilyl)amide, or an appropriate base known to one having ordinary skill in the art. The reaction may be carried out using acetonitrile as the solvent, or in another appropriate solvent such as tetrahydrofuran or diethyl ether. In some embodiments, the solvent is tetrahydrofuran. The reaction typically occurs at reduced temperature, such as - 78 °C or 0 °C; in some embodiments, the reaction may occur at ambient temperature. The reaction is typically complete within 1-18 hours. Scheme V
[00136] In some embodiments, a cyanoketone of formula III-5 may be converted to an aminopyrazole of formula V-I as shown in Scheme V. Such a reaction may be performed using an optionally substituted hydrazine to form the aminopyrazole. In some embodiments, the optionally substituted hydrazine is hydrazine or hydrazine monohydrate. The reaction is typically carried out in the presence of a Brønsted acid, such as acetic acid or hydrochloric acid. The reaction is carried out in an appropriate solvent such as methanol, ethanol, isopropanol, n-butanol, tert-butanol, or toluene. The reaction may be carried out at ambient or elevated temperature between 25-110 °C. The reaction is typically complete within 2-18 hours.
Attorney Docket No.57547-724.601 [00137] A compound of formula V-I may react with an appropriately substituted compound of formula I- 7, where ring A contains a suitable leaving group LG, to give a compound of Formula I. In some embodiments, such a leaving group LG may be a chloride, bromide, iodide or activated alcohol such as a mesylate or tosylate. In some embodiments, ring A may be aromatic and the leaving group may be an aryl chloride. In some embodiments, the reaction may occur in the presence of a suitable base such as sodium hydride, triethylamine, diisopropylethylamine, pyridine, potassium carbonate or another base known to one having ordinary skill in the art. Such reactions typically occur in a solvent such as tetrahydrofuran, dimethyl sulfoxide, 1,4-dioxane, N,N-dimethylformamide or N,N-dimethylacetamide. Reactions may occur at ambient temperature or at elevated temperatures from 60-110 °C. Reactions are typically complete within 1- 18 hours. [00138] In some embodiments, the reaction between a compound of formula V-I and a compound of formula I-7 may be carried out in the presence of an appropriate transition metal catalyst. In some embodiments the transition metal is a copper catalyst as in an Ullmann reaction. In some embodiments the catalyst is a palladium complex as in a Buchwald reaction. Such cross-coupling reactions will typically occur in the presence of a palladium catalyst in complex with a phosphine ligand, such as tetrakis(triphenylphosphine)palladium, bis(diphenylphosphino)ferrocene]dichloropalladium(II), BrettPhos palladacycle G3, or another catalyst system known to one having ordinary skill in the art. Such reactions typically proceed in the presence of a suitable base, such as sodium carbonate, potassium carbonate, potassium tert-butoxide, sodium acetate, potassium acetate, triethylamine or another base known to one having ordinary skill in the art. The reaction is typically carried out in a solvent such as 1,4-dioxane or toluene. The reaction will occur at elevated temperature, typically between 60-110 °C. Reactions are typically complete within 6-24 hours. Scheme VI
[00139] One having ordinary skill in the art will recognize that at times, it may be necessary to mask a reactive functional group or groups on a molecule with an appropriate protecting group. In some embodiments, the protecting group or groups may be carried through several synthetic steps. In some embodiments, the protecting group or groups may all be removed in a single global deprotection step. In some embodiments, the protecting group or groups will mask amine functional groups. In some
Attorney Docket No.57547-724.601 embodiments, the protecting group or groups will be tert-butylcarbamate groups. In some embodiments, the tert-butylcarbamate protected amine will be on ring B. A tert-butylcarbamate protecting group is typically removed via treatment with a Brønsted acid, such as trifluoroacetic acid, hydrogen chloride or hydrochloric acid. Typical cleavage reactions occur in an appropriate solvent such as ethyl acetate, 1,4-dioxane, diethyl ether or dichloromethane. Reactions typically proceed at sub-ambient or ambient temperature but may proceed at elevated temperature, typically between 0-60 °C. A compound of Formula I prepared under such conditions may be purified by standard methods including chromatography or recrystallization. In some embodiments the compound of Formula I is isolated directly from the deprotection reaction as a salt. In some embodiments the compound of Formula I is purified by preparative HPLC using an appropriate column and eluent conditions. Pharmaceutical Compositions [00140] In certain embodiments, the compound described herein is administered as a pure chemical. In some embodiments, the compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21st Ed. Mack Pub. Co., Easton, PA (2005)). [00141] Accordingly, provided herein is a pharmaceutical composition comprising a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a pharmaceutically acceptable excipient. [00142] In certain embodiments, the compound provided herein is substantially pure, in that it contains less than about 5%, or less than about 1%, or less than about 0.1% of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method. [00143] Pharmaceutical compositions are administered in a manner appropriate to the disease to be treated (or prevented). An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient’s disease, the particular form of the active ingredient, and the method of administration. In general, an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as increased overall response rate, increased duration of response, more frequent complete or partial remissions, or longer disease-free and/or overall survival, or a lessening of symptom severity. Optimal doses are generally determined using experimental models and/or clinical trials. The optimal dose depends upon the body mass, weight, or blood volume of the patient.
Attorney Docket No.57547-724.601 [00144] In some embodiments, the pharmaceutical composition is formulated for oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, intrapulmonary, intradermal, intrathecal, epidural, or intranasal administration. Parenteral administration includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some embodiments, the pharmaceutical composition is formulated for intravenous injection, oral administration, inhalation, nasal administration, topical administration, or ophthalmic administration. In some embodiments, the pharmaceutical composition is formulated for oral administration. In some embodiments, the pharmaceutical composition is formulated for intravenous injection. In some embodiments, the pharmaceutical composition is formulated as a tablet, a pill, a capsule, a liquid, an inhalant, a nasal spray solution, a suppository, a suspension, a gel, a colloid, a dispersion, a suspension, a solution, an emulsion, an ointment, a lotion, an eye drop, or an ear drop. In some embodiments, the pharmaceutical composition is formulated as a tablet. [00145] Suitable doses and dosage regimens are determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound disclosed herein. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. Methods [00146] Disclosed herein is a method of treating a tumor or tumor cells, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a cancer-targeted therapeutic agent to a subject identified as having the tumor or tumor cells, wherein the tumor or tumor cells comprise a gene amplification, whereby growth or size of the tumor or growth or number of tumor cells is reduced. [00147] Also disclosed herein is a method of delaying resistance to a cancer-targeted therapeutic agent, the method comprising: administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, to a subject in an amount sufficient to induce replication stress in tumor or tumor cells and administering a cancer-targeted therapeutic agent concurrently or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00148] Disclosed herein are methods of treating a tumor or tumor cells in a subject, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. In some cases, the subject has had one or more prior treatments with a first cancer- targeted therapeutic agent (also referred to herein as a “prior cancer-targeted therapeutic agent”) prior to treatment with a compound of Formula (I). In some cases, the compound of Formula (I) is administered in conjunction with the administration of a second cancer-targeted therapeutic agent (also referred to herein as a “selected cancer-targeted therapeutic agent”). [00149] Also disclosed herein is a method of treating a subject having a tumor or tumor cells that are non- responsive to a first (prior) cancer-targeted therapeutic agent comprising administering a compound of
Attorney Docket No.57547-724.601 Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a second (selected) cancer-targeted therapeutic agent to the subject. [00150] Also disclosed herein is a method of provoking a response in a subject having a tumor or tumor cells that are non-responsive or have decreased responsiveness to a first (prior) cancer-targeted therapeutic agent comprising administering a Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the first (prior) cancer-targeted therapeutic agent to the subject. [00151] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent is administered concurrent or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00152] In some embodiments of a method disclosed herein, the first (prior) cancer-targeted therapeutic agent is administered concurrent or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00153] In some embodiments of a method disclosed herein, the second (selected) cancer-targeted therapeutic agent is administered concurrent or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00154] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent is administered prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00155] In some embodiments of a method disclosed herein, the first (prior) cancer-targeted therapeutic agent is administered prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00156] In some embodiments of a method disclosed herein, the second (selected) cancer-targeted therapeutic agent is administered prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00157] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered in an amount sufficient to induce replication stress in the tumor or tumor cells. [00158] In some embodiments of a method disclosed herein, the subject is identified as having the tumor or tumor cells comprising a gene amplification. [00159] In some embodiments of a method disclosed herein, the gene amplification is a focal gene amplification. [00160] In some embodiments of a method disclosed herein, the gene amplification is an ecDNA-derived amplification. [00161] In some embodiments of a method disclosed herein, the gene amplification is comprised on ecDNA or an HSR (homogeneously staining region). [00162] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification.
Attorney Docket No.57547-724.601 [00163] In some embodiments of a method disclosed herein, the first (prior) cancer-targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification. [00164] In some embodiments of a method disclosed herein, the second (selected) cancer-targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification. [00165] In some embodiments of a method disclosed herein, the tumor or tumor cells comprise an ecDNA signature. [00166] In some embodiments of a method disclosed herein, cells comprised within the tumor or the tumor cells are ecDNA competent. For example, an ecDNA competent tumor cell may have detectable levels of ecDNA amplification or an ecDNA competent tumor cell has the capacity to generate ecDNA amplification in response to selective pressure such as targeted therapy (e.g., a cancer-targeted therapeutic agent described herein). [00167] In some embodiments of a method disclosed herein, treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the cancer-targeted therapeutic agent when administered alone. [00168] In some embodiments of a method disclosed herein, treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the first (prior) cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the first (prior) cancer-targeted therapeutic agent when administered alone. [00169] In some embodiments of a method disclosed herein, treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the second (selected) cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the second (selected) cancer-targeted therapeutic agent when administered alone. [00170] In some embodiments of a method disclosed herein, the greater effect is a synergistic effect. [00171] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer-targeted therapeutic agent is administered orally. [00172] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the first (prior) cancer- targeted therapeutic agent is administered orally.
Attorney Docket No.57547-724.601 [00173] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second (selected) cancer-targeted therapeutic agent is administered orally. [00174] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer-targeted therapeutic agent is administered parentally. [00175] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the first (prior) cancer- targeted therapeutic agent is administered parentally. [00176] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second (selected) cancer-targeted therapeutic agent is administered parentally. [00177] In some embodiments of a method disclosed herein, treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer-targeted therapeutic agent over a treatment period.In some embodiments of a method disclosed herein, treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the first (prior) cancer-targeted therapeutic agent over a treatment period. [00178] In some embodiments of a method disclosed herein, treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second (selected) cancer-targeted therapeutic agent over a treatment period. [00179] In some embodiments of a method disclosed herein, the gene amplification comprises an amplification of a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HER2, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3Cδ, PIK3CA/B, RET, and ROS1. [00180] In some embodiments of a method disclosed herein, the gene amplification comprises an amplification of a gene selected from the group consisting of CDK4, CDK6, c-MET, EGFR, FGFR1, FGFR2, FGFR3, and FGFR4. [00181] In some embodiments of a method disclosed herein, the first (prior) cancer-targeted therapeutic agent is different than the second (selected) cancer-targeted therapeutic agent. [00182] In some embodiments of a method disclosed herein, the first (prior) cancer-targeted therapeutic agent is the same as the second (selected) cancer-targeted therapeutic agent. [00183] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is selected from the group consisting of abemaciclib, ado-trastuzumab emtansine, afatinib, alectinib, ALRN-6924, AMG232, AMG-510, apatinib, ARS-3248, AXL1717, AZD-
Attorney Docket No.57547-724.601 3759, bevacizumab, BI 1701963, bortezomib, brigatinib, cabozantinib, capmatinib, ceritinib, cetuximab, CGM097, crizotinib, dabrafenib, dacomitinib, dasatinib, DS-3032b, encorafenib, entrectinib, ERAS-801, erdafitinib, erlotinib, everolimus, fam-trastuzumab deruxtecan, figitumumab, futibatinib, gefitinib, gossypol, HDM201, idasanutlin, imatinib, infigratinib, iniparib, lapatinib, larotrectinib, LEE011, lenvatinib, LGX818, lorlatinib, MEK162, MK-8242 SCH 900242, MRTX849, navitoclax, necitumumab, nilotinib, obatoclax, olaparib, OSI-906, osimertinib, palbociclib, panitumumab, PD-0332991, perisofine, pertuzumab, PF- 06873600, PF-07220060, PL225B, repotrectinib, ribociclib, RLY-4008, RO5045337, salinomycin, salirasib, SAR405838 MI-77301, sorafenib, sotorasib, sunitinib, tamoxifen, temsirolimus, tipifarnib, tivanitab, tofacitinib, trametinib, trastuzumab, tucatinib, UPR1376, VAL-083, vemurafenib, vemurafenib, vintafolide, and zoptarelin doxorubicin. [00184] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of EFGR, FGFR, CDK4/CDK6 or KRAS. In some cases, the EGFR inhibitor is erlotinib, gefitinib, or an analog thereof, or an antibody such as cetuximab, necitumumab, nimotuzumab, and panitumumab. In some cases, the FGFR inhibitor is erdafitinib, futibatinib, infigratinib, pemigatinib, RLY-4008, or an analog thereof. In some cases, the KRAS inhibitor is adagrasib, BI 1701963, sotorasib, or an analog thereof. In some cases, the CDK4/CDK6 inhibitor is abemaciclib, palbociclib, ribociclib, PF-06873600, PF-07220060, or an analog thereof. [00185] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of BRAF. In some embodiments, the BRAF inhibitors include ASN-003, AZ-304, AZ-628, DP-2874, EBI-907, EBI-945, GDC-0879, LYN 204, NMS-P285, NMS-P730, PF-04880594, TL-241, UAI-201,and UB-941. In some embodiments, the BRAF inhibitors include ABM-1310, agerafenib (RXDX-105), ARQ-736, BAL-3833, belvarafenib, BGB-3245, BI-882370, DAY101, lifirafenib, LUT-014, PF-07284890, PLX-8394, RX-208, VS-6766, and XL-281. In some embodiments, the BRAF inhibitors include dabrafenib, encorafenib, and vemurafenib. [00186] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of MDM2 or MDM4. In some embodiments, MDM2 inhibitors include AD-021.32, CYC700, DS-5272, MI-1061, MI-219, MI-43, MD-224, MK-8242, NU-8231, OM-301, PXN-527, Rigel-3, RO-2468, RO-5353, RO-5963, and SIL-43. In some embodiments, MDM2 inhibitors include ALRN-6924, APG-115, ASTX-295, ATSP-7041, BI-907828, CGM-097, idasanutlin, KRT-232 (AMG-232), MI-77301 (SAR405838, SAR299155), NVP-CGM097, RAIN-32 (milademetan), RG7112 (RO5045337), RG7388 (RG7775), serdemetan (JNJ-26854165), siremadlin, and UBX-0101. In some embodiments, the MDM4 inhibitors include 17AAG, 489-PXN, CTX1, FL-118, Inulanolide A, K-178, and SAH-p53-8. In some embodiments, the MDM4 inhibitors include APG-115, ALRN-6924, ATSP-7041, and BI-907828.
Attorney Docket No.57547-724.601 [00187] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of MET. In some embodiments, the MET small molecule inhibitors such as ABP-1130, BPI-1831, BPI-2021, BYON-3521, CG-203306, CX-1003, Debio-1144, EMD-94283, EMT-100, EMT-101, HE-003, LMV-12, LS-177, NX-125, OMO-2, PF-4254644, PRX-MET, PTX-2173, QBH-196, RP-1400, SAB-Y14, SAR-125844, SGX-126, SYD-3521, WXSH-0011, X-379, and XL-265, and anti-MET antibodies such as ABX-900, GB-263, FS-101, LY-3164530, LY-3343544, PMC- 002, and SAIT-301. In some embodiments, the MET small molecule inhibitors such as ABN-401, ABT-700, AMG-208, AMG-337, ARGX-111, BAY-85-3474, BMS-817378, bozitinib, BPI-9016M, glumetinib, golvatinib tartrate, GST-HG161, HQP-8361, I-020, JNJ-38877605, kanitinib, merestinib, MK-2461, MK- 8033, OMO-1, pamufetinib, S-49076, savolitinib, SPH-3348, tivantinib, SAR-125844, SCR-1515, and TPX- 0022, and anti-MET antibodies such as APL-101, CKD-702, EMB-01, EMI-137, ficlatuzumab, HLX-55, HS-10241, MCLA-129, MT-8633, NOV-1105, RC-108, REGN-5093, SHR-A1403, Sym-015, telisotuzumab vedotin. In some embodiments, the MET small molecule inhibitors such as amivantamab, capmatinib, crizotinib, and tepotinib. [00188] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of CDK4/6. In some embodiments, the CDK4/6 inhibitors include AG-122275, AM-5992, AU2-94, IIIM-985, IIIM-290, GW-491619, HEC-80797, MM-D37K, MS- 140, NP-102, QHRD-110, R-547, RGB-286199, RGT-419B, riviciclib, RO-0505124, THR-53, THR-79, TQB-3303, TY-302, VS2-370, XH-30002, and WXWH-0240. In some embodiments, the CDK4/6 inhibitors include auceliciclib, AT-7519, BEBT-209, BPI-1178, BPI-16350, CS-3002, fascaplysin, FCN-437, FN- 1501, GLR-2007, HS-10342, lerociclib, milciclib maleate, NUV-422, ON-123300, PF-06842874, PF- 06873600, PF-07220060, SHR-6390, TQB-3616, TY-302, voruciclib, and XZP-3287. In some embodiments, the CDK4/6 inhibitors include abemaciclib, palbociclib, ribociclib, and trilaciclib. [00189] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is palbociclib or abemaciclib. [00190] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of EGFR. In some embodiments, the EGFR inhibitors include small molecule inhibitors such as APL-1898, BDTX-1535, BLU-701, BPI-361175, CH-7233163, DS-2087, E-10C, FWD-1509, IN-A008, JS-111, JS-113, LL-191, LYN 205, neptinib, NT-004, ORIC-114, PRB-001, SIM-200, TGRX-360, WJ-13404, yinlitinib maleate, and ZSP-0391, and anti-EGFR antibodies such as 705, 707, ABX-900, CMAB-017, GB-263, KN-023, SSGJ-612, and SHR-A1307. In some embodiments, the EGFR inhibitors include small molecule inhibitors such as abivertinib, alflutinib mesylate, agerafenib (RXDX-105), ASK-120067, BBT-176, BDTX-189, BEBT-109, befortinib mesylate, beitatini,
Attorney Docket No.57547-724.601 BPI-7711, BPI-D0316, BLU-945, CK-101, dositinib, DFP-17729, DZD-9008, epertinib, epitinib (HMPL- 813), ES-072, FCN-411, FHND-9041, furmonertinib, GMA-204, Hemay-022, JRF-103, KP-673, larotinib, lazertinib, maihuatinib, marizomib, mobocertinib, naputinib tosilate, nazartinib, NRC-2694-A, OBX1-012, olafertinib, olmutinib, oritinib, pirotinib, poziotinib, SPH-1188, tarloxotinib, theliatinib (HMPL-309), TAS- 6417, TPC-064, TQB-3804, TY-9591, WSD-0922, XZP-5809, YK-029A, YZJ-0318, and zorifertinib, and anti-EGFR antibodies such as 602, C-005, CDP1, depatuxizumab, E01001, GC-1118A, GR-1401, HLX-07, HS-627, I-010, imgatuzumab, JMT-101, JZB-28, KN-026, MP-0274, QL-1203, SCT-200, serclutamab, SYN-004, and TAD-011. In some embodiments, the EGFR inhibitors include small molecule inhibitors such as afatinib, amivantamab, aumolertinib (almonertinib), dacomitinib, erlotinib, gefitinib, icotinib, lapatinib, osimertinib, and pyrotinib, and anti-EGFR antibodies such as cetuximab, necitumumab, nimotuzumab, and panitumumab. [00191] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is erlotinib. [00192] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of FGFR. [00193] In some embodiments, FGFR inhibitors include small molecule inhibitors such as ABSK-012, ABSK-061, AST-56100, BIO-1262, BGS-2219, EVT-601, FPI-1966, JAB-6000, KIN-3248, SAR-439115, SC-0011, and WXSH-0011, and anti- FGFR antibodies such as M-6123, OM-RCA-001. In some embodiments, FGFR inhibitors include small molecule inhibitors such as 3D-185, ABSK-011, ABSK-091, aldafermin, alofanib, AZD-4547, BFKB-8488A, BPI-17509, BPI-43487, CPL-304-110, derazantinib, E- 7090, EVER-4010001, FGF-401, fisogatinib, futibatinib, gunagratinib, H3B-6527, HH-185, HMPL-453, HS-236, ICP-105, ICP-192, infigratinib, MAX-40279, RLY-4008, rogaratinib, SAR-442501, SY-4798, TT- 00434, and zoligratinib (FF-284), and anti- FGFR antibodies such as bemarituzumab. In some embodiments, FGFR inhibitors include small molecule inhibitors such as erdafitinib and pemigatinib. [00194] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is infigratinib, futibatinib, or pemigatinib. [00195] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of KRAS. In some embodiments, the KRAS inhibitor include small molecule inhibitors such as ABREV01, ARS-1620, APG-1842, ATG-012, BBP-454, BEPT- 607, BI-2852, BI-1823911, BPI-421286, BTX-2541, COTI-219, IMM-1811900, JAB-21000, JAB-22000, JAB-23000, JAB-BX300, JP-002, KR-12, LYN 202, MRTX-1133, RAS-F, RMC-6236, RMC-6291, SDGR 5, STX-301, and YL-15293, and anti-KRAS antibodies such as SBT-100, SBT-102, and SBT-300. In some
Attorney Docket No.57547-724.601 embodiments, the KRAS include small molecule inhibitors such as adagrasib, ARS-3248, D-1553, GDC- 6036, JDQ-443, LY3537982, sotorasib (AMG 510), and BI 1701963. [00196] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is an inhibitor of c-MET, HER2, androgen receptor (AR), KIT, PDGFRA PI3K, AKT, BCL2, or MCL1. In some embodiments, the c-MET inhibitor includes crizotinib, tivantinib, cabozantinib, foretinib), or a monoclonal antibody against c-MET such as onartuzumab. [00197] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is a c-MET inhibitor. [00198] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent is tepotinib. [00199] In some embodiments of a method disclosed herein, the cancer-targeted therapeutic agent, the first (prior) cancer-targeted therapeutic agent, the second cancer-targeted therapeutic agent, or the selected cancer-targeted therapeutic agent targets a protein encoded by one or more genes provided in Table 3. TABLE 3: Example Genes
Attorney Docket No.57547-724.601
[00200] In some embodiments of a method disclosed herein, prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, the tumor or tumor cells comprise a gene amplification and wherein the cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification. [00201] In some embodiments of a method disclosed herein, prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, the tumor or tumor cells comprise a gene amplification and wherein the first (prior) cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification. [00202] In some embodiments of a method disclosed herein, prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, the tumor or tumor cells comprise a gene amplification and wherein the second cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification. [00203] In some embodiments of a method disclosed herein, prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, the tumor or tumor cells comprise a gene amplification and wherein the selected cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification. [00204] In some embodiments of a method disclosed herein, the subject received one or more administrations of the first (prior) cancer-targeted therapeutic agent prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and wherein the tumor or tumor cells developed resistance to the first (prior) cancer-targeted therapeutic agent.
Attorney Docket No.57547-724.601 [00205] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered concurrently or prior to the administration of the cancer-targeted therapeutic agent. [00206] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered concurrently or prior to the administration of the selected cancer-targeted therapeutic agent. [00207] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered concurrently or prior to the administration of the first (prior) cancer-targeted therapeutic agent. [00208] In some embodiments of a method disclosed herein, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered concurrently or prior to the administration of the second (selected) cancer-targeted therapeutic agent. [00209] In some embodiments of a method disclosed herein, the subject received one or more administrations of the first (prior) cancer-targeted therapeutic agent prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and wherein the tumor or tumor cells developed decreased responsiveness or resistance to the first (prior) cancer-targeted therapeutic agent. [00210] In some embodiments of a method disclosed herein, treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the cancer-targeted therapeutic agent when administered alone. In some embodiments of a method disclosed herein, treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the first (prior) cancer- targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the first (prior) cancer-targeted therapeutic agent when administered alone. [00211] In some embodiments of a method disclosed herein, treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the second (selected) cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the second (selected) cancer-targeted therapeutic agent when administered alone. [00212] In certain embodiments, different therapeutically effective dosages of the compounds disclosed herein will be utilized in formulating a pharmaceutical composition and/or in treatment regimens when the compounds disclosed herein are administered in combination with a second (selected) therapeutic agent.
Attorney Docket No.57547-724.601 Therapeutically effective dosages of drugs and other agents for use in combination treatment regimens are optionally determined by means similar to those set forth hereinabove for the actives themselves. Furthermore, the methods of prevention/treatment described herein encompasses the use of metronomic dosing, i.e., providing more frequent, lower doses in order to minimize toxic side effects. In some embodiments, a combination treatment regimen encompasses treatment regimens in which administration of a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is initiated prior to, during, or after treatment with a second (selected) agent described herein, and continues until any time during treatment with the second (selected) agent or after termination of treatment with the second (selected) agent. It also includes treatments in which a compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the second (selected) agent being used in combination are administered simultaneously or at different times and/or at decreasing or increasing intervals during the treatment period. Combination treatment further includes periodic treatments that start and stop at various times to assist with the clinical management of the patient. [00213] It is understood that the dosage regimen to treat, prevent, or ameliorate the condition(s) for which relief is sought, is modified in accordance with a variety of factors (e.g., the disease, disorder, or condition from which the subject suffers; the age, weight, sex, diet, and medical condition of the subject). Thus, in some instances, the dosage regimen employed varies and, in some embodiments, deviates from the dosage regimens set forth herein. For combination therapies described herein, dosages of the co-administered compounds vary depending on the type of co-drug employed, on the specific drug employed, on the disease or condition being treated, and so forth. [00214] The compounds described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, as well as combination therapies, are administered before, during, or after the occurrence of a disease or condition, and the timing of administering the composition containing a compound varies. [00215] In some embodiments, the compound described herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered in combination with an adjuvant. In one embodiment, the therapeutic effectiveness of one of the compounds described herein is enhanced by administration of an adjuvant (i.e., by itself the adjuvant has minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced). [00216] In some embodiments, the subject identified as having the tumor or tumor cells has cancer. In some embodiments, the cancer includes malignant tumors whose size can be decreased, whose growth or spread can be slowed or halted, or whose symptom is in remission or alleviated, reduced, and/or completely cured by deleting or suppressing and/or inhibiting functions of Chk1. Malignant tumors of interest are, but not limited to, head and neck cancer, gastrointestinal cancer (esophageal cancer, gastric cancer, duodenal cancer, liver cancer, biliary tract cancer (gallbladder, bile duct cancer, etc.), pancreatic cancer, colorectal cancer (colon cancer, rectal cancer, etc.), etc.), lung cancer (non-small cell lung cancer, small cell lung cancer, squamous cell lung carcinoma, mesothelioma, etc.), breast cancer, genital cancer (ovarian cancer,
Attorney Docket No.57547-724.601 uterine cancer, cervical cancer, endometrial cancer, etc.), urinary cancer (kidney cancer, bladder cancer, prostate cancer, testicular tumor, etc.), hematopoietic tumors (leukemia, malignant lymphoma, multiple myeloma, etc.), bone and soft tissue tumors (e.g., soft tissue sarcomas and osteosarcomas), skin cancer, brain tumor (e.g., glioblastoma) and the like. [00217] In some embodiments, the term cancer is used in accordance with its plain ordinary meaning in light of the present disclosure and refers to all types of cancer, neoplasm or malignant tumors found in mammals, including leukemias, lymphomas, melanomas, neuroendocrine tumors, carcinomas, and sarcomas. Exemplary cancers that may be treated with a compound disclosed herein, or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, pharmaceutical compositions include acute myeloid leukemia, adrenal cortical cancer, adrenal gland cancer, bladder cancer, bone cancer, brain cancer, breast cancer (e.g., ductal carcinoma, lobular carcinoma, primary, metastatic), breast cancer, cancer of the endocrine system, cancer of the hepatic stellate cells, cancer of the pancreatic stellate cells, cervical cancer, colon cancer, colorectal cancer, ductal carcinoma, endometrial cancer, esophageal cancer, gastric cancer, genitourinary tract cancer, glioblastoma, glioma, head and neck cancer, hepatocellular carcinoma, Hodgkin’s Disease, kidney cancer, leukemia (e.g., lymphoblastic leukemia, chronic lymphocytic leukemia, hairy cell leukemia), liver cancer (e.g., hepatocellular carcinoma), lobular carcinoma, lung cancer (e.g., non-small cell lung carcinoma, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, sarcoma), lymph node cancer, lymphoma (e.g., Mantel cell lymphoma, follicular lymphoma, diffuse large B-cell lymphoma, marginal zona lymphoma, Burkitt’s lymphoma, Non-Hodgkin’s Lymphoma) malignant carcinoid, malignant hypercalcemia, malignant pancreatic insulinoma, medullary thyroid cancer, Medulloblastoma, melanoma, mesothelioma, multiple myeloma muscle cancer, neoplasms of the endocrine or exocrine pancreas, neuroblastoma, ovarian cancer, Paget’s Disease of the Nipple, pancreatic cancer, papillary thyroid cancer, Phyllodes Tumors, premalignant skin lesions, primary thrombocytosis, prostate cancer (e.g. castration-resistant prostate cancer) rhabdomyosarcoma, salivary gland cancer, sarcoma, soft tissue sarcoma, squamous cell carcinoma (e.g., head, neck, or esophagus), stomach cancer, testicular cancer, thyroid cancer, urinary bladder cancer, or uterine cancer. In embodiments, the cancer is selected from bladder cancer, breast cancer, colon cancer, esophageal cancer, esophageal cancer, glioblastoma, liver cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, salivary gland cancer, soft tissue sarcoma, squamous cell lung carcinoma, stomach cancer, and uterine cancer. [00218] Gene amplification plays a role in the response of a tumor or tumor cells to cancer-directed therapies and in the development of resistance to targeted therapies. In some instances, gene amplification includes amplification of one or more genes, such as oncogenes, in a focal amplification, where the one or more oncogenes are in higher copy number, whereas surrounding genetic material (e.g., from the chromosomal location of such amplified gene) is not amplified or not at the same level of amplification. Focal amplifications may be located on ecDNA or ecDNA-derived, (i.e., derived from ecDNA, such as ecDNA that has reintegrated into a chromosomal location). ecDNA mediates an important and clinically
Attorney Docket No.57547-724.601 distinct mechanism of resistance to targeted therapies. Tumor cells with ecDNA and/or ecDNA-derived amplifications may become non-responsive, less responsive, or resistant to a targeted therapy. There are immediate therapeutic opportunities for utility of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof in combination with other therapies. In some embodiments, the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof may be used in combination with a therapeutic agent to treat an ecDNA+ cancer, ecDNA+ tumor or ecDNA+ tumor cells (i.e., tumor cells containing gene amplifications on ecDNA or derived from ecDNA). The combination of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and a therapeutic agent may be used to treat tumors, such as with one or more amplified oncogenes (e.g., BRAF, CDK4, CDK6, EGFR, FGFR, HER2, KRAS, MET, MDM2 amplifications); in some cases, the one or more amplified oncogenes comprise non-mutant forms of the oncogene and in some cases, the amplified oncogenes comprises mutant forms of the oncogenes. In some cases, the one or more amplified oncogenes are extrachromosomal (i.e., on ecDNA) and/or are ecDNA-derived and located on a chromosome. In some embodiments herein, the therapeutic agent used in combination with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof is an inhibitor of a protein encoded by a gene that is amplified on ecDNA or the ecDNA-derived amplification. [00219] The combinations described herein may be used to treat tumors that have developed resistance to another therapy such as a resistance to a targeted agent. In some cases, a tumor (or tumor cells) treated with a first (prior) targeted agent develops resistance to the first (prior) targeted agent or becomes less responsive or non-responsive to the first (prior) targeted agent. In some cases, the first (prior) therapeutic agent is an inhibitor of a protein encoded by a gene that is amplified on ecDNA or the ecDNA-derived amplification and the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and the first (prior) targeted agent may be used to treat such tumors or tumor cells. In some cases, the first (prior) therapeutic agent is an inhibitor of a protein encoded by a gene that is amplified on ecDNA or the ecDNA-derived amplification and the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and a second (selected) targeted agent may be used to treat such tumors or tumor cells, where the second (selected) targeted agent is an inhibitor of a different protein from the protein target of the first (prior) targeted agent. [00220] Provided herein are methods wherein inhibition of Chk1 by the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof exhibits synthetic lethality with a cancer-targeted agent. In some embodiments, synthetic lethality arises with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof in combination with a cancer targeted agent. In some cases, a tumor background is identified as hyper-sensitive to a Chk1 inhibitor and allows a sufficient therapeutic index to enable tolerated doses that are efficacious. In some embodiments, synthetic lethality arises with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof in combination with a cancer-targeted agent where the tumor
Attorney Docket No.57547-724.601 or tumor cells are ecDNA+ (i.e., contain ecDNA or ecDNA-derived gene amplification) . In some cases, Chk1 inhibition results in reduced ecDNA copy number. In some cases, Chk1 inhibition results in enhanced cytotoxicity in ecDNA+ cells. In some cases, enhanced cytotoxicity results from the combination of Chk1 inhibition and inhibition of a cancer-target, such as an oncogene. [00221] In some embodiments of a method disclosed herein, prior to treatment the tumor or tumor cells comprise ecDNA and wherein the treatment results in a reduction in the amount of ecDNA in the tumor or tumor cells. [00222] In some embodiments of a method disclosed herein, prior to treatment the tumor or tumor cells comprise ecDNA and wherein level or amount of ecDNA subsequent to the treatment is not increased as compared to prior to treatment. [00223] In some embodiments of a method disclosed herein, the method further comprises assessing a sample from a subject for the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature. In some cases, such assessment is performed prior to treatment, during a course of treatment or subsequent to treatment. [00224] In some embodiments of a method disclosed herein, the method further comprises obtaining information of the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature in the tumor or tumor cells from the subject prior to, during or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. In some cases, such information is obtained prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and a targeted cancer therapeutic agent. In some cases, such information is obtained during the course of treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof inhibitor and a targeted cancer therapeutic agent. In some cases, such information is obtained after treatment with a first (prior) targeted cancer therapeutic agent but prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and if the information indicates the presence of ecDNA, or an ecDNA-derived gene amplification, the subject is treated with a combination of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and the first (prior) targeted cancer therapeutic agent or with a combination of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof and a second (selected) targeted cancer therapeutic agent. [00225] In an aspect of methods herein, a tumor or tumor cells are determined to have an ecDNA signature. In some cases, a tumor or tumor cells are determined to have an ecDNA signature when the tumor or tumor cells have one or more characteristics associated with ecDNA+ tumors or tumor cells. For example, in some cases, the ecDNA signature is selected from the group consisting of a gene amplification; a focal gene amplification; characterization of a structural variation; a p53 loss of function mutation; absence of microsatellite instability (MSI-H); a low level of PD-L1 expression; a low level of tumor inflammation
Attorney Docket No.57547-724.601 signature (TIS); a low level of tumor mutational burden (TMB); an increased frequency of allele substitutions, insertions, or deletions (indels); and any combination thereof. [00226] In an aspect of methods herein, the tumor or tumor cells have an ecDNA signature. In some cases, the tumor or tumor cells develop the ecDNA signature after administration of a first (prior) cancer-targeted therapeutic agent. In some cases, the tumor or tumor cells develop the ecDNA signature prior to treatment. [00227] In some embodiments of a method disclosed herein, the information of the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature in the tumor or tumor cells is obtained from blood, tissue or one or more cells. [00228] In some embodiments of a method disclosed herein, the information of the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature in the tumor or tumor cells is obtained by liquid biopsy or tissue biopsy. Numbered Embodiments [00229] Embodiment 1: A method of treating a tumor or tumor cells, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a cancer-targeted therapeutic agent to a subject identified as having the tumor or tumor cells, wherein the tumor or tumor cells comprise a gene amplification, whereby growth or size of the tumor or growth or number of tumor cells is reduced. [00230] Embodiment 2: The method of embodiment 1, wherein the cancer-targeted therapeutic agent is administered concurrent or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00231] Embodiment 3: The method of embodiment 1 or embodiment 2, wherein the cancer-targeted therapeutic agent is administered prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00232] Embodiment 4: The method of any one of embodiments 1-3, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered in an amount sufficient to induce replication stress in the tumor or tumor cells. [00233] Embodiment 5: A method of delaying resistance to a cancer-targeted therapeutic agent, the method comprising: administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, to a subject in an amount sufficient to induce replication stress in tumor or tumor cells and administering a cancer-targeted therapeutic agent concurrently or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00234] Embodiment 6: The method of embodiment 5, wherein the subject is identified as having the tumor or tumor cells comprising a gene amplification. [00235] Embodiment 7: The method of any one of embodiments 1-4 or 6, wherein the gene amplification is a focal gene amplification.
Attorney Docket No.57547-724.601 [00236] Embodiment 8: The method of any one of embodiments 1-4, 6, or 7, wherein the gene amplification is an ecDNA-derived amplification. [00237] Embodiment 9: The method of any one of embodiments 1-4 or 6-8, wherein the gene amplification is comprised on ecDNA or an HSR (homogeneously staining region). [00238] Embodiment 10: The method of any one of embodiments 1-4 or 6-9, wherein the cancer-targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification. [00239] Embodiment 11: The method of any one of embodiments 1-10, wherein the tumor or tumor cells comprise an ecDNA signature. [00240] Embodiment 12: The method of any one of embodiments 1-11, wherein cells comprised within the tumor or the tumor cells are ecDNA competent. [00241] Embodiment 13: The method of any one of embodiments 1-12, wherein treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the cancer therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the cancer therapeutic agent when administered alone. [00242] Embodiment 14: The method of embodiment 13, wherein the greater effect is a synergistic effect. [00243] Embodiment 15: The method of any one of embodiments 1-14, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer- targeted therapeutic agent is administered orally. [00244] Embodiment 16: The method of any one of embodiments 1-14, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer- targeted therapeutic agent is administered parentally. [00245] Embodiment 17: The method of any one of embodiments 1-16, wherein treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the cancer-targeted therapeutic agent over a treatment period. [00246] Embodiment 18: The method of any one of embodiments 1-4 or 6-17, wherein the gene amplification comprises an amplification of a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HER2, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3Cδ, PIK3CA/B, RET, and ROS1. [00247] Embodiment 19: The method of any one of embodiments 1-18, wherein the cancer therapeutic agent is selected from the group consisting of abemaciclib, ado-trastuzumab emtansine, afatinib, alectinib, ALRN-6924, AMG232, AMG-510, apatinib, ARS-3248, AXL1717, AZD-3759, bevacizumab, BI 1701963, bortezomib, brigatinib, cabozantinib, capmatinib, ceritinib, cetuximab, CGM097, crizotinib, dabrafenib, dacomitinib, dasatinib, DS-3032b, encorafenib, entrectinib, ERAS-801, erdafitinib, erlotinib, everolimus, fam-trastuzumab deruxtecan, figitumumab, futibatinib, gefitinib, gossypol, HDM201, idasanutlin, imatinib,
Attorney Docket No.57547-724.601 infigratinib, iniparib, lapatinib, larotrectinib, LEE011, lenvatinib, LGX818, lorlatinib, MEK162, MK-8242 SCH 900242, MRTX849, navitoclax, necitumumab, nilotinib, obatoclax, olaparib, OSI-906, osimertinib, palbociclib, panitumumab, PD-0332991, perisofine, pertuzumab, PF-06873600, PF-07220060, PL225B, repotrectinib, ribociclib, RLY-4008, RO5045337, salinomycin, salirasib, SAR405838 MI-77301, sorafenib, sotorasib, sunitinib, tamoxifen, temsirolimus, tipifarnib, tivanitab, tofacitinib, trametinib, trastuzumab, tucatinib, UPR1376, VAL-083, vemurafenib, vemurafenib, vintafolide, and zoptarelin doxorubicin. [00248] Embodiment 20: A method of treating a subject having a tumor or tumor cells that are non- responsive to a first cancer-targeted therapeutic agent comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a second cancer- targeted therapeutic agent to the subject. [00249] Embodiment 21: The method of the embodiment 20, wherein prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, the tumor or tumor cells comprise a gene amplification and wherein the first cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification. [00250] Embodiment 22: The method of embodiment 21, wherein the subject received one or more administrations of the first cancer-targeted therapeutic agent prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and wherein the tumor or tumor cells developed resistance to the first cancer-targeted therapeutic agent. [00251] Embodiment 23: The method of any one of embodiments 20-22, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered concurrently or prior to the administration of the second cancer-targeted therapeutic agent. [00252] Embodiment 24: The method of any one of embodiments 21-23, wherein the gene amplification is a focal gene amplification. [00253] Embodiment 25: The method of any one of embodiments 21-24, wherein the gene amplification is an ecDNA-derived amplification. [00254] Embodiment 26: The method of any one of embodiments 21-25, wherein the gene amplification is comprised on ecDNA or an HSR (homogeneously staining region). [00255] Embodiment 27: The method of any one of embodiments 21-26, wherein the second cancer- targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification. [00256] Embodiment 28: The method of any one of embodiments 20-27, wherein the tumor or tumor cells comprise an ecDNA signature. [00257] Embodiment 29: The method of any one of embodiments 20-28, wherein cells comprised within the tumor or the tumor cells are ecDNA competent. [00258] Embodiment 30: The method of any one of embodiments 20-29, wherein treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the cancer therapeutic agent has a greater effect or a longer duration of effect on reduction of one or
Attorney Docket No.57547-724.601 more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the cancer therapeutic agent when administered alone. [00259] Embodiment 31: The method of embodiment 30, wherein the greater effect is a synergistic effect. [00260] Embodiment 32: The method of any one of embodiments 20-31, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second cancer-targeted therapeutic agent is administered orally. [00261] Embodiment 33: The method of any one of embodiments 20-31, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second cancer-targeted therapeutic agent is administered parentally. [00262] Embodiment 34: The method of any one of embodiments 20-33, wherein treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second cancer-targeted therapeutic agent over a treatment period. [00263] Embodiment 35: The method of any one of embodiments 21-34, wherein the gene amplification comprises an amplification of a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL- 2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3Cδ, PIK3CA/B, RET, and ROS1. [00264] Embodiment 36: The method of any one of embodiments 20-35, wherein the first cancer-targeted therapeutic agent is selected from the group consisting of abemaciclib, ado-trastuzumab emtansine, afatinib, alectinib, ALRN-6924, AMG232, AMG-510, apatinib, ARS-3248, AXL1717, AZD-3759, bevacizumab, BI 1701963, bortezomib, brigatinib, cabozantinib, capmatinib, ceritinib, cetuximab, CGM097, crizotinib, dabrafenib, dacomitinib, dasatinib, DS-3032b, encorafenib, entrectinib, ERAS-801, erdafitinib, erlotinib, everolimus, fam-trastuzumab deruxtecan, figitumumab, futibatinib, gefitinib, gossypol, HDM201, idasanutlin, imatinib, infigratinib, iniparib, lapatinib, larotrectinib, LEE011, lenvatinib, LGX818, lorlatinib, MEK162, MK-8242 SCH 900242, MRTX849, navitoclax, necitumumab, nilotinib, obatoclax, olaparib, OSI- 906, osimertinib, palbociclib, panitumumab, PD-0332991, perisofine, pertuzumab, PF-06873600, PF- 07220060, PL225B, repotrectinib, ribociclib, RLY-4008, RO5045337, salinomycin, salirasib, SAR405838 MI-77301, sorafenib, sotorasib, sunitinib, tamoxifen, temsirolimus, tipifarnib, tivanitab, tofacitinib, trametinib, trastuzumab, tucatinib, UPR1376, VAL-083, vemurafenib, vemurafenib, vintafolide, and zoptarelin doxorubicin. [00265] Embodiment 37: The method of any one of embodiments 20-35, wherein the second cancer- targeted therapeutic agent is selected from the group consisting of abemaciclib, ado-trastuzumab emtansine, afatinib, alectinib, ALRN-6924, AMG232, AMG-510, apatinib, ARS-3248, AXL1717, AZD-3759, bevacizumab, BI 1701963, bortezomib, brigatinib, cabozantinib, capmatinib, ceritinib, cetuximab, CGM097, crizotinib, dabrafenib, dacomitinib, dasatinib, DS-3032b, encorafenib, entrectinib, ERAS-801, erdafitinib, erlotinib, everolimus, fam-trastuzumab deruxtecan, figitumumab, futibatinib, gefitinib, gossypol, HDM201,
Attorney Docket No.57547-724.601 idasanutlin, imatinib, infigratinib, iniparib, lapatinib, larotrectinib, LEE011, lenvatinib, LGX818, lorlatinib, MEK162, MK-8242 SCH 900242, MRTX849, navitoclax, necitumumab, nilotinib, obatoclax, olaparib, OSI- 906, osimertinib, palbociclib, panitumumab, PD-0332991, perisofine, pertuzumab, PF-06873600, PF- 07220060, PL225B, repotrectinib, ribociclib, RLY-4008, RO5045337, salinomycin, salirasib, SAR405838 MI-77301, sorafenib, sotorasib, sunitinib, tamoxifen, temsirolimus, tipifarnib, tivanitab, tofacitinib, trametinib, trastuzumab, tucatinib, UPR1376, VAL-083, vemurafenib, vemurafenib, vintafolide, and zoptarelin doxorubicin. [00266] Embodiment 38: A method of provoking a response in a subject having a tumor or tumor cells that are non-responsive or have decreased responsiveness to a first cancer-targeted therapeutic agent comprising administering a Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the first cancer-targeted therapeutic agent to the subject. [00267] Embodiment 39: The method of the embodiment 38, wherein prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, the tumor or tumor cells comprise a gene amplification and wherein the first cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification. [00268] Embodiment 40: The method of embodiment 38 or embodiment 39, wherein the subject received one or more administrations of the first cancer-targeted therapeutic agent prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and wherein the tumor or tumor cells developed decreased responsiveness or resistance to the first cancer- targeted therapeutic agent. [00269] Embodiment 41: The method of embodiment 39 or embodiment 40, wherein the gene amplification is a focal gene amplification. [00270] Embodiment 42: The method of any one of embodiments 39-41, wherein the gene amplification is an ecDNA-derived amplification. [00271] Embodiment 43: The method of any one of embodiments 39-42, wherein the gene amplification is comprised on ecDNA or an HSR (homogeneously staining region). [00272] Embodiment 44: The method of any one of embodiments 38-43, wherein the tumor or tumor cells comprise an ecDNA signature. [00273] Embodiment 45: The method of any one of embodiments 38-44, wherein cells comprised within the tumor or the tumor cells are ecDNA competent. [00274] Embodiment 46: The method of any one of embodiments 38-45, wherein treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the first cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the first cancer-targeted therapeutic agent when administered alone. [00275] Embodiment 47: The method of embodiment 46, wherein the greater effect is a synergistic effect.
Attorney Docket No.57547-724.601 [00276] Embodiment 48: The method of any one of embodiments 38-47, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the first cancer-targeted therapeutic agent is administered orally. [00277] Embodiment 49: The method of any one of embodiments 38-47, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the second cancer-targeted therapeutic agent is administered parentally. [00278] Embodiment 50: The method of any one of embodiments 38-49, wherein treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the first cancer-targeted therapeutic agent over a treatment period. [00279] Embodiment 51: The method of any one of embodiments 39-50, wherein the gene amplification comprises an amplification of a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL- 2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3Cδ, PIK3CA/B, RET, and ROS1. [00280] Embodiment 52: The method of any one of embodiments 20-51, wherein the first cancer-targeted therapeutic agent is selected from the group consisting of abemaciclib, ado-trastuzumab emtansine, afatinib, alectinib, ALRN-6924, AMG232, AMG-510, apatinib, ARS-3248, AXL1717, AZD-3759, bevacizumab, BI 1701963, bortezomib, brigatinib, cabozantinib, capmatinib, ceritinib, cetuximab, CGM097, crizotinib, dabrafenib, dacomitinib, dasatinib, DS-3032b, encorafenib, entrectinib, ERAS-801, erdafitinib, erlotinib, everolimus, fam-trastuzumab deruxtecan, figitumumab, futibatinib, gefitinib, gossypol, HDM201, idasanutlin, imatinib, infigratinib, iniparib, lapatinib, larotrectinib, LEE011, lenvatinib, LGX818, lorlatinib, MEK162, MK-8242 SCH 900242, MRTX849, navitoclax, necitumumab, nilotinib, obatoclax, olaparib, OSI- 906, osimertinib, palbociclib, panitumumab, PD-0332991, perisofine, pertuzumab, PF-06873600, PF- 07220060, PL225B, repotrectinib, ribociclib, RLY-4008, RO5045337, salinomycin, salirasib, SAR405838 MI-77301, sorafenib, sotorasib, sunitinib, tamoxifen, temsirolimus, tipifarnib, tivanitab, tofacitinib, trametinib, trastuzumab, tucatinib, UPR1376, VAL-083, vemurafenib, vemurafenib, vintafolide, and zoptarelin doxorubicin. [00281] Embodiment 53: The method of any one of embodiments 1-52, wherein prior to treatment the tumor or tumor cells comprise ecDNA and wherein the treatment results in a reduction in the amount of ecDNA in the tumor or tumor cells. [00282] Embodiment 54: The method of any one of embodiments 1-52, wherein prior to treatment the tumor or tumor cells comprise ecDNA and wherein level or amount of ecDNA subsequent to the treatment is not increased as compared to prior to treatment. [00283] Embodiment 55: The method of any one of embodiments 1-54, wherein the method further comprises assessing a sample from a subject for the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature.
Attorney Docket No.57547-724.601 [00284] Embodiment 56: The method of any one of embodiments 1-55, wherein the method further comprises obtaining information of the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature in the tumor or tumor cells from the subject prior to, during or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. [00285] Embodiment 57: The method of embodiment 55, wherein the information is obtained from blood, tissue or one or more cells. [00286] Embodiment 58: The method of embodiment 55, wherein the information is obtained by liquid biopsy or tissue biopsy. EXAMPLES Example 1: Kinase HTRF biochemical assay [00287] Chk1 enzyme activity was measured using an HTRF KinEASE assay (Cisbio, catalog no. 62ST1PEC). Full-length human CHK1 protein (GenBank accession number NP_001265.1) was obtained from Carna Biosciences, Inc. (Kobe, Japan, catalog no.02-117). The enzyme reaction was carried out in assay buffer containing (final concentrations): CHK1 enzyme (0.012 ng/µL), MgCl2 (5 mM) and DTT (1 mM). To determine compound dose response, DMSO stock solutions were serially diluted in a 10-point concentration series in duplicate. Compound solution (50 nL) was added to 384-well assay plates (Greiner, catalog no.784075). To each well containing compound solution was added assay buffer solution (5 µL). Plates were centrifuged at 1000 rpm for 1 minute, then incubated at room temperature for 10 minutes. The reaction was started by addition of substrate buffer (5 µL/well) containing (final concentrations): STK substrate 1-biotin (120 nM) and ATP (1 mM). Assay plates were centrifuged at 1000 rpm for 1 minute, then incubated at room temperature for 60 minutes. The reaction was stopped by addition of detection buffer (Cisbio, 10 µL) containing (final concentrations): STK antibody-cryptate (0.25 nM) and streptavidin-XL665 (7.5 nM). Plates were centrifuged at 1000 rpm for 1 minute, then incubated at 25 °C for 2 hours. HTRF signal was read on an EnVision multimode plate reader (CisBio) in HTRF mode. Data were fit to dose- response curves using XLfit (IDBS, Surrey, UK) or Prism (GraphPad Software, La Jolla, CA, US) to calculate IC50 values for each compound tested. Example 2: AlphaLisa cellular assay [00288] Compound activity in cells was measured using an AlphaLISA® SureFire® Ultra™ p-CHK1 (Ser345) assay (Perkin Elmer, catalog no. ALSU-PCHK1-A10K). HT29 cells were cultured in McCoy 5A medium with 10% FBS and 1% penicillin-streptomycin and seeded to 96-well plates (Corning, catalog no. 3599). Compounds were serially diluted in DMSO over a 10-point dose range with 3-fold dilution and to each well containing cells was added compound solution. Plates were centrifuged at 1000 rpm for 30 seconds. Plates were incubated at 37 °C for 16 h. Supernatant was removed by flicking the plate against a paper towel. Wells were washed once with PBS solution. To each well was added freshly prepared lysis
Attorney Docket No.57547-724.601 buffer and plates were agitated on a plate shaker at 400 rpm for 30 min. The 96-well cell plates were centrifuged at 1500 rpm for 1 minute. From each well was transferred 10 µL of the lysates to a 384-well Optiplate™ (Perkin Elmer, catalog no.6007290). To each well was added Acceptor Mix (5 µL) and the plates were sealed and wrapped in foil. Plates were agitated on a plate shaker for 2 minutes, then incubated at room temperature for 1 h. To each well was added Donor Mix (5 µL) and the plates were sealed and wrapped in foil. Plates were agitated on a plate shaker for 2 minutes, then incubated at room temperature for 1 h. AlphaLisa signal was read on an EnVision multimode plate reader (Perkin Elmer). Data were fit to dose-response curves using XLfit (IDBS, Surrey, UK) or Prism (GraphPad Software, La Jolla, CA, US) to calculate IC50 values for each compound tested. [00289] The data from example 1 and 2 is found in table 4. TABLE 4
Attorney Docket No.57547-724.601
Attorney Docket No.57547-724.601
Example 3: Synergistic activity of Compound 31 with additional therapeutic agents [00290] In vivo anti-tumor activity and tolerability of Compound 31 in combination with various targeted agents was evaluated in mice using a series of cell line derived xenograft (CDX) and patient derived xenograft (PDX) tumor models representing various solid tumors harboring focal amplifications on ecDNA (e.g., focal amplifications of one or more oncogenes). For each study, mice were implanted with the tumor cells and once the tumors were established (e.g., reached a volume of about 100-350 mm3), the mice were started on the therapeutic regimens as further described below. For each study, synergy of the combination therapy compared to corresponding single agent arms was determined using the Fractional Product Method (Webb et al., 1963). A summary of the results is shown in Table 5. Fraction unaffected (fu) is the % where tumor growth inhibition was not observed. The fu observed with the combination treatment (fu)A+B (“observed fu”) was compared to the predicted fu calculated as the product of the observed fu for the single treatments (fu)A x (fu)B. If (fu)A+B = (fu)A x (fu)B then the combination was determined to be additive; if (fu)A+B < (fu)A x (fu)B then the combination was determined to be synergistic. Table 5: Synergy of Compound 31 in combination with targeted therapeutic agents
Attorney Docket No.57547-724.601
PO = orally; QD = once daily; Q2D = once every other day [00291] Collectively, these findings demonstrate that combination of Compound 31 plus a targeted agent can result in significant and synergistic anti-tumor activity, including tumor regressions, in tumors bearing oncogene amplification on ecDNA. FGFR [00292] The combination of Compound 31 (50 mg/kg PO dosed Q2D) plus the pan-FGFR inhibitor infigratinib (15 mg/kg PO dosed QD) was evaluated in the ecDNA+ FGFR2 amplified gastric cancer SNU- 16 CDX and CTG-0353 PDX models. Results are shown in FIG.1A and FIG.1B, respectively. Survival curves for the therapies CTG-0353 PDX model are shown in FIG.1C. In both models, the combination therapy demonstrated durable and significant tumor growth inhibition, including tumor regressions, when compared to vehicle. The combination of Compound 31 plus infigratinib was determined to be synergistic. [00293] The combination of Compound 31 (50 mg/kg PO dosed Q2D) plus the pan-FGFR inhibitor futibatinib (12.5 mg/kg PO dosed QD) was evaluated in the ecDNA+ FGFR2 amplified gastric cancer SNU- 16 CDX model. Results are shown in FIG.1D. The combination therapy demonstrated durable and significant tumor growth inhibition, including tumor regressions, when compared to vehicle or either agent alone. [00294] The combination of Compound 31 (50 mg/kg PO dosed Q2D) plus the pan-FGFR inhibitor pemigatinib (1 mg/kg PO dosed QD) was evaluated in the ecDNA+ FGFR2 amplified gastric cancer SNU- 16 CDX model. Results are shown in FIG.1E. The combination therapy demonstrated durable and significant tumor growth inhibition, including tumor regressions, when compared to vehicle or either agent alone. CDK4/6 [00295] The combination of Compound 31 (50 mg/kg PO dosed Q2D) plus the CDK4/6 inhibitors palbociclib (50 mg/kg PO dosed QD) or abemaciclib (10.5 mg/kg PO dosed QD) was evaluated in the ecDNA+ CDK4 amplified osteosarcoma SJSA-1 CDX tumor model. Results are shown in FIG.2A (Palbociclib) and FIG.2B (abemaciclib). The combination of Compound 31 plus palbociclib or abemaciclib
Attorney Docket No.57547-724.601 resulted in significant anti-tumor activity, including tumor regressions, when compared to vehicle. The combination of Compound 31 plus abemaciclib was determined to be synergistic. EGFR [00296] The combination of Compound 31 (50 mg/kg PO dosed Q2D) plus the EGFR inhibitor erlotinib (50 mg/kg PO dosed QD) was evaluated in the ecDNA+ EGFR amplified NSCLC PDX tumor models LU1206. Results are shown in FIG.3. The combination therapy resulted in significant tumor growth inhibition when compared to vehicle, and the therapy was determined to be synergistic. MET [00297] The combination of Compound 31 (50 mg/kg PO dosed Q2D) plus the MET inhibitor tepotinib (25 mg/kg PO dosed Q2D) was evaluated in the ecDNA+ MET amplified NSCLC PDX tumor models LU1902. T Results are shown in FIG.4. he combination therapy resulted in significant tumor growth inhibition when compared to vehicle; The combination therapy with tepotinib resulted in complete tumor regressions. The combination therapy was determined to be synergistic. Example 4 Suppression of ecDNA amplification [00298] Prolonged treatment of SNU-16 tumor cells in vitro and SNU-16 CDX tumors in vivo with the pan-FGFR tyrosine kinase inhibitor infigratinib resulted in tumor cell stasis for a period of 1-2 weeks but acquired resistance to infigratinib treatment occurred resulting in re-initiation of tumor growth. Infigratinib resistance was directly correlated with increased amplification of FGFR2 (copy number) on ecDNA. Combination treatment of infigratinib plus Compound 31 blocked the increase of FGFR2 copy number on ecDNA that otherwise was induced by single agent infigratinib. Results for the SNU-16 tumor cells in vitro are shown in FIG.5. [00299] The examples and embodiments described herein are for illustrative purposes only and in some embodiments, various modifications or changes are to be included within the purview of disclosure and scope of the appended claims.
Claims
Attorney Docket No.57547-724.601 CLAIMS WHAT IS CLAIMED IS: 1. A method of treating a tumor or tumor cells, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a selected cancer-targeted therapeutic agent to a subject identified as having the tumor or tumor cells, wherein the tumor or tumor cells comprise a gene amplification, whereby growth or size of the tumor or growth or number of tumor cells is reduced. 2 A method of delaying resistance to a selected cancer-targeted therapeutic agent, the method comprising: administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, to a subject in an amount sufficient to induce replication stress in tumor or tumor cells and administering the selected cancer-targeted therapeutic agent concurrently or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. 3 A method of treating a subject having a tumor or tumor cells that are non-responsive to a prior cancer-targeted therapeutic agent comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a selected cancer- targeted therapeutic agent to the subject. 4 The method of claim 3, wherein the subject received one or more administrations of the prior cancer-targeted therapeutic agent prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and wherein the tumor or tumor cells developed decreased responsiveness or resistance to the prior cancer-targeted therapeutic agent. 5 A method of provoking a response in a subject having a tumor or tumor cells that are non-responsive or have decreased responsiveness to a prior cancer-targeted therapeutic agent comprising administering a Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and a selected cancer-targeted therapeutic agent to the subject; wherein the prior cancer-targeted therapeutic agent is the same as the selected cancer-targeted therapeutic agent. 6 The method of any one of claims 3-5, wherein prior to treatment with the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, the tumor or tumor cells comprise a gene amplification and wherein the prior cancer-targeted therapeutic agent has an activity directed against a protein encoded by a gene contained within the gene amplification. 7 The method of any one of claims 1-6, wherein the selected cancer-targeted therapeutic agent is administered concurrent or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. 8 The method of any one of claims 1-6, wherein the selected cancer-targeted therapeutic agent is administered prior to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
Attorney Docket No.57547-724.601 9. The method of any one of claims 1-8, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is administered in an amount sufficient to induce replication stress in the tumor or tumor cells. 10. The method of any one of claims 1-9, wherein the subject is identified as having the tumor or tumor cells comprising a gene amplification. 11. The method of claim 10, wherein the gene amplification is a focal gene amplification. 12. The method of claim 10 or 11, wherein the gene amplification is an ecDNA-derived amplification. 13. The method of any one of claims 10-12, wherein the gene amplification is comprised on ecDNA or an HSR (homogeneously staining region). 14. The method of any one of claims 10-13, wherein the tumor or tumor cells comprise an ecDNA signature. 15. The method of any one of claims 10-14, wherein the selected cancer-targeted therapeutic agent is directed against a protein encoded by a gene contained within the gene amplification. 16. The method of any one of claims 10-15, wherein cells comprised within the tumor or the tumor cells are ecDNA competent. 17. The method of any one of claims 1-16, wherein treatment with both the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and the selected cancer-targeted therapeutic agent has a greater effect or a longer duration of effect on reduction of one or more of tumor growth, tumor size, number of tumor cells or tumor metastasis as compared to the treatment with either the compound of Formula (I) or the selected cancer-targeted therapeutic agent when administered alone. 18. The method of claim 17, wherein the greater effect is a synergistic effect. 19. The method of any one of claims 1-18, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the selected cancer-targeted therapeutic agent is administered orally. 20. The method of any one of claims 1-19, wherein treatment comprises administering multiple doses of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, and/or the selected cancer-targeted therapeutic agent over a treatment period. 21. The method of any one of claims 1-20, wherein the gene amplification comprises an amplification of a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3Cδ, PIK3CA/B, RET, and ROS1. 22. The method of any one of claims 1-21, wherein the gene amplification comprises an amplification of a gene selected from the group consisting of CDK4, CDK6, c-MET, EGFR, FGFR1, FGFR2, FGFR3, and FGFR4.
Attorney Docket No.57547-724.601 23. The method of any one of claims 1-22, wherein the selected cancer therapeutic agent is an FGFR inhibitor. 24. The method of claim 23, wherein the FGFR inhibitor is infigratinib, futibatinib, or pemigatinib. 25. The method of any one of claims 1-22, wherein the selected cancer therapeutic agent is a CDK4/6 inhibitor. 26. The method of claim 25, wherein the CDK4/6 inhibitor is palbociclib or abemaciclib. 27. The method of any one of claims 1-22, wherein the selected cancer therapeutic agent is an EGFR inhibitor. 28. The method of claim 27, wherein the EGFR inhibitor is erlotinib. 29. The method of any one of claims 1-22, wherein the selected cancer therapeutic agent is a c-MET inhibitor. 30. The method of claim 29, wherein the c-MET inhibitor is tepotinib. 31. The method of any one of claims 1-30, wherein prior to treatment the tumor or tumor cells comprise ecDNA and wherein the treatment results in a reduction in the amount of ecDNA in the tumor or tumor cells. 32. The method of any one of claims 1-30, wherein prior to treatment the tumor or tumor cells comprise ecDNA and wherein level or amount of ecDNA subsequent to the treatment is not increased as compared to prior to treatment. 33. The method of any one of claims 1-32, wherein the method further comprises assessing a sample from a subject for the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature. 34. The method of any one of claims 1-33, wherein the method further comprises obtaining information of the presence or level of one or more of a gene amplification, a focal gene amplification, ecDNA, HSR or an ecDNA signature in the tumor or tumor cells from the subject prior to, during or subsequent to the administration of the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof. 35. The method of claim 34, wherein the information is obtained from blood, tissue or one or more cells. 36. The method of claim 34, wherein the information is obtained by liquid biopsy or tissue biopsy. 37. The method of any one of claims 1-36, wherein the prior cancer-targeted therapeutic agent is targeted to the protein encoded by a gene selected from the group consisting of ABCB1, AKT, ALK, AR, BCL-2, BCR-ABL, BRAF, CDK4, CDK6, c-MET, EGFR, ER, ERBB3, ERRB2, AK, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GR, HRAS, IGF1R, KIT, KRAS, MCL-1, MDM2, MDM4, MTOR, MYC, MYCL, MYCN, NRAS, NRG1, NTRK1, NTRK2, NTRK3, PDGFR, PIK3Cδ, PIK3CA/B, RET, and ROS1. 38. The method of any one of claims 1-37, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is
Attorney Docket No.57547-724.601
wherein: Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each R1 is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2- C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two R1 on the same atom are taken together to form an oxo; n is 0-4; R is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, or heterocycloalkyl; R is hydrogen, deuterium, halogen, -CN, -NO2, -OH, -ORa, -NRcRd, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, or heterocycloalkyl; R is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, or heterocycloalkyl; W is N or CRW; R is hydrogen, deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, - NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R; X is N or CRX; R is hydrogen, deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, - NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R;
Attorney Docket No.57547-724.601 Y is N or CRY; RY is hydrogen, deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, - NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R; Z is N or CRZ; R is hydrogen, deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, -OC(=O)NRcRd, - SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, -NRbC(=O)Ra, - NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is optionally substituted with one or more R; provided that at least one of W, X, Y, or Z is N; L is -O- or -NR5-; R is hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, cycloalkyl, or heterocycloalkyl; Ring B is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; each R6 is independently deuterium, halogen, -CN, -NO2, -OH, -ORa, -OC(=O)Ra, -OC(=O)ORb, - OC(=O)NRcRd, -SH, -SRa, -S(=O)Ra, -S(=O)2Ra, -S(=O)2NRcRd, -NRcRd, -NRbC(=O)NRcRd, - NRbC(=O)Ra, -NRbC(=O)ORb, -NRbS(=O)2Ra, -C(=O)Ra, -C(=O)ORb, -C(=O)NRcRd, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C1-C6heteroalkyl, C2- C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; or two R6 on the same atom are taken together to form an oxo; or two R6 on the same carbon are taken together to form a cycloalkyl or a heterocycloalkyl; each optionally substituted with one or more R; or two R6 on different atoms are taken together to form a cycloalkyl, a heterocycloalkyl, an aryl, or a heteroaryl; each optionally substituted with one or more R; m is 0-8; each Ra is independently C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; each Rb is independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
Attorney Docket No.57547-724.601 C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; and each Rc and Rd are independently hydrogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6deuteroalkyl, C1-C6hydroxyalkyl, C1-C6aminoalkyl, C2-C6alkenyl, C2-C6alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, C1-C6alkylene(cycloalkyl), C1-C6alkylene(heterocycloalkyl), C1-C6alkylene(aryl), or C1-C6alkylene(heteroaryl); wherein each alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl is independently optionally substituted with one or more R; or Rc and Rd are taken together with the atom to which they are attached to form a heterocycloalkyl optionally substituted with one or more R; each R is independently halogen, -CN, -OH, -OC1-C3alkyl, -OC1-C3haloalkyl, -SC1-C3alkyl, -S(=O)C1- C3alkyl, -S(=O)2C1-C3alkyl, -S(=O)2NH2, -S(=O)2NHC1-C3alkyl, -S(=O)2N(C1-C3alkyl)2, -NH2, -NHC1- C3alkyl, -N(C1-C3alkyl)2, -C(=O)C1-C3alkyl, -C(=O)OH, -C(=O)OC1-C3alkyl, -C(=O)NH2, - C(=O)NHC1-C3alkyl, -C(=O)N(C1-C3alkyl)2, C1-C3alkyl, C1-C3haloalkyl, C1-C3deuteroalkyl, C1- C3hydroxyalkyl, C1-C3aminoalkyl, C1-C3heteroalkyl, or C3-C6cycloalkyl; or two R on the same atom form an oxo. 39. The method of any one of claims 1-37, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof, is a compound of Formula (Ib):
40. The method of any one of claims 1-39, wherein the compound of Formula (I), or a pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof,
pharmaceutically acceptable salt, solvate, tautomer, or stereoisomer thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263385347P | 2022-11-29 | 2022-11-29 | |
US63/385,347 | 2022-11-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024118596A1 true WO2024118596A1 (en) | 2024-06-06 |
Family
ID=91324869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/081334 WO2024118596A1 (en) | 2022-11-29 | 2023-11-28 | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024118596A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022087326A1 (en) * | 2020-10-23 | 2022-04-28 | Celgene Corporation | Heterocyclic compounds and their use for treatment of helminthic infections and diseases |
WO2022114189A1 (en) * | 2020-11-30 | 2022-06-02 | 住友ファーマ株式会社 | 5-heteroaryl-1h-pyrazol-3-amine derivative |
WO2022251502A1 (en) * | 2021-05-27 | 2022-12-01 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors and uses thereof |
WO2023229032A1 (en) * | 2022-05-27 | 2023-11-30 | 住友ファーマ株式会社 | Therapeutic for cancer refractory to immune checkpoint inhibitor |
WO2023230477A1 (en) * | 2022-05-24 | 2023-11-30 | Boundless Bio, Inc. | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof |
-
2023
- 2023-11-28 WO PCT/US2023/081334 patent/WO2024118596A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022087326A1 (en) * | 2020-10-23 | 2022-04-28 | Celgene Corporation | Heterocyclic compounds and their use for treatment of helminthic infections and diseases |
WO2022114189A1 (en) * | 2020-11-30 | 2022-06-02 | 住友ファーマ株式会社 | 5-heteroaryl-1h-pyrazol-3-amine derivative |
WO2022251502A1 (en) * | 2021-05-27 | 2022-12-01 | Boundless Bio, Inc. | Checkpoint kinase 1 (chk1) inhibitors and uses thereof |
WO2023230477A1 (en) * | 2022-05-24 | 2023-11-30 | Boundless Bio, Inc. | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof |
WO2023229032A1 (en) * | 2022-05-27 | 2023-11-30 | 住友ファーマ株式会社 | Therapeutic for cancer refractory to immune checkpoint inhibitor |
Non-Patent Citations (2)
Title |
---|
NEIZER-ASHUN, F. ET AL.: "Reality CHEK: Understanding the biology and clinical potential of CHKI", CANCER LETTERS, vol. 497, 2021, pages 202 - 211, XP086378588, DOI: 10.1016/j.canlet.2020.09.016 * |
ZHANG, Y. ET AL.: "Roles of Chk1 in cell biology and cancer therapy", INT. J. CANCER, vol. 134, 2014, pages 1013 - 1023, XP071288245, DOI: 10.1002/ijc.28226 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11707462B2 (en) | Checkpoint kinase 1 (CHK1) inhibitors and uses thereof | |
CN107406438B (en) | Inhibitors of bromodomains | |
EP3010917B1 (en) | Novel substituted bicyclic compounds as bromodomain inhibitors | |
CN113454085B (en) | AZA heterobicyclic inhibitors of MAT2A and methods for treating cancer | |
JP7337395B2 (en) | 2H-indazole derivatives as CDK4 and CDK6 inhibitors and their therapeutic use | |
JP2021512092A (en) | PRC2 inhibitor | |
US11939329B2 (en) | PARP1 inhibitors and uses thereof | |
WO2023230477A1 (en) | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
EP4301735A1 (en) | Ribonucleotide reductase (rnr) inhibitors and uses thereof | |
WO2023155892A1 (en) | Membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof | |
JP2022530866A (en) | Diazanaphthalene derivative as a PRC2 inhibitor | |
JP2024534421A (en) | Sulfamide ribonucleotide reductase (RNR) inhibitors and uses thereof | |
WO2023174397A1 (en) | Pyrazole membrane-associated tyrosine-and threonine-specific cdc2-inhibitory kinase (pkmyt1) inhibitors and uses thereof | |
WO2024118596A1 (en) | Checkpoint kinase 1 (chk1) inhibitors combinations and uses thereof | |
JP2024534420A (en) | Cyclic sulfonamide ribonucleotide reductase (RNR) inhibitors and uses thereof | |
TW202340190A (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof | |
US20240208934A1 (en) | Ulk1/2 inhibitors and their use thereof | |
WO2024118564A1 (en) | Checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
EP4114371A1 (en) | Alpha substituted stat inhibitors and compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23898692 Country of ref document: EP Kind code of ref document: A1 |